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Chronic infection with the hepatitis C virus infection (HCV) affects 
over 170 million individuals worldwide. In this thesis the natural 
history and management of hepatitis C in North- East London was 
investigated. 
The prevalence of cirrhosis in patients with chronic hepatitis C 
rises with increasing duration of infection. In Asian patients 
infected at birth, infection over 60 years causes cirrhosis in 71 % of 
infected individuals. Since the rate of fibrosis progression in Asian 
patients is the same as that seen in Caucasian patients, it is likely 
that similar rates of cirrhosis will be seen in all patients who are 
infected with HCV for over 60 years. Factors found to be 
associated with fibrosis progression were:- age and alcohol 
excess. Insulin resistance was associated with fibrosis 
progression. However, elevated serum ferritin or hepatiC iron 
were not. 
Knowledge of hepatitis C in the East of London was examined 
and found to be poor despite the Department of Health 
information campaign. Educational meetings and postal surveys 
improved the level of knowledge of HCV. However as our group 
only assessed knowledge immediately after completion of the 
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sessions, such a testing regime does not address long-term 
knowledge retention. 
We examined current and novel management strategies for 
patients with chronic HCV. Current therapy involves pegylated 
interferon and ribavirin. We found that insulin resistance was a 
poor predictor of sustained virological response. Chinese herbal 
treatments for hepatitis C are widely used but poorly studied. Our 
group designed a randomised controlled double blind study to 
assess whether Chinese herbal treatment is effective and results 
from this study show that recruitment and retention in trials of 
alternative therapies are problematic and that the herbal remedy 
had little effect on viraemia and quality of life, although liver 
function tests did improve a little. 
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'If you want a good fire in your stove you must put 
into it good clean wood and good coal, free from 
rubbish; therefore, put into your stomach proper 
food in a proper way, that your stomach may take 
good care of it, making good blood which is vitality'. 
~s about nine tenths of the diseases flesh is heir to 
are caused by ignorant or wilful abuse of the 
stomach and liver, evel}' person should make it their 
business to study themselves, their habits and 
appetites; and if wrong, correct them as far as 
possible, for good health is better than riches'. 
Virtue's Household Physician. A twentieth Century 
Medica. Virtue and Co Ltd. 1920. 
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BACKGROUND AND AIMS 
The aims of my thesis were as follows:-
1) Impact of HeV on immigrants from Bangladesh 
and Pakistan 
Prior to starting research I worked as a hepatology registrar both 
on the wards and liver clinics at Barts and the London NHS Trust. 
Whilst there I noticed a large proportion of first and second 
generation patients from Pakistan and Bangaldesh who were 
infected with HCV. When tracing their mode of acquisition and 
duration of infection I noted that the majority of these patients had 
acquired HCV infection in childhood whilst living in their country of 
origin. My clinical duties were to attend the liver histopathology 
meetings and check all histopathology reports prior to inserting 
them in the notes. I noted anecdotally that a high proportion of 
Bengali and Pakistani patients had developed cirrhosis or 
hepatocellular carcinoma in the fourth or fifth decades of life. The 
indigenous Caucasian patients did not seem to have this same 
degree of cirrhosis or rates of HCC. I hypothesised that patients 
born in Bangladesh or Pakistan acquire their infection at a 
younger age and are subsequently at a much higher risk of long-
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term complications from this infection by the fourth or fifth decade 
of life. This thesis describes this work 
2) GP knowledge of HeV 
Many of our patients had received inaccurate information from 
their GPs about chronic hepatitis C. Also, around this time I had 
been asked to give a round the table discussion to local GPs 
about hepatitis C. At this meeting, it became evident that a lot of 
the GPs were misinformed about this condition which was very 
concerning as they are the first health care professionals to see 
patients with hepatitis C. I therefore set up a study to try and 
improve GPs knowledge about hepatitis C. Before evaluating 
ways to improve this knowledge it was necessary to examine their 
baseline knowledge about this condition. 
3) Improving the care of patients with symptomatic 
HCV 
Whilst conducting my research we were approached by a 
commercial group who wanted to study a new herbal remedy for 
the treatment of hepatitis C. There were a lot of patients in our 
hospital who had strong views on using antiviral therapy that had 
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been tested on animals. Also there were a large proportion of 
patients who had terminated treatment due to side-effects from 
treatment or relapsed after completing treatment. I agreed to 
manage the study on behalf of the group. 
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CHAPTER 1: INTRODUCTION 
1.1 General Overview 
The Hepatitis C virus (HCV) was first identified in 1989 (Choo et 
al. 1989). This discovery illuminated many dark corners in the 
natural history of the infection formerly known as non-A, non-B 
hepatitis. Hepatitis C is a global health problem and the World 
Health Organisation (WHO) estimates over 170 million individuals 
worldwide to be infected with hepatitis C virus. Approximately 80-
90% of these individuals will progress over a number of years to 
chronic liver disease (Gish et al. 1997). The prevalence of 
infection varies in different countries and regions within the same 
country. 
In the under-developed world the incidence of new infections with 
HCV is still high mainly as a consequence of the use of 
unscreened blood transfusions and unsafe parenteral exposure. 
Some countries for example Egypt have extremely high 
prevalence rates of 20%, which is thought to be caused by the 
use of unsterilised equipment during schistosomiasis prevention 
programmes, which were introduced after the Second World War 
(Arthur et al. 1997). 
23 
The virus is transmitted by blood-to-blood contact and most 
infections in the Western world were acquired either through 
intravenous drug abuse or through transfusion of blood or blood 
products prior to the advent of anti-HCV screening in 1992. In the 
developed world, the incidence of new infections with HCV is 
decreasing and the prevalence varies from 0.5- 2% (Anon 1997). 
We face a substantial rise in the prevalence of end-stage liver 
disease as a high proportion of individuals with HCV infection in 
the USA and the UK were infected 20-25 years ago by sharing of 
drug injection equipment (Armstrong et al. 2000). In the UK, 
between 200 000 and 400 000 individuals are believed to harbour 
the infection, most of whom are asymptomatic and have yet to be 
diagnosed. In the underdeveloped world, iatrogenic transmission 
from inadequately sterilised medical equipment or unscreened 
blood transfusion is the main route of transmission and still 
persists today (EI-Ahmady et al. 1994). Epidemiological studies 
suggest a limited role for sexual transmission, however sexual 
transmission of hepatitis C is facilitated by co-infection with H IV 
(Bresters et al. 1993). The risk of vertical transmission seems to 
be low « 6% of children becoming HCV positive) unless the 
mother is HIV positive or has a particularly high level viraemia 
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(Giovannini et al. 1990). The virus has not been shown to be 
transmitted by breast feeding. 
By studying patients infected 20 to 30 years ago the natural 
history of chronic hepatitis C infection over 2-3 decades has been 
determined and the outcome is variable with around 30% of 
patients developing cirrhosis after 30 years (Poynard et al. 1997). 
Hence chronic HCV is a slowly progressive disease which leads 
to cirrhosis over several decades. Independent factors associated 
with an increased rate of fibrosis progression include age at 
infection greater than 40 years, daily consumption of 50g or more 
of alcohol and male sex (Poynard et at 1997). Other factors are 
immunodeficiency such as HIV and co-infection with HBV. 
Infection with the hepatitis C virus results in a variety of hepatic 
and extrahepatic diseases. In a minority of patients, infection 
results in an acute hepatitis with symptoms resembling other 
forms of acute hepatitis. The mean incubation period is seven 
weeks and symptoms last for 2-12 weeks. 60-800/0 of patients 
with acute hepatitis progress to chronic HCV. Chronic HCV 
patients may have symptoms of fatigue, muscle aches, anorexia, 
right upper quadrant pain, and nausea but more often than not 
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they have no symptoms. Symptoms and signs of chronic liver 
disease often occur later in the disease although some patients 
with chronic HCV cirrhosis remain asymptomatic. HCV infections 
have been associated with a number of immunological disorders 
including autoimmune hepatitis, Sjorgren's syndrome, lichen 
planus, thyroiditis, membranous glomerulonephretis, polyarteritis 
nodosa and essential mixed cryoglobulinaemia (Lunel. 1994; 
Marcellin et al. 1993). Hepatocellular carcinoma is commonly 
associated with chronic HCV infection, probably as a 
consequence of cirrhosis or as a result of chronic 
necroinflammation, but HCV does not have a direct carcinogenic 
effect (Bruix et al. 1989).Suspected individuals with HCV infection 
should be tested for HCV antibody by enzyme-linked 
immunosorbent assay (ELlSA) (Courouce et al. 1994). All patients 
with positive antibody tests and those patients thought to be at 
risk of HCV infection despite negative or indeterminate serological 
tests should undergo polymerase chain reaction (PCR) testing of 
serum for viraemia. The results of routine liver tests correlate 
poorly with both necroinflammatory and fibrosis scores found on 
liver biopsy. Liver biopsy is therefore usually performed before 
initiation of antiviral treatment and remains the most accurate 
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measure of the extent of liver disease. It is also useful to exclude 
other diagnosis such as alcohol induced liver disease. 
A" patients with chronic HCV should be referred for treatment and 
effective treatments are now available for hepatitis C. The goal of 
treatment is to achieve a sustained virological response (PCR-
negativity six months after the end of treatment) (Davis et al. 
2002). In chronic hepatitis C, variables such as low pre-treatment 
HCV RNA levels, HCV genotype (2 or 3), female sex, younger 
age, less hepatic fibrosis on liver biopsy and lower body weight 
have an increased likelihood of a sustained response (National 
Institutes of Health Consensus Development Conference 
Statement: Hepatitis C). The beneficial effects of interferon alpha 
in hepatitis C were first reported in 1986 (National Institutes of 
Health Consensus Development Conference Statement: Hepatitis 
C). In 1997 a course of interferon alpha administered 
subcutaneously at a dose of 3MU thrice weekly for 48 weeks was 
the optimal therapy of this disease with sustained virological 
response of 12% to 16% (National Institutes of Health Consensus 
Development Conference Statement : Hepatitis C ). The addition 
of ribavirin to alpha interferon resulted in improved response rates 
of 35% to 45% . pegylated interferons have further improved 
response rates, such that 50-600/0 of patients can expect to have a 
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sustained response with combination treatment using 
peginterferon and ribavirin. This has therefore been proposed as 
the new standard of treatment for chronic hepatitis C. 
1.2 Incidence and Prevalence of hepatitis C in 
the UK 
The prevalence in the UK is not known, but estimated to be 
between 0.1 to 1 per cent, whilst in Scotland it is around 0.60/0. It 
is very difficult to gain the true prevalence of HCV infection in the 
UK as there is marked variation in the epidemiological studies 
performed. This is because prevalence varies from area to area 
and according to risk behaviour present in the population studied. 
Information is available from laboratories in England and Wales 
on positive testing for HCV infection. Since 1990, surveillance of 
HCV has been carried out by the Public Health Laboratory Service 
Communicable Disease Surveillance Centre. Between 1992 and 
1996 a total of 5232 reports of confirmed HCV infection were 
received from laboratories in England and Wales. The majority of 
reports were in the 25-34 year age group (1974 of 5232 (38%» 
and the 35-44 year age group (1417 of 5232 (27%) with more 
than twice as many reports in males than females (Ramsey et al. 
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1998). Risk factor information was available for 2976 (57%) 
laboratory reports and the commonest risk factor was injecting 
drug use (80%) followed by receipt of blood products and 
transfusions. Laboratory reports of HCV mainly reflect population 
based reporting of positive HCV testing and there will be a large 
number of asymptomatic HCV patients who have not been tested. 
Surveillance of blood-borne virus infections carried out by the 
Public Health Laboratory Service Communicable Disease 
Surveillance Centre and the National Blood Authority detected 
HCV infection in 0.002 per cent of donations from new blood 
donors in England and Wales. This however will be an 
underestimation of the prevalence in the general population as 
injecting drug users are prevented from donating. Public Health 
Laboratory Service (PH LS) data show that prevalence of hepatitis 
C is much higher in specific groups:- 0.2- 0.4% in antenatal clinic 
attenders, 0.720/0 in organ donors; 1.07- 2.75 % in Genito-Urinary 
Medicine and 60-85% amongst injecting drug users. 
Ethnic minorities have been poorly represented in these 
epidemiological studies on prevalence of hepatitis C in the UK 
and there have been very few studies performed in Asia. The 
prevalence of HCV infection is believed to be similar in different 
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parts of Asia, with an average seroprevalence of HCV antibody 
less than 2.5 % in healthy adults although prevalence is much 
higher in at risk groups (Parker et al. 1999; Pradat et al. 2000; 
Akhtar et aI.2002). The prevalence of HCV is high in Asia due to 
lack of routine screening of donated blood, injecting drug use, 
traditional medical practices or medical treatment under sub-
optimal conditions that involve blood contamination. 
In summary, the UK has a relatively low prevalence of HCV 
infection; estimated by the Department of Health to be 200 000 to 
400 000 patients (Hepatitis C Strategy for the UK Department of 
Health). As few as 10% of these individuals are aware of their 
infection (Hepatitis C Strategy for the UK Department of Health). 
The remainder of patients with chronic hepatitis Care 
asymptomatic and are not aware that they are suffering from a 
progressive liver disorder. The main exposure group in the UK is 
injecting drug users who have the highest prevalence rates. The 
decline in the incidence of cases of HCV in the UK has been due 
to the elimination of the transmission of HCV by blood and blood 
products through exclusion of infected donors using the second -
generation antibody assay to HCV and by virus inactivation 
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procedures; although injecting drug use is likely to be the main 
method of continued transmission. It may be expected that the 
reduction in incident cases will eventually lead to a decrease in 
the prevalence of HCV infection. However, although the incidence 
of HCV infection may be decreasing, the prevalence of liver 
disease caused by HCV is on the rise. This is because there is a 
significant lag, often 20 years or longer, between the onset of 
infection and clinical manifestations of liver disease. 
1.3 Transmission of Hepatitis C 
Large studies on transmission of hepatitis C have come from the 
United States; whilst information concerning transmission in the 
UK is gradually emerging. Post-transfusion hepatitis was first 
recognised as an entity in the 1940s, Its occurrence was 
dramatically reduced by the implementation of HBsAg blood 
donor screening in the late 1960s (Alter 1995). However despite 
this 10% of transfusion recipients continued to develop post-
transfusion hepatitis. The discovery of the hepatitis C virus in 
1989 showed that this virus was responsible for the cause of 
more than 90% of non-A, non-B (NANB) post-transfusion hepatitis 
(Alter 1995). By 1992 with the availability of routine blood 
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screening for HCV antibody in most countries it soon became 
apparent that hepatitis C is efficiently transmitted by blood or 
blood products. It can survive in dried blood for longer periods 
than most other viruses (even HIV) - survival for up to 3 months 
has been reported (Alter 1995). It is imperative that health 
professionals educate their patients about transmission of 
hepatitis C so that measures can be taken to prevent infection. 
Information about the dangers inherent in any kind of blood to 
blood contact needs to be made freely accessible to the general 
public and HCV infected patients need to be provided with 
information which will prevent them from transmitting the virus. 
Transfusion of blood and blood products 
The widespread availability of donor screening in 1992 in 
developed countries meant that transmission of HCV via blood or 
blood products is virtually non-existent (Alter H. 1995; Lee et al. 
1991; Donahue et al. 1992) . In the developing world 
transmission through unscreened blood or blood products still 
remains a major route of HCV spread (Mansell et al. 1995). In 
most Western countries this group is on the decrease and now 
represents at least 15% of the total HCV population. It comprises 
older patients who were infected between the late 1940s to the 
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early 1990s (Alter H. 1995). Nearly all patients with hemophilia 
born prior to 1986 were infected with hepatitis C because of the 
presence of the virus in blood supplies and products. Since 1986 
donated blood products such as clotting factors have been 
subject to various inactivation processes designed to kill viruses 
and bacteria. Nevertheless, patient groups advocate quite 
understandably recombinant (genetically engineered) blood 
products to reduce the risk of inadvertent transmission of 
unidentified pathogens (Alter 1995). 
Intravenous drug users (IOU) 
In developed countries this group represents a significant 
proportion of the more recently infected HCV population. 
Intravenous drug users (IVDU) have infection rates as high as 60-
80% and the majority contract hepatitis C within the first year of 
injecting (Alter et al. 1995). HCV is a very resistant virus that can 
survive the cleaning techniques of equipment recommended to 
prevent the spread of HIV. Therefore, it can also be spread by 
sharing of spoons, ampoules, water, filters, tourniquets and other 
paraphernalia as well as contaminated hypodermic needles and 
syringes (Alter et al. 1994). Needle exchange centres have been 
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found to be cost-effective and result in a reduction of prevalence 
of HCV in this population. 
Sexual transmission 
HCV is not spread very effectively by the sexual route possibly 
due to low levels of virus in genital fluids and tissues or due to 
lack of appropriate target cells in the genital tract (Vandelli et al. 
2004; Clarke et al. 2006). Male homosexuals and sexual partners 
of drug addicts with HCV infection have low rates of HCV 
transmission (Alary et al. 2005). However co-infected patients 
with HIV are more likely to be able to pass on HCV via sexual 
intercourse possibly due to higher viral loads in body fluids such 
as semen (Vandelli et al. 2004; Clarke et al. 2006; Alary et al. 
2005). 
Intrafamilial transmission 
Household contact may account for cases of intrafamilial 
transmission. The virus can be harboured in tiny quantities of 
blood or body fluids and there are extensive opportunities for it to 
jump to a new host (Alter et al. 1995 ). Injection of saliva from 
HCV infected patients into chimpanzees has resulted in HCV 
34 
transmission (Taber et al. 1978). Possible risks of transmission 
include toothbrush or razor sharing, although the risk is very small 
(Alter MJ. 1994). 
Occupational exposure from needlestick injuries 
Health care workers are prone to needlestick injuries. Needlestick 
injuries from a hepatitis C patient have a 2 % likelihood of 
transmission of HCV to the health care worker (Alter M. 1995; 
Alter M. 1994). Department of Health guidelines advocate that 
serum should be obtained from the worker at baseline, 6 weeks, 
12 weeks, and 24 weeks after exposure. Serum is tested for HCV 
RNA at 6 and 12 weeks and for anti-HCV at 12 weeks and 24 
weeks (Ramsay M. 1999) 
Maternal-foetal transmission 
Maternal-foetal transmission is rare occurring in less than 50/0 of 
deliveries from HCV-infected mothers in the Western world 
(Yeung et al. 2001; Steininger et al. 2003). When the 
transmission occurs is unclear - it may occur in utero, 
intrapartum or both. The risk of HCV transmission increases 
during vaginal delivery with high maternal viraemia (> 10 6 copies 
Iml), infantile hypoxia and intrapartum exposure to virus 
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contaminated maternal blood (Yeung et al. 2001; Steininger et al. 
2003; Ruff A. 1994). There is no treatment for HCV infection that 
is currently approved for use in pregnancy or in the neonate. In 
non-infected babies clearance time of antibodies is significantly 
longer if the mother is viraemic. 
Mothers with both HIV and HCV have about 8-12 % probability of 
passing the virus on to their baby (England et al. 2006; Pembreya 
et al. 2005). Elective caesarian section in these co-infected 
mothers results in a reduced risk of vertical transmission of HCV 
(England et al. 2006; Pembreya et al. 2005). HCV pregnant 
women and the delivery team need to discuss means of 
minimising the possibility of transmission to the baby. 
Breast feeding does not appear to significantly increase the risk of 
neonatal HCV infection as long as the nipples are not traumatised 
and there is no blood contact (Pembreya et al. 2005; Pappalardo 
B; 2003). Neonates from mothers who replicate HCV should have 
a PCR HCV tested at 12-15 months of age. The diagnosis of 
perinatal infection is made from the persistence of anti-HCV in the 
serum for more than 12 months from birth and the detection of 
HCV RNA in at least two post delivery samples. 
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Rare cases of transmission 
HCV may also be transmitted intranasally during cocaine use 
probably through blood contact. Nosocomial transmission (patient 
to patient) has been documented by inadequately sterilised EEG 
pads, filters of anaesthetic masks and colonoscopy and dialysis 
machines (Alter M. 1995; Roth D. 1995). Universal precautions 
and scrupulous aseptic techniques are recommended to limit the 
spread of infection in this setting. 
There is around 50 010 chance of the recipients of an organ from a 
HCV positive donor developing hepatitis after transplantation 
(Terrault et al. 1995). 
Transmission in developing countries 
The mode and timing of acquisition of HCV infection in 
Bangladesh, India and Pakistan differs significantly from that in 
the UK. HCV is spread by the lack of routine screening of donated 
blood, injecting drug useage, traditional medicine practices or 
medical treatment under suboptimal hygienic conditions that 
involve blood contamination and tattooing (Parker et al. 1999; 
Aktar et al. 2002; Abdel-Aziz et al. 2000; Mollah et al. 2003). They 
acquire their infection at a younger age, and are subsequently at 
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much higher risk for long-term complications of this infection by 
the fourth or fifth decade of life (Nguyen et al. 2003). 
Other practices which are implicated in HCV transmission in 
developing countries include the practice of circumcision and 
tattooing in un-sterile conditions and the presence of injection 
shops in some countries. The highest prevalence of HCV is found 
in Egypt which may be due to the use of parenteral anti-
schistosomial therapy (Manse" et al. 1995). A significant proportion 
of 'sporadic' cases of HCV may have been infected by cosmetic 
contact, especially tattOOing. In past years acupuncture and 
vaccination programmes were strongly implicated as vectors in the 
spread of HCV, due to the fact that traditional measures may not 
have been sufficient to kill HCV or as a result of 'shared needle' 
vaccination programmes. All vaccination programmes should be 
carried out by personnel who are well educated about the risks of 
HCV transmission and this programme should be extended to 
barbers, dentists, cosmetic surgery professionals, tattooists and 
acupuncturists. 
In summary, HCV infection will continue to have a global impact 
on health in the future. Healthcare professionals and the public 
must be made aware of HCV, and treatment of drug misuse and 
dependency needs to be increased (Hepatitis C. Strategy for 
38 
England Published by the Department of Health). There must be 
raised public awareness of those at high risk of infection, 
especially injecting drug users and those in prison. Needle 
exchange programmes have been shown to be a useful strategy 
in lowering HCV prevalence amongst drug users in the USA (Alter 
M. 1994). The high rates of progression to chronic infection with 
end-stage liver disease and resultant liver complications means 
that more effective education and public health programmes are 
required to prevent transmission; as to date treatments with 
pegylated interferon and ribavirin are poorly tolerated and have a 
50% rate of cure (Hepatitis C. Strategy for England Published by 
the Department of Health). 
1.4 Natural History of Hepatitis C 
Hepatitis C virus is a common cause of cirrhosis and 
hepatocellular carcinoma and is now the single leading indication 
for liver transplantation. However, the natural history of this 
infection is variable and difficult to assess as it often has a largely 
asymptomatic onset together with a protracted highly variable 
silent course of 20-40 years (Seeff et al. 2002). In this disease 
there are often multiple host, viral or environmental factors that 
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can affect the rate of fibrosis progression. By understanding the 
natural history and factors influencing progression of chronic 
hepatitis C to the development of cirrhosis and hepatocellular 
carcinoma we may be able to halt this progression. 
The majority of our information on natural history comes from 
three types of studies:- retrospective, prospective and cohort 
studies (Seeff et al. A & B 2002) (see Table 1). 
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Table 1 - Natural History of Hepatitis C- retrospective, prospective and cohort studies 
and cross-sectional studies with mathematical modelling. 
Method of study Author Country No of Interval from Cirrhosis HeC(%) Liver 
(reference) patients exposure (%, death 
(mean or (%) 
range of 
means, 
RETROSPECTIVE Kiyosawa3 Japan 231 10-29 35.1 23.4 · 
Tong 4 USA 131 14-28 51.0 10.6 15.3 
Vano Japan 70 . 50.0 . · 
Niedarau Germany 838 8-22 16.8 2.0 3.7 
Gonion USA 216 19 65.0 3.7 · 
Gordon USA 195 20 21.0 1.0 · 
Takahashi Japan 333 19 17.4 18.0 · 
PROSPECTIVE DiBiseeglie USA 65 9.7 12.3 0 3.7 
Koretz USA 80 16.0 7.0 1.3 1.3 
Mattson Sweden 61 13.0 8.0 . 1.6 
Tremolada Haly 136 7.6 16.6 0.7 3.7 
Hopf Germany 86 3-20 24 . 6 
COHORT Seen USA 103 20 15 1.9 2.7 
Seen USA 17 45-50 5.9 0 5.9 
Kenny- Ireland 376 17 2.0 0 0 
Walsh 
Vogt Germany 458 17 0.3 0 0 
Rodger Australia 88 25 4 0 1 
Thomas USA 819 8-15 1.0 0 2.1 
Wiesa Germany 1018 20 0.4 0 0 
Cross-sectional Poynard France 2235 0.133 Metavir Meantime 
Study with (1987) single units per fromHCV 
mathematical bioples year Infection to 
modelling using 70 0.183 Metavlr elrrhosls 
estimated paired units per 0'30 years 
duration of biopsies year 
Infection 
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1.41 Retrospective Studies 
Retrospective studies have produced the most severe outcomes 
with a high rate of progression to cirrhosis and hepatocellular 
carcinoma (Kiyosawa et al. (1996); Tong et al. 1995; Yano et a!. 
1996; Niedarau et al. 1998; Gordon et al. 1993; Takahashi et al. 
1993). These studies assess patients with established chronic 
hepatitis and attempt to trace back in time to the moment of acute 
onset based on the presumed time of infection. These seven 
retrospective studies are a representative group of studies from 
Japan, USA and Europe with an interval from exposure ranging 
between 9-29 years. Cirrhosis was identified in 17 % to 55% 
(mean 350/0), development of HCC in 1-230/0 and liver related 
mortality in 4-150/0. Kiyosawa et al. (1996) was one of the first 
studies to show from frequent serial biopsies that there was 
sequential progression from acute hepatitis to chronic persistent 
hepatitis to chronic active hepatitis to cirrhosis and then to HCC. 
The severe outcomes can be explained firstly by the fact that all 
these studies took place in academic centres which result in 
'referral bias' because these tertiary referral centres were likely to 
attract patients with well-established and serious liver disease. 
They are not representative of all HCV- infected patients in the 
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general population (Seeft et at 2002). Secondly, in Japan chronic 
HCV infection is common and strongly associated with HCC and it 
is difficult to extrapolate these results to other populations (Seeft 
et al. 2002). 
1.42 Prospective Studies (Transfusion associated 
HeV infection) 
Long- term prospective follow-up of patients with transfusion-
associated HCV infection revealed that acute non-A, non-S 
hepatitis progressed to chronic hepatitis ( Di Bisceglie et at 1991; 
Koretz et al. 1993; Mattson et al. 1993; Tremolada et al. 1992; 
Hopf et at 1990). These studies were extensions of previous six 
month trials of the incidence and causes of transfusion associated 
hepatitis. This is the preferred way of studying natural history and 
focuses on a whole population. They yielded differing results from 
the retrospective studies. Five prospective studies with a known 
onset of acute infection were conducted in US and Europe; with 
an interval from exposure ranging between 8-20 years. These 
studies revealed that progression from acute to chronic hepatitis C 
was common. Study results showed wide variations in the 
frequency of histologically defined cirrhosis (8-24 %), HCC {0.7-
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1.3 %) and liver related death (2 -6 0/0). These studies were not 
initially designed for long follow-up (8-20 years) and are 
insufficient to determine most of the serious sequelae of chronic 
hepatitis C (5eeft et al. 2002). Biopsies were mainly performed on 
patients with more severe liver disease. The role of alcohol in 
progression was not taken into account (5eeft et al. 2002). 
1.43 Retrospective-Prospective Studies 
In these studies the date of initial exposure to HCV was known 
retrospectively and investigators traced these patients 15 years 
later; in this way all patients were prospectively reviewed even 
those who cleared infection (Seeff et al. 1998; Seeff et al. 1998; 
Kenny-Walsh E. 1999; Vogt et al. 1999; Rodger et al. 2000; 
Thomas et al. 2000; Wiese et al. 2000). Seven retrospective-
prospective studies have been performed; six comprising young 
patients (Seeft et al. 1998; Kenny-Walsh 1999; Vogt et al. 1999; 
Rodger et al. 2000; Thomas et al. 2000; Wiese et al. 2000) and 
one study middle-aged patients (Seeff et al. 1998). The time 
interval from exposure ranged from 9-50 years. Cirrhosis 
developed in 0.3 to 15%, HCC in 0 -1.9% and liver related 
mortality from 0 -2.8%. These studies have the advantages of 
studying a heterogenous population with a variety of ages and 
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sexes from the outset of the disease. The lowest rates of 
progression appear to be in young people especially young 
women (Kenny-Walsh 1999; Vogt et al. 1999). However, both 
these groups are special cases in that they were infected with 
HCV due to a point outbreak by contaminated anti-O 
immunoglobulin. 
Seeff et al. (2002) noted discordance in mean frequency 
progression to cirrhosis according to study design. The mean 
frequency progression was 420/0 for retrospective studies, 11 % for 
prospective studies and 2.1 % for retrospective- prospective cohort 
studies (Seeff et al (2002). 
1.44 Other Studies assessing natural history 
Poynard et al. (1997) performed a single biopsy cross-sectional 
study of 2 235 patients in whom duration of infection was 
estimated from the date of acquisition of HCV. A series of risk 
factors were analysed to determine influence on progression of 
fibrosis. This study comprised 30% of people who were infected 
through blood transfusion and 250/0 through iv drug abuse. 
Poynard's group developed a scoring system called the Metavir 
scoring system for assessing the grade and stage of 
histopathological changes seen in chronic hepatitis C, that is used 
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mainly in France. The median rate of fibrosis progression using 
Metavir was 0.133 unit per year. This gave a mean time from HCV 
infection to development of cirrhosis of 30 years. Three factors 
increased the rate of fibrosis progression:- age greater than 40 
years at the time of infection, followed by alcohol consumption 
more than 50g per day and then male sex. There were 70 patients 
who had paired biopsies in which fibrosis rates were 0.183 unit 
per year. These patients were in the control arms of interferon 
treatment trials and no information as to the time interval between 
these biopsies were available. Some individuals progressed 
rapidly to cirrhosis (102 patients in 9.5 years) (Table 2). In 68 
patients minimal fibrosis was present after 20 years infection with 
an estimated time from infection to cirrhosis of greater than 50 
years. This study relies heavily on a single liver biopsy and an 
estimated duration of infection. 
Table 2. The length of time of progression to cirrhosis in HCV-
infected patients due to risk factors (Poynard et al. 1997). 
Age <40 alcohol <50 Male 36 yrs to cirrhosis 
Age <40 alcohol <50 Female 42 yrs to cirrhosis 
Age> 40 alcohol <50 Male 13 yrs to cirrhosis 
Age> 40 alcohol <50 Female 20 yrs to cirrhosis 
Age >40 alcohol> 50 Male and Female 15 yrs to cirrhosis 
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A subsequent cross-sectional study of 2313 patients in 2001 was 
reported by Poynard (Poynard et al. 2001). Patients were infected 
either through blood transfusion or iv drug abuse. Disease 
progression was modelled using the Hazard Function in terms of 
linearity. During the first 10 years of infection there was little 
progression (except patients infected after the age of 50), the next 
15 years involved slow progression, an intermediate period 
occurred during the next 10 years, followed by a further five years 
where progression was greatest. At 60 years of age 500/0 of 
patients would develop severe disease. These estimates are in 
concordance with the progression intervals of retrospective 
studies and prospective studies. 
However, these studies firstly rely heavily on a single liver biopsy 
and an estimated duration of infection and there is little 
prospectively collected data. Poynard does include 70 paired 
biopsies of patients making up the control arms of treatment 
studies, but the time interval between these biopsies is not 
available. Secondly, the variable outcomes among HCV-infected 
patients and studies from patients infected via blood transfusion 
argues against linear progression 
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The untreated control arm of a study on antiviral therapy helped to 
address this further. Patients with mild hepatitis C who were not 
offered treatment with interferon were followed regularly with 
repeat biopsy every 31 months (Ryder et al. 1999). In this control 
group of 151 patients, 270/0 progressed by one or more fibrosis 
points. This data suggests that even mild hepatitis C is a 
progressive disease with progression of fibrosis occurring at a rate 
of 0.146 Knodell fibrosis unit per year. Assuming the development 
of fibrosis is linear the authors estimate the overall time from 
infection to cirrhosis is 27.5 years. 
1.45 Outcome in Children 
Hepatitis C infection of children is rare as perinatal spread is 
uncommon. Vogt et al. (1999) has reported the largest outcome 
study in 458 children (14.6% were HCV antibody positive) 
undergoing cardiac surgery before the implementation of blood 
donor screening and followed up 12-27 years later. 45 % of 
children spontaneously cleared the virus during this period. A liver 
biopsy was performed in 17 of the 37 (55%) remaining viraemic 
patients and 1 (0.3%) child was found to have developed 
Cirrhosis. 
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Losasciulli et al. (1997) followed up 114 children with childhood 
leukaemia of which 56 (49%) were found to be HCV RNA positive 
after chemotherapy. After a period of 17 years all the HCV RNA 
positive cohort were asymptomatic and sixteen of the 56 (29%) 
had spontaneously cleared the virus. No liver biopsy was 
performed. Garcia-Monzon et a!. (1998) compared 24 HCV 
infected children and 22 HCV infected adults over a mean follow-
up of 11 years and despite similar viral loads fibrosis was 
markedly less in children. Luban et al. (1999) reviewed 5,446 
children that had received blood transfusion between 1982 and 
1992. Of 1,753 children tested so far 36 (2 %) are HCV positive 
and 7 out of the 36 were biopsied a mean 13.6 years from 
exposure with only one child having early bridging fibrosis. 
Data for children is still sparse and duration of follow-up 
insufficient to determine most of the serious sequelae of chronic 
hepatitis C. However, the studies so far suggest mild outcomes 
over the first two decades of infection with a high rate of 
spontaneous recovery (29-45%). 
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1.46 Fibrosis progression in patients with normal liver 
enzymes 
10 to 40 % of HCV infected patients have persistently normal liver 
enzymes and this subgroup has a lower risk of progression to 
cirrhosis. Patients who have normal AL T levels recorded on 
several occasions, usually have mild degrees of hepatitis disease 
activity and either no or minimal fibrosis (Marcellin P. 1999, 
Martinot-Peignoux et al. 2001; Persico et al. 2000). Mathurin et 
al. (1998) reviewed 204 patients and found that the median 
progression rate of fibrosis was significantly lower in patients with 
normal liver enzymes (0.05 Metavir points per year) compared 
with 0.13 points per year in those with elevated AL T levels. 
1.47 Outcome after the development of cirrhosis 
The outcome after the development of cirrhosis has been 
reviewed in two studies. The EUROHEP study was a 
retrospective 5 year follow-up study of 384 patients with 
compensated cirrhosis due to HCV (Fattovich et al. 1997). The 
risk of decompensation after a mean of 5 years (9-124 months) 
was 18% and of HCC 70/0. The 5 year survival was 91% in all 
patients, but 50% in those with decompensated cirrhosis. Serfarty 
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et al. (1998) followed 668 cirrhotic patients for a mean of 40 
months (6-72 months) (31). The risk of decompensation was 
14.5%), with a risk of HCC of 1.6%. The 2 year and 4 year survival 
rate was 96% and 84% respectively. 
Benvegnu et al. (2004) revealed that there was significant 
morbidity and mortality during the first decade after diagnosis of 
compensated cirrhoisis due to HCV and/or HBV. Hepatocellular 
carcinoma was the most frequent and life threatening 
complication in both HCV and HBV/HCV related cirrhosis 
(Benvegnu et al. 2004) .. 
1.48 Fibrosis progression in ethnic minorities 
There are few studies on natural history of chronic hepatitis C in 
minority populations however information from cross-sectional 
studies suggest that fibrosis progression differs among ethnic 
groups. 
A retrospective study of 355 chronic hepatitis C patients in 
America revealed that African-Americans had significantly less 
piecemeal necrosis and less chance of cirrhosis than non-African 
Americans. This was despite the fact that they had a longer mean 
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duration of infection and were older at the time of biopsy (Wiley et 
al. 2002). African-Americans have a higher rate of HCC. These 
findings have been confirmed by other studies (Reddy et al. 1999) 
and are thought to be due to differences in phenotypic human 
leukocyte antigen (HLA) gene expression and less immune 
recognition of HCV-infected hepatocytes (Wiley et al. 2002; Reddy 
et al. 1999). 
Subgroup analysis of other minority groups such as Hispanics in 
America show higher histological activity and fibrosis score than 
Caucasians (Mallet et al. 2002), and a study of 256 patients 
showed that Hispanics have a three-fold higher fibrosis 
progression rate (n=66; 0.215 mean stages/year) compared with 
Caucasians (n=47; 0.084 mean stages/year; p < 0.02) which was 
thought to be related either to a longer estimated duration of 
disease or higher prevalence of metabolic syndrome amongst this 
group (Bonacini et al. 2001). 
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1.49 Factors associated with more rapid progression 
Factors associated with more rapid disease progression include 
older age of infection, male sex and history of heavy alcohol use 
(Freeman et al. 2001; Poynard et al. 1997; Poynard et al. 2001). 
Immune deficiency such as hypogammaglobulinaemia or HIV 
infection together with steatosis, obesity and diabetes are 
associated with more rapid progression of fibrosis. Virological 
factors such as viral load and genotype have not been associated 
with the rate of progression of fibrosis (Poynard et al. 2001). 
Age at onset of infection is an important determinant of disease 
progression and severity. Poynard et al. (1997) found that the 
rate of progression was correlated directly with age of onset of 
infection, male sex and alcohol consumption. In the hazard 
function model, nearly all patients infected after the age of 40 
developed cirrhosis within 16 years (Poynard et al. 1997; Poynard 
et al. 2001). Male sex and high consumption of alcohol (> 50 g 
per day) were associated with greater fibrosis progression 
(Freeman et al. 2001; Poynard et al. 1997; Poynard et al. 2001; 
Ryder et al. 1999). Oarby et al. (1997) reported that suppressed 
immunity such as HIV can have a faster rate of progression with 
significantly higher mortality from liver disease in patients co-
infected with HIV. This also is found in liver transplant recipients 
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where cirrhosis occurs in up to 300/0 of patients after 5 years 
(Berenguer et al. 2000). Similarly co-infection with HBV has a 
synergistic effect on fibrosis progression. 
There is strong evidence of an association between chronic 
hepatitis C and diabetes mellitus (Allison et al. 1994). Insulin 
resistance plays an important role in the development of type 2 
diabetes mellitus, preceding diabetes by 10 to 20 years. HCV 
infection can induce insulin resistance and insulin resistance may 
increase the rate of fibrosis progression in HCV patients (Hui et al. 
2003). 
Chronic hepatitis C is associated with hepatic steatosis to a 
greater extent than other liver conditions. There is growing 
evidence that hepatic steatosis is associated with more severe 
liver disease in patients with hepatitis C (Adinolfi et al. 2001). 
The natural history of hepatitis C is difficult to determine due to an 
asymptomatic acute phase hepatitis followed in 60-80% of cases 
by a silent protracted chronic phase of 20-40 years. A mixture of 
retrospective, prospective and cohort studies reveal that the 
natural history of hepatitis C is highly variable, however during the 
first 20 years it appears that about 200/0 of patients have evidence 
of cirrhosis. After this period we can only make estimations about 
the long-term outcome, it could theoretically plateau, progress 
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linearly or increase exponentially. Each patient differs according 
to the duration of infection and presence of factors associated with 
more rapid disease progression and should be assessed 
accordingly. 
1.5 Diagnosis and Treatment of Hepatitis C 
Hepatitis C virus (HCV) is a major cause of chronic hepatitis that 
progresses in some patients to cirrhosis and hepatocellular 
carcinoma (HCC). The natural history of HCV-related liver 
disease is variable among individuals, but without effective 
treatment strategies, hepatitis C-related morbidity and mortality is 
expected to increase nearly 3-fold over the next few years. This is 
because most patients were infected in the 70s and 80s when 
many people experimented with intravenous drugs. Since 
infection leads to cirrhosis in 20-30 years it is probable that many 
of these patients will develop end stage liver disease in the next 
few years. Accordingly, current hepatitis C therapies are aimed at 
eradication of HCV infection to prevent progression to end-stage 
liver disease and its associated complications. 
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1.51 Diagnosis of HCV 
The incidence of HCV is decreasing in Europe, as a result of 
available and accessible medical and diagnostic facilities for a 
large part of the population (WHO). All patients, who are antibody 
positive for hepatitis C virus, require their diagnosis confirmed by 
PCR HCV testing, and the severity of disease assessed before 
initiating treatment. Liver function tests are a poor screening tool 
for HCV- as 500/0 of infected patients have normal transaminases, 
despite having evidence of necroinflammatory liver disease with 
or without cirrhosis (Alberti et al. 1992). 
The diagnosis of acute and chronic hepatitis C is based on 
antibody tests (anti-HCV). All patients who have detectable 
antibodies against the hepatitis C virus should have a sample of 
serum analysed for the presence of virus (qualitative assay) by a 
sensitive nucleic acid detection assay (a polymerase chain 
reaction (PCR) assay) to detect viral RNA (Pawlotsky J. 2002). 
Patients may also be seen who are antibody negative, but have a 
detectable viral load on PCR. These patients may be heavily 
immunosuppressed or have contracted the infection within the 
previous few weeks (antibody response can take a few months to 
develop). Some patients have detectable antibodies, but are 
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persistently PCR negative; they have been exposed to HCV but 
have eliminated the virus spontaneously. 
Following confirmation of the diagnosis it is important to counsel 
the patient about infectivity and the effects of infection on partners 
and family members. Prior to beginning therapy, other virological 
tools, including liver biopsy, HCV genotype determination and 
HCV quantification come into play to tailor treatment to the 
individual patient and determine its efficacy (Pawlotsky J. 2002). 
Six major genotypes and more than 50 subtypes of HCV have 
been described. The different HCV genotypes have marked 
geographic variation in their relative frequencies and response 
together with duration of treatment (Pawlotsky J. 2002; Saadeh et 
al. 2001). 
In patients with genotypes 2 and 3, the frequency of sustained 
responses to short-term (6 months) therapy is so high that under 
these circumstances the need for liver biopsy is less compelling. 
For most patients with other genotypes the value of pre-treatment 
liver biopsy may outweigh its risks as it excludes other causes of 
liver injury and helps in deciding the timing of treatment (Saadeh 
et al. 2001). 
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Acute hepatitis C 
Acute hepatitis C is rarely recognised and largely under-
diagnosed (Gerlach et al. 2001). Up to 150/0 spontaneously clear 
the virus after an acute phase whilst the remaining 850/0 develop 
chronic hepatitis. HCV rarely causes acute liver failure. Factors 
such as age, genetic factors and ALT profile have been 
associated with an increased risk of chronicity (Gerlach et al. 
2001; Gerlach et al. 2001). 
Pegylated interferon therapy in acute hepatitis C can induce 
high sustained virological response rates, is well tolerated and 
reduces the risk of evolution of chronicity (Kamal et al. 2006; 
Wedemeyer et al. 2006). Initiation of pegylated interferon at week 
8 or 12 weeks resulted in higher sustained virological rates than 
initiation at week 20 (Kamal et al. 2006; Wedemeyer et al. 2006). 
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Chronic hepatitis C 
All patients with chronic HCV should be assessed for treatment. 
Variables that correlate with a higher likelihood of a sustained 
response to therapy include low pre-treatment HCV RNA levels, 
HCV genotype (2 or 3), female sex, younger age, less hepatic 
fibrosis on liver biopsy and lower body weight (Seeff L. 2002). 
Patients with HCV should be warned that alcohol abuse has been 
shown to increase the severity of hepatitis C with more rapid 
progression to cirrhosis and hepatocellular carcinoma (Harris et 
al. 2001; Peteres et al. 2002). Only recently have effective 
treatments become available for hepatitis C. The goal of treatment 
is to achieve sustained virological response (PCR negative) 6 
months post-treatment which leads to histological improvement 
(Davis G. 2002). The beneficial effects of interferon alpha in 
hepatitis C were first reported in 1986 (National Institutes of 
Health Consensus Development Conference Panel Statement: 
Management of hepatitis C: 2002). In 1997 a course of interferon 
alpha administered subcutaneously at a dose of 3MU thrice 
weekly for 48 weeks was the optimal therapy of this disease with 
sustained virological response of 12% to 160/0 (National Institutes 
of Health Consensus Development Conference Panel Statement: 
Management of hepatitis C: 1997 and 2002). The addition of 
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ribavirin to alpha interferon improved response rates to 350/0 to 
45%) (McHutchison et al. 1999). Pegylated interferons have further 
improved response rates, such that 50-60% of patients can expect 
to have a sustained response with combination treatment using 
peginterferon and ribavirin (National Institutes of Health 
Consensus Development Conference Panel Statement: 
Management of hepatitis C: 2002). 
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1.52 Standard treatment for hepatitis C 
Pegylation is the process by which an inert molecule of 
polyethylene glycol (PEG) is covalently attached to a protein 
giving it a higher molecular weight and resulting in an increase in 
serum half-life. Two forms of pegylated interferon have been 
developed: Pegylated interferon alfa 2a (interferon a2a bound to 
40kDa molecule of PEG) and Pegylated interferon alpha 2b 
(interferon-a2b bound to 12kDA size PEG) (National Institutes of 
Health Consensus Development Conference Panel Statement: 
Management of hepatitis C: 2002; Alberti et al. 2003). The 
pegylated interferons are a once per week subcutaneous 
injection. Both Pegylated interferon alfa 2a (40 KD PegllFNa2a) 
and Pegylated interferon alpha 2b (12 KD PegllFNa2b) have 
different pharmacokinetics and pharmacodynamic properties; 40 
KD Peg!IFNa2a having a longer half-life and smaller volume of 
distribution compared to 12 KD Peg! IFNa2b «National Institutes 
of Health Consensus Development Conference Panel Statement: 
Management of hepatitis C: 2002). 40 KD PegllFNa2a is 
excreted mainly by the liver and is administered at a standard 
dose of 180ug; whilst 12 KO PegllFNa2b is excreted mainly by the 
kidney and is dosed by body weight (Alberti et al. 2003). 
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With the combination of peginterferon and ribavirin patients with 
genotype 1 achieve sustained viral response rates of 40-450/0 
after 48 weeks of treatment compared with rates approaching 
80% with genotypes 2 or 3 after a 24 week course (Manns et al. 
2001; Fried et al. 2002). Patients with genotype 2 and 3 may only 
need 24 weeks of treatment. Trials with the 40 KO PegllFNa2a 
show that patients with genotype 2 and 3 require a dose of 
ribavirin of 800mg daily to achieve optimal response rates, 
whereas 1000 to 1200 mg daily is needed for patients with 
genotype 1 (Manns et al. 2001; Fried et al. 2002). Analysis of 
quantitative PCR HCV at 12 week in genotype 1 treated patients 
is a predictive tool of future response (Pawlotsky J. 2002). 
Patients who are PCR HCV negative or who have >2 log HCV 
RNA drop have a high chance of achieving a sustained virological 
response at 48 weeks (Pawlotsky J. 2002). 
The side-effect profile of the pegylated interferon is similar to that 
seen with unmodified interferons (National Institutes of Health 
Consensus Development Conference Panel Statement: 
Management of hepatitis C: 2002; Alberti et al. 2003). 
Interferon based therapies are administered by subcutaneous 
injection and have a wide range of side-effects that significantly 
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impair an individuals' quality of life whilst they are receiving 
therapy. However, the majority of the unwanted side effects settle 
when therapy is discontinued. Pegylated interferon produce a 
similar side effect profile to unmodified interferon and include 
fatigue and flu-like symptoms (headache, myalgia, fever, rigors 
and joint pain) which usually occur a few hours after injection and 
may improve with oral paracetamol. Symptoms gradually improve 
by perseverance after 4-6 weeks of treatment. In addition patients 
may develop neuropsychiatric symptoms (irritability, depression, 
insomnia), nausea and thinning of the hair. The mild depression 
associated with interferon based therapies usually responds well 
to standard anti-depressant agents. Serious neuropsychiatric 
side effects to interferons can occur and include depression, 
paranOia, severe anxiety and psychosis (Alberti et al. 2003). In 
patients with a history of substance abuse, the psychiatric 
changes can lead to a disastrous relapse in alcohol or drug 
abuse. All patients receiving interferon should be closely 
monitored. Severe, suicidal depression does occasionally occur 
(and is more common in those with a previous history of serious 
psychiatric illness) and if this occurs treatment should be 
discontinued (National Institutes of Health Consensus 
Development Conference Panel Statement: Management of 
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hepatitis C: 2002; Alberti et al. 2003). In a majority of cases 
interferon causes mild neutropenia and thrombocytopenia and 
regular full blood counts and, if necessary dose adjustments, are 
required. Ribavirin comes in tablet form and may cause a mild 
haemolytic anaemia with a 2-3 gm fall in haemoglobin 
concentration and, again, regular monitoring and dose 
modifications are necessary. It is best avoided in patients with 
significant pulmonary or cardiovascular disease. Erythropoietin 
analogues can be used to treat the anaemia. Other side effects 
associated with ribavirin therapy include a dry cough, nausea and 
mouth ulceration. Very occasionally interferon based therapies 
induce autoimmune diseases, in particular thyroid disease. 
Ribavirin is teratogenic and female patients should have 
pregnancy tests performed prior to treatment and must avoid 
pregnancy during therapy and for six months thereafter as 
ribavirin has a very long terminal half life. Since ribavirin may 
accumulate in sperm, men should not father children whilst 
receiving therapy and for six months after discontinuation. 
Pegylated interferon monotherapy should be given to those 
patients in which ribavirin is contraindicated. 
Combination treatment with PEG-IFN (40 KO Peg/lFNa2a and 12 
KO Peg IFNa2b) and ribavirin has a side-effect profile very similar 
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to unmodified interferon and ribavirin, although the frequency of 
depression may be reduced with the 40 KO Peg/lFNa2a 
(Peglntron(r) Product Information; PEGASYS(r) Product 
Information). Premature withdrawal from therapy due to adverse 
events in the two pivotal clinical studies with pegylated interferons 
were of the order of 10-14%, which is similar to that with 
unmodified interferon and ribavirin (11%) (Manns et al. 2001; 
Fried et al. 2002) suggesting that the increase in efficacy seen 
with the pegylated interferons is not associated with an increase in 
adverse events. 
1.53 Which groups of patients should be treated? 
All patients should be assessed for the benefits and risks of 
therapy. For many patients a liver biopsy aids the assessment by 
both identifying the aetiology of liver disease and the degree of 
liver damage. When selecting patients with chronic hepatitis C for 
treatment one needs to identify those patients who are likely to 
develop significant liver damage. At present at our center all liver 
biopsies are scored using the modified histological activity index 
(modified HAI (Ishak) scoring system), and those patients with a 
fibrosis score greater than 2 qualify for treatment. A proportion of 
patients with minimal fibrosis but marked necroinflammation (total 
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necroinfiammatory score of greater than 3), have a higher 
potential for developing progressive disease and are also eligible 
for treatment. In chronic hepatitis C as described previously 
fibrosis progression is not linear. Therefore the cohort of patients 
with mild disease who do not qualify for treatment should have a 
repeat liver biopsy every 3-5 years to assess fibrosis progression. 
Those patients with fibrosis progression are offered treatment 
whilst those with no progression should continue being followed 
up. Our practice is very similar to national guidelines (National 
Institutes of Health Consensus Development Conference Panel 
Statement: Management of hepatitis C: 2002; Alberti et al. 2003). 
Treatment is also considered for extrahepatic manisfestations of 
HCV such as cryoglobulinaemia (National Institutes of Health 
Consensus Development Conference Panel Statement: 
Management of hepatitis C: 2002; Alberti et al. 2003). 
Treatment of patients with cirrhosis have revealed response rates 
to be lower with frequent serious side-effects (Lee et al. 2006). In 
compensated cirrhosis combination therapy with interferon alpha 
(3MU thrice daily) and ribavirin (1000mg-1200mg/day) results in 
SVR of 34% to 440/0 (Lee et al. 2006). Treatment of 
decompensated cirrhosis or recurrent hepatitis C after 
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transplantation may not be beneficial and should be undertaken 
with caution ideally in clinical trials. 
1.54 Previous non-responders or relapsers 
The success of retreating a patient who has failed a first course 
of antiviral therapy is dependent on a number of factors:- a 
previous relapse, previous treatment with interferon monotherapy, 
HCV genotype ( 2 and 3), low HCV RNA and having a significant 
decrease in HCV RNA levels during the initial course of treatment 
(Oavis G 2002). Retreatment of non-responders to standard 
interferon monotherapy using peginterferon and ribavirin has 
yielded SVR rates of 34% to 40% (Davis G. 2002). Retreatment of 
patients who relapsed after interferon monotherapy using 
peginterferon and ribavirin resulted in SVR of about 600/0 (Oavis 
G. 2002). 
1.55 Other Treatment Groups 
Treatment of children and pregnant women with HCV 
An estimated 100 000 children in the United States are chronically 
infected with HCV (Guido et al. 1998). Although the natural history 
of HCV infection acquired in childhood seems benign in the 
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majority of instances, infection can take an aggressive course in a 
proportion of cases leading to cirrhosis and end-stage liver 
disease during childhood. There should be increased awareness 
of prevention of perinatal transmission which is the major cause of 
new cases of HCV in children. There are very few studies on 
treatment in childhood; small studies on interferon monotherapy 
have reported sustained virological response rates of 350/0 to 400/0 
(Guido et a1.1998). Treatment for pregnant women with HCV is 
contraindicated. 
Treatment of mild disease 
Treatment with unmodified interferon and ribavirin was associated 
with relatively low response rates and unpleasant side effects. 
Therefore many patients and their clinicians felt at the time that 
treatment for this slowly progressive disease was often worse 
than the disease itself. As a result most treatment algorithms 
recommended that only patients with biopsy proven 
moderate/severe disease should receive treatment and this 
approach proved popular with both patients and their physicians. 
Lately, the increased response rates and reduced side effects 
seen with the pegylated interferons and ribavirin suggests that this 
approach may no longer be appropriate and increasingly clinicians 
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recommend that patients receive therapy without undergoing a 
liver biopsy. This approach is particularly appropriate for patients 
with genotypes 2 and 3 where 24 weeks of therapy is sufficient to 
eradicate the virus in nearly 800/0 of patients. 
A particular subset of patients with mild disease are those with 
normal liver function tests. Patients with normal serum alanine 
transaminases on three successive measurements, each 
measurement several weeks apart are classified as patients with 
'normal AL Ts'. Up to 25% of patients with chronic HCV infection 
have normal serum transaminases and the majority of these 
patients have minimal disease on liver biopsy (Bacon et at 2002). 
Early studies suggested that disease flares with an increase in 
serum ALT could occur when such patients were given interferon. 
Zeuzem et al. (2000) examined the benefits of treating such 
patients with pegylated interferon and ribavirin by conducting a 
randomised controlled clinical trial in this population using the 
40KD pegylated interferon alfa 2a plus ribavirin. There was no 
evidence from this study that patients with 'normal AL Ts' develop 
disease exacerbations when treated with the 40KD pegylated 
interferon and sustained virological response rates in these 
patients were similar to the response rates seen in other clinical 
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trials with this pegylated interferon. The SVR. in patients treated 
for 24 and 48 weeks with 40KD pegylated interferon alfa 2a and 
ribavirin (at a dose of 800mg) were 30% and 52% respectively 
(Zeuzem et al. 2000). This study was in concordance with 
previous observations which suggests that patients with genotype 
1 HCV infection need 48 weeks of therapy whilst patients with 
genotypes 2 and 3 require 24 weeks treatment. 
Treatment of Patients With Hepatitis C and HIV Co-Infection 
Until recently coinfected patients with HIV and HCV often died 
from the opportunistic infections associated with HIV related 
immunosuppression. However with the introduction of effective 
antiretroviral therapies the life expectancy of patients with HIV 
has been markedly lengthened (Graham et al. 2001). As a result, 
in the Western world liver disease secondary to chronic HCV 
infection is now becoming a major cause of morbidity and 
mortality among HIV-infected patients. Co-infected patients who 
are infected with both HIV and HCV as a result have more 
rapidly progressive liver disease and clinical trials with standard 
treatment regimes suggest that they respond poorly to 
combination therapy with standard interferon and ribavirin 
(Graham et al. 2001). 
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The effectiveness of pegylated interferons in the management of 
patients with HIV/HCV co-infection has been studied in two 
randomised clinical trials. The RIBAVIC study compared PEG IFN 
a2b and ribavirin with standard combination treatment (unmodified 
interferon and ribavirin) resulting in a SVR of 150/0 in genotype 1 
and 430/0 in genotype 2/3 patients (Perronne et al. 2004). PEGIFN 
was significantly more effective than IFN but 340/0 of patients 
discontinued pegylated interferon and ribavirin treatment due to 
side effects (compared to 36% in standard combination group) 
(Perronne et al. 2004). The APRICOT study comprised three arms 
:- standard combination, peginterferon a2a and placebo, and 
peginterferon a2a and ribavirin (800mg/day). SVR were 29% in 
genotype 1 and 62% in genotype 2/3 and 15% of patients 
discontinued treatment due to adverse events (Torriani et al. 
2004). 
Interactions between antiretroviral drugs and ribavirin can be 
harmful. Zidovudine should be used with caution when ribavirin is 
given, because both may produce anaemia (Dieterich D. 2002; 
Fried M. 2002). Didanosine should be avoided when taking 
ribavirin as there is a high risk of pancreatitis and lactic acidosis in 
all treated patients as well of liver decompensation in cirrhotic 
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patients (Salmon-Ceron et al. 2001; Kakuda et al. 2001). Patients 
should be advised of the possibility of experiencing severe weight 
loss, mimicking a rapid progression of Iipoatrophy, due to the 
potentiation of mitochondrial damage in the subcutaneous fat 
tissue when taking ribavirin and some nucleoside analogues 
(Garcia-Benayas et al. 2002). 
1.6 Fibrosis and Disease Progression 
In many patients with hepatitis C infection, progression of disease 
leads to fibrosis which is progressive and largely irreversible. It is 
the progression of fibrosis that ultimately leads to architectural 
distortion of the liver and cirrhosis. For these reasons, the rate of 
progression of fibrosis is the defining feature of the natural history 
of chronic hepatitis C. In some individuals the rate of fibrosis 
progression is rapid with its associated long term complications 
such as liver failure, portal hypertension and hepatocellular 
carcinoma whilst in other patients progression is slow after many 
decades of infection. The assessment of the stage and rapidity of 
progression are essential in determining prognosis and the need 
of therapy in individual patients. 
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Fibrosis is characterized by the deposition of collagen and other 
extracellular matrix proteins and their organization in complex 
polymers, which are insoluble and induce loss of the liver 
architecture. In chronic hepatitis C active fibrosis begins around the 
portal areas (periportal or zone 1 fibrosis) and gradually extends 
out into the lobules towards the central veins (zone 3) with septa 
formation and then bridging fibrosis (Dhillon et al. 1995). The final 
stage of fibrosis constitutes cirrhosis with extensive fibrosis linking 
portal and central areas and the nodular regeneration of the liver 
parenchyma (Figure 1). The hepatic stellate cell has emerged as 
the key fibrogenic cell in the liver and are activated from a 
quiescent lipocyte phenotype to a fibroblastic phenotype. In chronic 
hepatitis C the major fibrogenic cytokine, transforming growth 
factor (TGF-b) is increased and produces connective tissue growth 
factor which correlate with the degree of liver fibrosis (Olaso et al. 
1998). Conversion of stellate cells to a fibrogenic state occurs in 
the presence of TGF-b. This new myofibroblastic phenotype can 
proliferate, attract leucocytes and produce extracellular collagen 
and matrix proteins. During the fibrogenesis process, a basal 
membrane appears separating the hepatocytes from sinusoidal 
blood and disrupting the exchange of nutrients between blood and 
hepatocytes (capillarisation of the sinusoids). Liver fibrosis is 
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characterized by the transformation from normal extracellular 
matrix (basal membrane) into a reticular and dense matrix (fibrillar 
type) which is more resistant to enzymatic degradation. 
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Figure 1 The Metavir fibrosis staging system. 
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Liver biopsy remains the gold standard to assess the status of liver 
inflammation, potential progression of fibrosis, and the presence or 
absence of cirrhosis. Transcutaneous liver biopsy is the usual 
method, but transjugular biopsy may be useful for patients with 
clotting problems or ascites. A number of scoring systems have 
been defined. The Metavir scheme has been used by the French 
Metavir Cooperative study Group (Figure 1). The modified 
histological activity index or modified Ishak has been validated as a 
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suitable scoring system for chronic hepatitis C (Ishak et al. 1995; 
Westin et al. 1999). Fibrosis is identified in liver biopsies by 
connective tissue stains, such as trichrome, Azan or picrosirios red 
that identify extracellular matrix. Immunostaining of collagen can 
also be performed. Histologically chronic hepatitis C is difficult to 
distinguish from acute hepatitis and is often mild, but cirrhosis 
commonly develops. Other features include lymphoid follicles in 
portal tracts, damaged interlobular bile ducts, acinar activity 
including apoptotic bodies, large droplet steatosis, Iymphocytes in 
sinusoids, granulomas and Mallory bodies (Dhillon et al. 1995; 
Scheuer et al. 1996). However liver biopsy is prone to sampling 
error, it cannot be used to quantify the amount of scarring and has 
the potential for medical complications. The development of non-
invasive markers is an important future research goal, because 
they could be used to detect the extent of liver fibrosis, to define 
the natural history of disease, and to follow disease progression. 
There have been many studies on fibrosis in chronic hepatitis C ; 
most studies have been cross-sectional based on a single liver 
biopsy whilst a smaller number are longitudinal and based on 
patients who have two liver biopsies. There have been few 
prospective studies in chronic hepatitis C and those that have 
been performed have been limited in size. 
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Cross-sectional studies using mathematical modeling performed 
on large numbers of patients with a single liver biopsy suggest that 
the average (median) rate of progression of fibrosis in chronic 
hepatitis C is 0.13 Metavir fibrosis pOints per year (Poynard et al. 
1997). The average patient would develop cirrhosis in 30 years. 
The rate of fibrosis progression was higher for men than women 
(0.15 vs 0.11 fibrosis units per year), older than younger patients 
(0.33 if infected over the age of 50 vs 0.09 if below the age of 20 
years) and in heavy alcohol drinkers than in non-drinkers (0.17 vs 
0.12). The estimated average time for development of cirrhosis 
ranges from as short as 13 years in men to as long as 42 years in 
women. 
A more recent cross sectional study with mathematical modeling 
of 2213 patients proposed a new model for fibrosis progression in 
chronic hepatitis C in which fibrosis progression occurs at different 
linear rates in 4 consecutive phases of infection with acceleration 
after 50 years of age (Poynard et al. 2001). The first phase of 
infection represents the initial 10 years of infection followed by the 
second phase (lasting 15 years) where fibrosis progression is slow. 
This then proceeds to an intermediate third phase (lasting 10 
years) and lastly a rapid fourth phase. In this model the delay to 
the development of cirrhosis is approximately 40 years. In this 
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study only a small proportion of patients had an estimated duration 
of infection more than 20 years. The risk estimates suggested by 
Poynard et al. will probably be lower in unselected populations and 
progression is probably non-linear with advanced stages 
associated with accelerating, non-linear progression (Lagging et al. 
2002). 
There have been three recent longitudinal studies (1 prospective 
and 2 retrospective) of untreated patients with chronic hepatitis C 
who underwent 2 liver biopsies 3 to 8 years apart (Marcellin et al. 
2001; Ghany et al. 2000; Alberti et al. 2001). These three studies 
showed similar average rates of progression of fibrosis that 
predicted the development of cirrhosis in the average patient after 
30 to 40 years of infection. 
It is host rather than viral factors that are associated with disease 
progression. There is no relationship between genotype or viral 
load and fibrosis progression. The major factors known to be 
associated with fibrosis progression are i) older age at infection 
(>50 years of age); ii) male gender; iii) excessive alcohol 
consumption (> 50g per day); iv) co-existent HBV infection or 
,immunosuppression (Poynard et al. 2001.) Hepatic steatosis, 
obesity, diabetes mellitus and iron overload may contribute to more 
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rapid progression of fibrosis (Hourigan et al. 1999; Angelucci et al. 
2002). 
1.7 Relationship of Hepatitis C to Steatosis, 
Diabetes Mellitus and Insulin Resistance 
1.71 Steatosis and Hepatitis C 
Liver steatosis is common in patients with HCV, occurring in 
approximately 50% of biopsy specimens and is higher than in 
patients with chronic hepatitis B or autoimmune hepatitis (Scheuer 
et al. 1992; Bach et al. 1992). 
Liver steatosis develops in chronic hepatitis C patients by two 
mechanisms. 
Metabolic steatosis is independent of the HCV virus and is due 
to factors that cause non-alcoholic fatty liver disease (NAFLD). 
These are due to the metabolic syndrome such as diabetes, 
hypertension, obesity and dyslipidaemia (Adinolfi et al. 2001; 
Monto et al. 2002). This occurs in genotypes other than 3 and the 
degree of steatosis correlates with body mass index and visceral 
fat suggesting that insulin resistance may play a role. 
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The second mechanism of hepatocyte steatosis is HCV or viral 
induced and is due to a direct effect of the HCV itself (Rubbia-
Brandt et al. 2000), occurring mainly in genotype 3 strains. The 
degree of steatosis correlates with the level of HCV viremia and 
intrahepatic concentration of HCV RNA. This type of steatosis is 
directly linked with HCV replication and disappears on viral 
eradication of the genotype 3 strain. Relapse of the infection 
results in recurrence of the steatosis. 
Several cross-sectional studies confirm that body mass index 
(BM I) and infection with genotype 3 are two independent risk 
factors for steatosis in patients with chronic hepatitis C (Adinolfi et 
al. 2001; Monto et al. 2002). 
The mechanisms of HCV - induced steatosis in patients infected 
with genotype 3 are not fully understood. In humans the degree of 
steatosis is directly related with the amount of core protein. In 
vitro and in vivo studies confirm that HCV core protein can induce 
steatosis in transfected cells and transgenic mice (Barba et al. 
1997; Moriya et al. 1997). Studies on hepatoma cell lines have 
shown that HCV-induced steatosis is a result of the interaction 
between HCV via non structural protein NS5A or core protein, and 
triglyceride turnover (Shi et al. 2002). HCV is associated with 
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betalipoproteins (LDL and VLDL) in sera from infected patients 
and the LDL receptor is the receptor for the entry of HCV into 
hepatocytes (Thomssen et a!. 1992; Monazahian et a!. 1999). 
Serum levels of apoprotein B (a component of VLDL) is low and 
inversely related to the degree of steatosis and is corrected by 
HCV eradication. This suggests that steatosis in patients infected 
with genotype 3 could be the result of HCV- induced 
hypobetalipoproteinemia. These findings are consistent with the 
observation that the HCV core protein inhibits the activity of 
microsomal triglyceride transfer protein and the secretion of VLDL 
in transgenic mice developing steatosis (Perlemuter et al. 2002). 
Another mechanism involved in HCV induced steatosis could be 
mitochondrial dysfunction as is shown in transgenic mice 
expressing HCV proteins and developing steatosis ( Okuda et al. 
2002). 
There is no clear explanation why only steatosis associated with 
genotype 3 in human is viral in origin. In vitro expression models 
do not show a distinction between genotype 3 transfected 
hepatoma-cell lines compared to HCV core type 1 b, however 
these models may not be helpful as the level of HCV core protein 
is much higher in transfected cells than in the liver of infected 
patients (Abid et a!. 2002). 
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The impact of steatosis on the natural history of chronic 
hepatitis C 
Cross- sectional studies have proved the relationship between the 
degree of steatosis and the severity of fibrosis. In patients with a 
known date of acquisition of HCV, the progression rate of fibrosis 
is significantly higher in those with moderate to severe steatosis 
than those with no or mild steatosis (Adinolfi et al 2001; Serfarty 
et al. 2002). In patients with paired biopsies the degree of 
steatosis at initial biopsy is predictive of fibrosis progression 
(Westin et al. 2002; Serfarty et al 2001). 
Correlation between metabolic steatosis and fibrosis has been 
shown in obese patients, where non-alcoholic fatty liver disease 
(NAFLO) is contributing as suggested by the presence of 
perisinusoidal and centrilobular fibrosis (Ong et al. 2001; Clouston 
et al. 2001). The association between viral steatosis and 
fibrogenesis is still controversial at present as studies show 
conflicting results; and this could be due to the younger age of 
patients infected with genotype 3. 
The effect of antiviral treatment on steatosis 
In viral steatosis patients infected with genotype 3 strains of HCV 
treated with interferon alone or combination treatment have shown 
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significant reductions in the degree of steatosis in sustained 
virological responders (Poynard et al. 2002). This effect is 
independent of weight loss or reduction in alcohol consumption. In 
contrast there is no significant change of steatosis in sustained 
responders with non-genotype 3 strains. Normalisation of 
cholesterol in non-genotype 3 patients can result in reversal of 
steatosis (Poynard et a!. 2002). 
Three large cohort studies have investigated the impact of 
steatosis on antiviral therapy (Poynard et a!. 2002; Bjora et a!. 
2002; Akuta et al. 2002). In two studies steatosis was 
characterised into viral or metabolic steatosis (Poynard et al. 
2002; Bjora et a!. 2002), whilst in one study all patients were 
genotype 2 and hence metabolic (Akuta et al. 2002). The 
presence of moderate to severe steatosis (ie > 30%) at pre-
treatment liver biopsy in metabolic steatosis was highly predictive 
of failure to achieve a sustained viral response (SVR). Steatosis in 
genotype 1 patients resulted in two-fold decrease of the response 
rate (combination therapy) and threefold in genotype 2 (interferon 
monotherapy). Patients with non-genotype 3 strains should be 
advised to correct their risk factors for steatosis before starting 
anitiviral treatment as severe steatosis is a predictive factor of 
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treatment failure. Conversely, in genotype 3 response rates were 
similar between patients with and without steatosis. 
1.72 Hepatitis C and Diabetes Mellitus 
Chronic liver disease that leads to cirrhosis is a major cause of 
death in many areas of the world. Hepatocellular carcinoma 
(HCC) is one of the most common cancers in the world and 
develops in people with advanced chronic liver disease. Recently 
there is growing evidence that type 2 diabetes mellitus increases 
the risk of chronic liver disease and HCC. 
There is strong evidence of an association between chronic 
hepatitis C and diabetes mellitus. Allison et al. (1994) reported 
that in patients with cirrhosis being assessed for liver 
transplantation those patients with an aetiology of HCV were 
independently associated with type 2 diabetes. 
HCV infection has a significantly stronger association with 
diabetes than other liver diseases irrespective of whether cirrhosis 
was present. The Third National Health and Nutrition Examination 
Survey (N-HANES 111) showed that the rate of type 2 diabetes 
was three times more likely in HCV infected patients 40 years of 
age or older than patients without HCV infection. Conversely, 
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HCV positivity was higher among diabetic patients than the 
general population. Patients who undergo liver transplantation for 
HCV are more likely to become diabetic than for other liver 
conditions. 
Hepatocellular carcinoma is also associated with diabetes 
mellitus. Early epidemiological studies showed no association 
between diabetes mellitus and hepatocellular carcinoma, however 
lately several studies show a significant association (EI-Serag et 
al. 2001; EI-Serag et al. 2004). Lawson et al. (1986) reported a 
four fold increased incidence of diabetes in patients with HCC 
compared to controls. A large cohort study in Denmark reported a 
standardised incidence ratio of HCC of 4.0 in diabetic men (950/0 
Cl: 3.5-4.6) and 2.1 (950/0 Cl 1.6-2.7) in diabetic women as 
compared to the general population. Subsequent studies from 
United States and Europe have also confirmed this association 
(Wideroff et al. 1997). 
1.73 Insulin Resistance In HeV 
Insulin resistance plays an important role in the development of 
type 2 diabetes mellitus, preceding diabetes by 10 to 20 years. 
HCV infection can induce insulin resistance and insulin resistance 
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itself may increase the rate of fibrosis progression in HCV patients 
(Hui et al. 2003). The mechanisms by which HCV leads to insulin 
resistance and predisposes to Type 2 diabetes mellitus is not 
known. Insulin resistance is higher in non-genotype 3 patients. It 
is hypothesised that obesity especially central type body fat 
distribution and metabolic steatosis is associated with insulin 
resistance and secondary hyperinsulinaemia. Intracellular fat 
accumulation in mice models can result in defects in insulin 
signalling and insulin resistance (Kim et al. 2001). 
Studies from transgenic mice that specifically express the HCV 
core protein at high levels in hepatocytes show that hepatic insulin 
resistance can be induced by HCV core protein alone and is due 
to increased levels of tumour necrosis factor alpha (TNF-a) 
(Shintani et al. 2004). Insulins' action is mediated by binding to a 
cell surface insulin receptor, a ligand activated tyrosine kinase. 
Once insulin binds there is phosphorylation of the tyrosine kinase 
leading to a cascade of phosphorylation of a family of insulin 
receptor substrates (IRS 1-4). TNF-a inhibits phosphorylation of 
IRS-1 which may result in insulin resistance and type 2 diabetes. 
Insulin resistance and defects of IRS-1 are present before the 
development of steatosis suggesting that insulin resistance occurs 
first. The mice did not become diabetic until they were challenged 
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with a high fat diet which is similar to humans where an 
environmental stressor leads to diabetes. 
SUMMARY 
In the first part of the introduction I have set the scene and 
reviewed the knowledge of hepatitis C. At that time, hepatitis C 
represented a major public health problem world-wide and was a 
common cause of cirrhosis and hepatocellular carcinoma as well 
as the most common reason for liver transplantation. Hepatitis C 
is carried in the blood which is the main vehicle of infection and I 
have reviewed the common routes of transmission in both 
developed and developing countries and discussed which high 
risk groups should be offered treatment. Studies on natural history 
of chronic hepatitis C have differed widely and rarely exceeded 
two decades. Certain factors are associated with rapid 
progression to severe liver disease such as age> 40, alcohol 
consumption, male gender and co-infection with HIV and hepatitis 
B and immunosuppressive treatment. Finally, I discussed the 
methods of diagnosing hepatitis C and treatment of this condition. 
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1.80 Knowledge of Hepatitis C amongst Primary 
Health Care Professsionals 
General practitioners (GPs) are often the first health care 
professionals to see infected individuals. Given the fact that HCV 
infection is often silent until the very late stages it is imperative 
that GPs are aware of the risk factors, diagnosis, management 
and complications of this common, treatable infection to facilitate 
early diagnosis and referral. 
In France and Australia, primary care physicians have little 
knowledge about hepatitis C (Ouzan et al. 2003; Ouzan et al. 
2003; Shehab et al. 2001). In France, primary care physicians 
knowledge of HCV screening practices and investigation of risk 
factors are poor as is the natural history of this disease. In 
Australia, there was a wide range of responses, especially from 
non-English speaking backgrounds, regarding modes of 
acquisition of HCV in patients, rates of progression to cirrhosis 
and hepatocellular carcinoma and optimal antiviral therapy. This 
suggests a need to improve proviSion of appropriate educational 
resources that will facilitate general practice management of a 
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common and important public health problem. An educational 
outreach programme to improve health professionals knowledge 
about hepatitis C was piloted in Minnesota (Fischer et al. 2000). 
It achieved significant improvements in knowledge and high 
satisfaction ratings amongst the 1150 delegates that took part. 
The authors conclude that for an educational initiative to be 
successful it needs to be valuable to healthcare staff, have good 
incentives, repeated exposures, commitment by key stakeholders 
and a well- organized implementation plan. 
In the last few years hepatitis C has been extensively covered at 
national meetings, medical journals and popular press. The UK 
has a relatively low prevalence of HCV infection; it is estimated by 
the Department of Health to be between 200 000 to 400 000 
patients. As few as 100/0 of these individuals are aware of their 
infection. The remainder of patients with chronic hepatitis Care 
asymptomatic and are not aware that they are suffering from a 
progressive liver disorder. Considering the high proportion of 
people who are still unaware of their infection the Department of 
Health wrote to all GPs to inform them about hepatitis C and 
provided them with educational material to improve their 
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knowledge of this virus. The 45 page booklet sent to all GPs was 
developed with experts and key stakeholders in line with the 
principles set out in the NHS Plan (Hepatitis C Strategy for the 
UK; Department of Health). Its main aims are to prevent new 
cases of hepatitis C infection, identify those who are chronically 
infected by increasing testing for hepatitis C and to offer specialist 
advice and appropriate treatment via co-ordinated pathways of 
patient care thus facilitating prevention, diagnosis and appropriate 
referral at an early stage 
1.81 Screening 
Prevention and control of HCV infection in the UK must focus not 
only on reducing transmission in groups at high risk of infection, 
but also on the early identification of persons with chronic 
infection. The early treatment of hepatitis C with pegylated 
interferon and ribavirin is more likely to be successful in 
eradicating the virus, reducing transmission, and halting 
progression of fibrosis. Screening programmes are in place for a 
variety of medical conditions and are successful if the condition is 
common, and the screening test inexpensive, non invasive and 
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sensitive. Once identified the condition must be treatable and 
effective. 
Hepatitis C screening offers several benefits:- treatment can be 
offered to cure the patients or slow disease progression. Lifestyle 
modifications can be made such as ceasing alcohol intake and 
vaccinations for hepatitis A and B. Family members can take 
precautions against transmission and public awareness is 
increased. The National Hepatitis Screening Survey investigated 
a screening programme for hepatitis C in 40 centres in the United 
States. 13 997 subjects took part and 9 270 completed the study 
(Kaur et al. 1996; Lapane et al. 1998). This involved a detailed 
questionnaire followed by liver function tests and two antibody 
tests for HCV ( EIA-2 followed by confirmatory RIBA). 70/0 of 
patients were HCV positive, however this figure was higher than 
would have been expected from the prevalence of HCV in the 
United States. The reason for this is due to selection bias. 730/0 of 
patients had at least one risk factor, whilst Flamm et al. (1998) 
found that only 120/0 had no risk factor. The study concluded that 
it was much more cost-effective to pre-screen patients for 
hepatitis C risk factors and then only to test patients who had one 
or more risk factor. 
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The Department of Health (DoH) have advised testing of patients 
with the following risk factors:- past or current history of injecting 
drug use, history of receiving transfusion of blood or blood 
products, organ transplantation prior to the introduction of blood 
screening in 1991, needlesick injuries, tattooing or body piercing, 
sexual relations with a HCV infected partner, babies of a hepatitis 
C mother, renal dialysis patient, and people exposed to hepatitis 
C in other countries. 
SUMMARY 
In this section of the introduction, I have reviewed the present 
knowledge of general practitioners concerning chronic hepatitis C 
in the UK and discussed the current initiatives from the 
Department of Health to improve awareness of this disease 
(Hepatitis C Strategy for the UK. Department of Health). Primary 
care professionals knowledge in Europe and the United States 
and ways of improving this knowledge were also discussed 
(Ouzan et al. 2003; Ouzan et al. 2003; Shehab et al. 2001; 
Fischer et al. 2000; Dev et al. 2002; Zdanuk et al. 2001). 
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1.90 Complementary and Alternative 
Treatments of Chronic Hepatitis C 
The only approved treatment for hepatitis C is pegylated 
interferon and ribavirin which results in a sustained virological 
response of 50-60% of patients (Baker D. 2003). This treatment is 
poorly tolerated and expensive (Liang et al. 2000). It is highly 
desirable to develop alternative treatments for those patients who 
are not suitable candidates for standard treatment or who do not 
respond to treatment. Due to the high incidence of viral hepatitis 
in China, traditional Chinese Medicine has had a long history of 
treating chronic hepatitis. It is a popular treatment amongst 
hepatitis C patients with 41 % of patients in American liver disease 
outpatient clinics having used some form of Chinese herbal 
medicine within the past four weeks (Seeff et al. 2001). 
Coon et al. (2004) recently performed a systematic review of 
complementary and alternative treatments for hepatitis C. They 
searched six electronic databases for randomised clinical trails: 
Medline (via Pubmed), Embase, CINAHL, Amed (Alternative and 
Allied Medicine Database, British library Medical Information 
Centre), The Cochrane Library and the British Library Index of 
Conference Proceedings (from October 2002). Reference lists of 
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all papers were extensively searched for further publications. 
Each study was assessed using the Jadad scoring system for 
quality of the study (Jadad et al. 1996). 
The search revealed a total of 142 relevant studies of which finally 
27 studies (1709 patients in total) were included. The remainder 
were excluded due to no specific hepatitis diagnosis, mixture of 
hepatitis Band C patients, non-randomised trials or where clinical 
end-points were not measured. Only 11 out of 27 studies had well 
executed study design. 
Supplements 
1. Antioxidants 
Seven randomised trials of antioxidants comprising 463 patients 
have been published. In one trial Vitamin E treatment was 
compared to placebo (Von Herbay et al. 1997). There were 
statistically significant reductions in alanine aminotransferase 
(AL n in the vitamin E arm, however reductions did not occur 
exclusively in every patient and normalisation of liver enzymes 
were not seen. The remaining six studies combined antioxidants 
with interferon-alpha and no significant virological response 
between treatment arms were seen (Look et al. 1999, Neri et al. 
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2000, Andreana et al. 1997; Grant et al. 2000; Bernhard et al. 
1998; Ideo et al. 1999). 
No serious adverse events were reported in these trials at these 
doses. 
2. Thymic extracts 
Five randomised clinical trials of thymic extracts totalling 256 
patients have been published. In two trials patients received the 
synthetic polypeptide thymosin alpha 1 (Andreone et al. 1996) or 
complete thymic formula alone (Raymond et al. 1998). The 
complete thymic formula comprises bovine glandular extracts of 
thymosin, thymopoeitin and thymic humoral factors together with 
herbs, vitamins, enzymes and minerals. No significant difference 
in virological or biochemical response was seen between thymic 
extract or placebo. Thymosin alpha1 in two patients produced 
localised irritation at the injection site (Andreone et al. 1996) and 
complete thymic extract produced thrombocytopenia in one 
patients also taking naproxen (Raymond et al. 1998). 
In the three remaining studies the thymosin alpha 1 was 
combined with interferon and compared with either interferon or 
placebo alone (Sherman et al. 1998, Moscarella et al. 1998, 
Sherman et al. 1994). The combination arm was superior in terms 
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of significantly higher virological and biochemical responses at the 
end of treatment, together with increased numbers of patients 
with a sustained response at 6 or 12 months. Nausea and 
vomiting were more common in the combination arm. 
3. Zinc 
One randomised clinical study with zinc combined with interferon 
alpha was performed (Takagi et al. 2001). The combination group 
had significantly higher numbers of complete or incomplete 
responders (18/32 vs 8/36; p< 0.006). This may be explained by 
the increased number of low viral loads in patients in the 
combination arm as compared to interferon alpha arm alone. 
Side-effect profile was similar in both groups. Seven patients 
withdrew from the study; four from the interferon-alpha group 
alone (erythema multiforme, severe fatigue, headache, loss of 
consciousness) and three from the combination group ( loss of 
sleep, serious headache and interstitial pneumonia). 
4. Traditional Chinese medicine 
The main function of the liver in Chinese herbal medicine is to 
control the flow of intrinsic vital energy called qi. By contrOlling the 
free flow of qi it produces harmony of four systems: emotions, 
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digestion, menstruation, and secretion of bile. The liver also 
stores blood and controls function of tendons. Liver dysfunction 
results in following states: stagnation and depressive syndromes, 
deficiency syndromes and excess syndromes. 
Hepatitis is not mentioned in Chinese herbal medicine, however 
acute hepatitis resembles the damp heat syndrome. Patients who 
develop symptoms later in the chronic stage have a low-grade 
damp heat syndrome, with excess combined with deficiency. The 
herbs should drain the liver of excess heat and dampness, and 
support deficiency conditions while calming the emotions. 
Seven randomised studies of traditional Chinese medicine were 
found; six of which were of poor quality (score one on Jadad 
scale).( Han et al. 1997; Pei et al. 1996; Batey et al. 1998; Chen 
et al. 1998; Jiang et al. 1999; Xiao et al. 1999; Vu et al. 1995). 
The best quality trial compared Chinese herbs with placebo and 
found a significant reduction in AL T levels during treatment, but 
no decreases in HCV RNA levels (Batey et al. 1998). However 
four patients on the active herbal preparation developed 
palpitations, diarrhoea and abdominal discomfort. No significant 
difference was seen between Chinese herbal preparations and 
interferon (Chen et al. 1998). In combinations of herbal treatment 
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and interferon-alpha there was a trend towards normalisation of 
AL T and clearance of HCV RNA in the combination group. The 
problem with some of these studies is their poor study design, 
small numbers and the unknown effects of the control treatment 
preparations. More work is needed to evaluate the safety of these 
herbal preparations. 
5. Glycyrrhiza glabra (licorice) 
Stronger Neo Minophagen C (SNMC) is a formulation consisting 
of 0.20/0 glycyrrhizin, 0.1 % cysteine and 2 % glycine in 
physiological saline. Four randomised studies have been 
performed (Fujiyama et at 1998; Suzuki et al. 1996, Van Rossum 
et al. 1999; Tsubota et al. 1999). Patients receiving SNMC 
combined with interferon alpha found no significant difference in 
biochemical or virological response. The European study 
comparing SNMC alone with placebo showed reductions in AL T 
only during the treatment period (Van Rossum et aI.1999). This 
was also the case for the study comparing SNMC against SNMC 
and ursodeoxycholic acid, where there were statistically 
significant differences in liver enzyme levels between the 
treatment groups but these re-elevated after the study (Tsubota et 
al. 1999). There was no statistically significant difference in the 
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occurrence of side-effects in the SNMC arm, although Van 
Rossum et al (1999) reported cold/flu like symptoms in the 160mg 
SNMC group in his study. 
6. Oxymatrine (constituents of Sophora japonica) 
In one study oxymatrine was compared to general liver protective 
agents (Li et al. 1998) and at the end of treatment were found to 
have significant differences in the number of patients with 
normalised HCV RNA levels between groups. Information 
regarding the safety of oxymatrine was not available in this study. 
7. Silymarin (milk thistle) 
Silymarin is an extract of Milk Thistle (silybum marianurn). 900/0 of 
the herb's components contains silibinin which has been used as 
a treatment for liver disease and jaundice (Flora et al. 1998). 
Silymarin in experimental studies acts as an antioxidant or free-
radical scavenger preventing gluthathione depletion and free 
radical destruction (Campos et al. 1989). One large scale trial 
showed benefits of silymarin in patients with cirrhosis of all 
causes especially in patients with Child's A cirrhosis and alcohol-
induced liver disease (Ferenci et al. 1989). However, the design 
of this study was poor. Silymarin had no significant side effects. 
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There have been no randomised controlled studies of silymarin 
therapy alone on chronic hepatitis C. However, pilot studies 
suggest that silymarin can decrease AL T levels but has no effect 
on viral load. 
Significant improvements in biochemical and/or virological 
response were found in studies using Vitamin E, thymic extract, 
zinc, traditional Chinese medicine, Glycyrrhiza glabra and 
oxymatrine. Studies of thymic extract, zinc and Bing Gan 
decoction in combination with interferon alpha and oxymatrine 
alone have shown greater clearance of hepatitis C virus than 
placebo. The methodological design was poor in a number of 
studies and extrapolation of the results is difficult for the following 
reasons:-
i) The sustained virological response 6 months after 
stopping treatment was not measured. 
ii) Trials consisted of no more than 26 weeks of treatment, 
whilst conventional therapy (pegylated interferon and 
ribavirin) for genotype 1 patients continues for 48 weeks 
(Di Bisceglie et a!. 2002). 
iii) Patients response to conventional therapy is dependent 
on several favourable host and viral characteristics and 
whether this is also the case for complementary 
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treatment has not been elucidated as yet. It is not clear if 
non-responders were recruited into these studies. 
iv) Over half of the studies did not have proper blinding 
procedures or reporting of randomisation and 
withdrawals. 
Several of the studies have poor study design and more studies 
are needed to evaluate the role of complementary and alternative 
treatments together with their safety profiles for hepatitis C. 
1.91 Quality of Life Assessments in Chronic HCV 
In the last 10 years there has been an impetus to develop 
subjective measures of health to monitor medical outcomes 
(Geigle et at. 1990). These should incorporate measures of 
physical mobility, emotional wellbeing, social life and overall 
wellbeing. Any measure must be short, easy to complete, 
acceptable to patients and be fully validated for the illness 
process to be investigated. One of the more widely used 
questionnaires that meets these criteria has been the Nottingham 
health profile which comprises 38 items (see appendix). However 
this has been criticised due to its inability to detect low levels of 
disability. 
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A new questionnaire, the short form 36 (SF 36) is a shortened 
version of a battery of 149 health status questions that was 
developed from the Rand Corporation's health insurance 
experiment in the United States rNare et al. 1980; Stewart et al. 
1992). The SF36 is a short questionnaire (Table 3) with 36 items 
measuring eight multi-item variables: physical functioning (10 
items), social functioning (2 items), role limitations due to physical 
problems (4 items), role limitations due to emotional problems (3 
items), mental health (5 items), energy and vitality (4 items), pain 
(2 items), and general perception of health (5 items). 
1) Physical functioning (PF) - extent to which health limits 
physical activities such as self-care, walking, climbing 
stairs. 
2) Role Functioning- Physical (RP) - extent to which physical 
health interferes with work or other daily activities such as 
accomplishing less than wanted. 
3) Role Functioning - Emotional (RE) - extent to which 
emotional problems interfere with work or other daily 
activities. 
4) Bodily Pain (BP) - intensity of pain and effect of pain on 
normal work. 
5) Vitality (VT) - feeling energetic and full of pep. 
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6) Mental Health (MH) - general mental health, including 
depression. 
7) Social Functioning (SF) - extent to which physical health or 
emotional problems interfere with normal social activities. 
8) General Health (GH) - personal evaluation of health. 
The last item relates to changes in respondents' health over the 
last year. Modifications to six items were required to make it 
acceptable to British patients. Each variable item scores are 
coded, summed and transformed on to a scale from 0 (worst 
possible health state) to 100 (best possible health state). If an 
item is left blank then the developers suggest a method of gaining 
scores for missing values. 
The SF 36 has been shown to be acceptable to patients, has 
good test-retest properties and a valid measure of the health 
status of a wide range of patients (Brazier et al. 1992; Garratt et 
al. 1993). However it does not contain a variable on sleep. There 
was also a lower response rate among those over 65 years and 
different questionnaires may be required (Brazier et al. 1992). 
Many patients with chronic hepatitis C are asymptomatic; 
however non-specific symptoms such as fatigue, irritability, 
nausea, anorexia, headache, abdominal discomfort, right upper 
abdominal pain and even cognitive impairment have been 
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described (Conry et al. 1996; Poynard et al. 2002; Forton et al. 
2002; Bayliss et al. 1999). A number of studies have now 
challenged this previous belief that hepatitis C is an asymptomatic 
disease. Patients with chronic hepatitis C have been found to 
have a reduced health related quality of life ~are et al. 1994; 
Davis et al. 1994; Carithers et al. 1996; Bayliss et al. 1998). The 
causes of impaired health related quality of life in chronic hepatitis 
C is unknown, however psychiatric symptoms and emotional 
distress are more common amongst hepatitis C patients (Fontana 
et al. 2002). This study reviewed 220 untreated patients and 
detected emotional stress in 35% of the study population 
(compared to 10% in the general population) and the emotional 
stress correlated with a lowered health related quality of life. Both 
previous exposure to alcohol or intravenous drug abuse were not 
associated with emotional distress. Significant elevated scores for 
depression, anxiety, psychoticism, somatisation and obsessive-
compulsive disorders were detected in 28-40% of patients, whilst 
psychiatric and medical co-morbidities arose in 71 % of patients. 
Patients without cirrhosis also show reductions in both mental and 
physical health-related quality of life (SF36) (Foster et al. 1998). 
Patients with previous intravenous drug use have psychological 
104 
disturbances that impair their quality of life (Kendall et al. 1995; 
Lipsitz et al. 1994). The study by Foster et al. (1998) excluded 
patients with drug abuse and Davis et al. (1994) made 
adjustments for co-morbidities which can be associated with 
impaired quality of life. Both studies reported that the reduced 
health related quality of life is due to infection with hepatitis C 
itself. Three studies have looked at the effect of treatment for 
hepatitis C on health related quality of life data (Oavis et al. 1994: 
Hunt et al 1997; Bonkovsky et al. 1999). Oavis et al. (1994) found 
that the measure of health related quality of life (Sickness Impact 
Profile - see appendix) was insensitive to distinguish between 
responders and non-responders and Hunt et al. (1997) used a 
small sample that had insufficient power to detect a difference. 
Bonkovsky et al. (1999) concluded that health related quality of 
life (SF 36) was significantly impaired in patients with chronic 
hepatitiS C in the presence or absence of cirrhosis. The 
impairment is as large as other chronic illnesses such as diabetes 
mellitus and chronic arthritis. Treatment with interferon results in 
improvements in quality of life and the degree of improvement is 
directly related to the sustained virological and/or biochemical 
response to treatment. It appears that the SF 36 is better suited 
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for evaluating health related quality of life in patients with chronic 
hepatitis C and measuring the efficacy of treatment outcomes. 
SUMMARY 
In the last section of the introduction, I have reviewed the efficacy 
of complementary and alternative therapies of chronic hepatitis C 
together with quality of life assessments in chronic hepatitis C. 
106 
CHAPTER 2: METHODS 
2.1 Patient Population and Databases 
i) Patient Population 
The patient population described in this thesis all originate from 
North East London and all were attending Barts and the Royal 
London Hospitals for clinical care. This patient population has 
been used in several of the studies that follow:-
1) Natural History of Chronic Hepatitis C Infection: Life-Long 
follow-up of an unselected population infected in early 
childhood. 
2) Factors involved in progression of liver fibrosis in patients 
with Non-alcoholic steatohepatitis (NASH), hepatitis C and 
hepatitis B 
3) The Role of Steatosis in Fibrosis Progression 
4) Influence of Iron on Fibrosis Progression and Causation of 
Diabetes Mellitus in a Population with Chronic Hepatitis C 
5) Clinical Significance of Insulin Resistance in Hepatitis C 
Virus Infection 
The North East sector of London contains a diverse population. A 
high proportion of immigrants - over 30% are from 'ethnic minority 
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groups' which include first and second generation immigrants from 
Pakistan and Bangladesh (Figure 2). Health care services for 
immigrants in North East London are provided free under the 
provisions of The United Kingdom National Health Service. The 
mature immigrant communities in East London have excellent 
access to local health care services with a well developed system 
of Bengali speaking health care advocates and translators. 
Until 2003 patients with HCV and other hepatological disorders in 
North East London were managed by local gastroenterologists 
with an interest in liver disease working in one of the three 
regional hospitals (Barts and The London, The Homerton and 
Newham District General Hospital). During the period 1992 -2003 
none of the hospitals provided a tertiary referral service for 
patients with liver disease (although a transjugular liver biopsy 
service was provided by Barts and The Royal London in response 
to a request from the haemophilia service). Patients with 
advanced liver disease were referred to The Liver Unit at The 
Royal Free Hospital in the adjacent health care sector (London 
Central). Patients with hepatological disorders that did not require 
transfer to a tertiary referral center were managed locally. Patients 
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the virology service at Barts and The Royal London but refer 
patients with viral liver disease to a hospital outside the sector 
were excluded from the analysis. 
For patients with chronic HCV infection the diagnosis was 
established by serological and virological testing at a single, 
central laboratory. 
In accordance with national guidelines all patients who were 
viraemic (i.e. HCV RNA positive by PCR testing) had a liver 
biopsy performed, at their local hospital, and the tissue samples 
were sent to Barts and The London where they were examined by 
one of three consultant pathologists with an interest in 
gastroenterology/hepatology. All 3 pathologists operated under 
the same guidelines and scored the liver biopsy specimens 
according to a common system. These guidelines state that all 
patients who are HCV RNA positive should have a liver biopsy 
performed to assess the degree of fibrosis and/or suitability for 
treatment (Department of Health, NICE guidelines, Freeman et al. 
2003). 
Patients were recruited into these studies by searching through 
two independently maintained clinical databases. Appropriate 
patients were retrieved from each database (see relevant sections 
for the details of selection criteria for each of the studies). 
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ii) Central Virology Database 
This database has been used in several studies described below 
between the period 1992 -2003. The central virology database is 
stationed at Barts and the Royal London Hospital NHS Trust and 
contains a computerized record of all viral hepatitis patients dating 
from 1992. In this database information comprising viral serology 
(hepatitis B and hepatitis C) together with estimations of viral load 
(qualitative and quantitative) using Polymerase Chain Reaction 
for both HBV DNA and HCV RNA and genotyping for hepatitis C 
patients are available. From the virology database patients who 
were HCV RNA polymerase chain reaction positive (by qualitative 
PCR testing with a sensitivity of 50 IU/ml) were identified. HCV 
genotype was determined through sequencing of polymerase 
chain reaction amplicons from the 5' Non-Coding Region 
(TRUGENETM HCV 5'NC Genotyping Kit, Visible Genetics Inc., 
NJ, USA). This was performed by Dr Ines Ushiro-Lumb in the 
Department of Virology. 
The duration of antiviral therapy for HCV is determined by the 
genotype of the infecting virus. Patients infected with HCV 
genotype 2 or 3 received 24 weeks of therapy; whilst patients 
infected with HCV genotype 1 received 48 weeks treatment. If the 
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qualitative PCR HCV RNA assay (Cobas Amplicor TM HCV 
Monitor [version 2.0], Roche Diagnostics) was negative six months 
after completion of full course of antiviral treatment then the patient 
was considered to have had a sustained virological response to 
treatment. 
iii) Central Histopathology Database 
The central histopathology database has been used in several 
studies described below between the period 1992 -2003. This 
database is at Barts and the Royal London Hospital NHS Trust. 
The pathology department at Barts and the Royal London 
provides a pathology service to all three local district general 
hospitals and therefore contains a complete record of all liver 
biopsies throughout the region. 
There is a computerized record of all cytology and pathology 
reports that are stored at three sites:- St Bartholomews' Hospital, 
Royal London Hospital or London Chest Hospital. A reference 
number for the liver biopsy specimen can be found on the 
computer and this then has to be searched manually in the 
respective pathology library. Liver biopsies since 1983 were 
searched using this database. 
Histopathology reports for patients with HCV who had undergone 
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a liver biopsy were retrieved from the local pathology database by 
manual searching under the terms' viral hepatitis' or 'hepatitis C'. 
Biopsies were fixed, paraffin-embedded, and stained with 
haematoxylin, eosin, reticulin, PAS, Perls', Van Geison and Victoria 
Blue. Each biopsy was reviewed by one of the three histopathology 
consultants who specialise in gastrointestinal/liver pathology and 
then rescored by a second independent pathologist. Disagreements 
were resolved by discussion to reach a consensus score. 
According to Desmet et al. (1994) scores for necroinflammatory 
changes and architectural alterations were graded separately. The 
liver biopsies were scored using the Modified Ishak scoring system 
(Ishak et al. 1995) with fibrosis stage scored on a scale from 0 to 6. 
Portal and lobular necroinflammatory grades were also recorded 
using this same scoring system (Ishak et al. 1995). Steatosis was 
assessed as the percentage of hepatocytes containing 
macrovesicular fat droplets and was graded as no steatosis, mild 
«33% of hepatocytes affected), moderate (33%-66% of 
hepatocytes affected) or severe (> 660/0 of hepatocytes affected) 
steatosis. Two independent histopathologists graded hepatocyte 
and macrophage iron stores on a scale of 0 to 4 on Perls' Prussian 
blue liver sections ( Searle et al. 1994; Brissot et al. 1981). 
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For paired liver biopsies the stage, grade, degree of steatosis were 
recorded using each biopsy slide and accompanying pathology 
report. The degree of steatosis was recorded from the first biopsy in 
the series. Paired biopsies comprised 48 HCV patients and 11 HBV 
patients. 
Both the virology and histopathology databases were used in the 
following studies. All studies were approved by the local ethics 
committee (East London and the City Local Research Ethics 
Committee - PI 02/260 and P/02/240). 
1) Natural History of Chronic Hepatitis C Infection: Life-Long 
follow-up of an unselected population infected in early 
childhood 
2) Factors involved in progression of liver fibrosis in patients 
with Non-alcoholic steatohepatitis (NASH), hepatitis C and 
hepatitis B 
3) Influence of Iron on Fibrosis Progression and Causation of 
Diabetes Mellitus in a Population with Chronic Hepatitis 
4) Clinical Significance of Insulin Resistance in Hepatitis C 
Virus Infection 
iv) Patient Details 
Patient details such as age, sex, diabetes mellitus or impaired 
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glucose tolerance, plasma levels of glucose, insulin and C peptide 
and lipid profile, AST/ALT ratio, ferritin and ethnicity were obtained 
from the PAS hospital database that has computerized details of 
each patients details and blood results. If this was not available 
then patient notes were searched or previous blood samples 
analysed. Alcohol intake, mode of infection of hepatitis B or C and 
estimated date of infection were obtained from the medical 
records and questioning of patients at subsequent clinic 
attendances. Height which could not be retrieved from the medical 
records were obtained from telephone calls to the practice nurse of 
the patients' general practitioner. Body mass index was calculated 
for each patient by dividing the weight (kilograms) of the patient by 
their {height (meters)} 2. 
Impaired glucose tolerance was defined by the WHO classification 
as a fasting plasma glucose less than 7.0 mmolll and random 
venous plasma glucose two hours after an oral glucose tolerance 
test of between 7.8 and 11.1 mmolll. 
Patients were classified as diabetic according to the American 
Diabetes Association classification criteria -
1) Symptoms of diabetes together with a plasma glucose 
concentration more than or equal to 11.1 mmolll 
2) Fasting plasma glucose more than or equal to 7.0 mmolll 
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3) 2 hour post load glucose of more than or equal to 11.1 mmol/I 
during an oral glucose tolerance test. 
Serum ferritin was defined according to the WHO classification as 
raised in men if the level was greater than 300 ug/I and in women 
greater than 200 ug/I. 
Alcohol Intake was defined as non-drinker of alcohol, mild/moderate 
alcohol consumption if <14 units per week for females and <21 units 
of alcohol for males and heavy alcohol consumption if above these 
levels per week (Alcohol Concern 1999). 
Fasting plasma glucose, AL T and AST were measured using 
Olympus AU 640 (Olympus UK Limited). However, fasting insulin 
was analysed using the DPC Immulite 2000 analyser, Diagnostics 
Products Cooporation. HbA 1 c was measured by high pressure 
liquid chromatography using the H 1-Auto A 1 c, HA-8140 A Menarini 
Diagnostics. 
The gold standard for in vivo measurement of insulin resistance is 
the euglycaemic hyperinsulinemic clamp technique (American 
Diabetes Association. Consensus development conference on 
insulin resistance 1998). However, as this technique can induce 
severe hypoglycaemia, and cirrhotic patients are especially at risk 
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of this, we decided to use the Homeostasis model assessment for 
insulin resistance (HOMA-IR). This has previously been validated 
against insulin sensitivity measured directly with the euglycaemicl 
hyperinsulinaemic clamp technique in both diabetic and non-diabetic 
subjects (Emoto et al. 1999; Sonora et al. 2000). Using HOMA-IR 






fasting insulin (u U/ml) x fasting plasma glucose(mmolll) 
22.5 
2.2 Statistical Analysis and Patient Selection 
i) Natural History of Chronic Hepatitis C Infection: Life-Long 
follow-up of an unselected population infected in early 
childhood. 
Patients were divided into two groups - Asian patients and 
Caucasian patients. To begin with, simple univariate relationships 
between the fibrosis score and other factors were investigated 
using the Mann Whitney U test (ethnicity and gender) or 
Spearman's rank correlation coefficients (relationship with age). 
As both age and ethnicity were associated with the fibrosis score 
in univariate analyses, and the Asian patients were known to be 
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older than the Caucasian patients, the relationship between 
ethnicity and the score was investigated using a linear regression 
model, after adjusting for age differences between the two 
populations. This allowed us to isolate the relationship between 
ethnicity and the fibrosis score that could not be explained by 
differences in ages between the two populations. The possible 
confounding effects of other factors, including sex, HCV genotype, 
alcohol consumption and body mass (BMI), were then removed by 
incorporating these factors into the same multivariable regression 
model. The possibility that the relationship between fibrosis score 
and age differed by either ethnic group or sex was investigated by 
incorporating interaction terms between ethnic group, sex and age 
into the multivariable model. 
For the purposes of these linear regression analyses, the fibrosis 
score was taken as the dependent variable in the model. 
Although the fibrosis score is not strictly quantitative (it is an 
ordinal variable taking values from 0 to 6), visual assessment of 
the values confirmed that it would be reasonable to make this 
assumption for the purposes of our analyses. Inspection of the 
residuals from the multivariable regression analyses confirmed 
that this assumption was reasonable. However, as a sensitivity 
analysis, we also modeled the odds that a patient had cirrhosis 
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(fibrosis score of 6) using multivariable logistic regression. The 
conclusions reached from this approach were consistent with 
those from the linear regression models (results not presented). 
Paired biopsies in 48 patients were used to calculate the annual 
rate of fibrosis progression (the difference in the two scores 
divided by the time between the biopsies) and these rates were 
compared between groups using the Mann-Whitney U test. 
Comparisons of factors in different subgroups of the study 
population were performed using Chi-squared or Fisher's exact 
tests (for qualitative variables) or Mann-Whitney U tests (for 
quantitative variables). Correlations between pairs of quantitative 
variables were performed using Spearman's rank correlation 
methods. 
Statistical analyses were performed with the assistance of Prof 
CA Sabin, Department of Primary Care and Population SCiences, 
Royal Free and University College Medical School, London. 
ii) Influence of Iron on Fibrosis Progression and Causation 
of Diabetes Mellitus in a Population with Chronic Hepatitis C 
Due to the heavily skewed nature of ferritin levels, levels were 
summarized using medians and ranges, and by calculation of the 
proportion of men with a ferritin level greater than 300 ug/I and 
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women with a ferritin level greater than 200 ug/1. Comparisons of 
ferritin levels in different subgroups of the population were 
performed using Mann-Whitney U tests (for comparisons of the 
median values) and Chi-squared or Fisher's exact tests (for 
comparisons of the proportion of men with a ferritin level greater 
than 300 ug/I and women with a ferritin level greater than 200 
ug/I). Relationships between the presence of iron deposition or a 
diagnosis of diabetes/impaired glucose tolerance and 
demographic and clinical status were performed in a similar way. 
Factors independently associated with the stage of fibrosis were 
identified using multivariable linear regression models, by treating 
the stage of fibrosis as the outcome in the analysis. 
Statistical analyses were performed with the assistance of Prof C 
Sabin. 
iii) Clinical Significance of Insulin Resistance in Hepatitis C 
Virus Infection 
Comparisons of factors in different subgroups of this study 
population were performed using Chi-squared or Fisher's exact 
tests (for categorical variables) and Mann-Whitney U tests (for 
numerical variables). Correlations between pairs of numerical 
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variables were analysed using Spearman's rank correlation 
methods. 
Factors independently associated with stage of fibrosis were 
identified using multivariate linear regression analyses. Factors 
independently associated with sustained virological response 
were identified using multivariable logistic regression. 
All analyses were performed using the Statistical Analysis System 
(SAS) version 8.02. All p-values are two-sided and were 
considered to be significant if they were less than 0.05. 
2.3 Clinical Significance of Insulin Resistance in 
Hepatitis C Virus Infection 
Methods 
a) Patients and Protocol 
This was an open labelled study in which consecutive patients with 
chronic HCV who required antiviral therapy were enrolled. Antiviral 
treatment for HCV comprises a full course of treatment with 
pegylated interferon 2a plus ribavirin . 
HCV infected patients with a liver biopsy confirming this diagnosis 
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who were eligible for antiviral therapy were considered for inclusion 
in the study. Patients were required to have had a recent liver 
biopsy (within the last six months from starting date of the study) 
showing mild, moderate or severe disease. Patients with evidence 
of cirrhosis on biopsy were only accepted for entry into the study if 
they had compensated cirrhosis (Child-Pugh score A). Entry 
criteria included patients aged between 18-70 years who were 
HCV antibody and HCV RNA positive. Patients with other causes of 
liver disease were excluded from this study. All patients had to be 
willing to use effective contraception during the duration of the 
study. Exclusion criteria included patients who were diabetic, 
pregnant, unable to take effective contraception during the trial, had 
an abnormal ECG, decompensated cirrhosis (Child-Pugh score of 
B or C) or any contraindication to combination treatment. Patients 
who were diabetic according to the American Diabetes Association 
classification criteria (described previously) were excluded from the 
study. 
Each patient had characteristics such as body mass index (BMI). 
alcohol intake, ethnicity and HCV genotype recorded. A total of 59 
patients were recruited of whom 49 were male and 10 female (Table 
1). Ages varied from 34-60 years. 30 patients were Caucasians and 
29 patients Asian. 
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b) Liver Biopsy 
Each patient had a liver biopsy that was prepared as previously 
described. The biopsies were examined as described above. The 
liver biopsies were scored using the Modified Ishak scoring system 
and steatosis was assessed. 
The majority of patients (85.20/0) in this study had stage 1-4 
according to modified Ishak scoring on liver biopsy. 
c) Laboratory Investigations 
Before starting antiviral treatment patients had the following blood 
tests. They were required to fast for 12 hours and venous blood was 
then drawn for fasting plasma glucose, insulin, alanine 
aminotransferase (AL T) and aspartate aminotransferase (AST) , 
values and glycosylated haemoglobin (HbA 1 c). 
We decided to use the Homeostasis model assessment to measure 
insulin resistance (HOMA-IR). 
The duration of therapy was determined by the genotype of the 
infecting virus. They received a full course of treatment unless they 
chose to stop treatment prematurely. If patients were unable to 
tolerate one of the antiviral treatments then the dose of either the 
offending pegylated interferon or ribavirin were reduced 
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respectively to see if this was tolerated better, before considering 
stopping treatment altogether. The sustained virological response 
to treatment was determined for all patients completing treatment. 
All patients began treatment, however seven (11.50/0) did not tolerate 
treatment and withdrew during the first 12 weeks. In these patients 
we tried first to reduce the dose of the offending antiviral agent, to 
make it more tolerable to the patient. They still were unable to 
tolerate treatment and eventually withdrew. This left a total of 52 
(88.1 0/0) patients, comprising 27 Caucasians and 25 Asians, who 
completed treatment. 
2.4 Knowledge of Chronic Hepatitis C among 
East London Primary Care 





A self-administered questionnaire of eight closed and two open 
ended questions was devised. Questions comprised the most 
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important information a GP requires in order to screen, test, 
diagnose and refer patients with HCV for treatment. All answers to 
our questions could be found within the DoH Hepatitis C booklet, 
sent to all GPs in the UK in August 2002. Ten senior 
practitioners were chosen from primary care trusts in the East 
End. Dr Comfort Ossonaya chaired the meeting and the 
questionnaire was reviewed by all members for content and 
relevance to them. Six of the panel suggested two further open 
ended questions, which we included. 
Permission was obtained from four primary care trusts in the 
South East sector of London to pilot the study. The 250 South 
East London GPs were randomly selected from 750 GPs and the 
revised questionnaire then mailed to 250 GPs in the South East 
in June 2003. GPs were asked to FAX their replies to a central 
office. 
Following the success of the pilot study we then decided to send 
out the questionnaire to the original target population of GPs in 
the North East London. 600 GPs were selected randomly from 
650 GPs in the North East and the questionnaire was mailed to 
the GPs as detailed above. 
The majority of GP practices have multiple partners whilst less 
than 5 % of GP practices were single partners. The South East 
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region serves an underprivileged area with high levels of 
unemployment where 300/0 of the population comprise 2nd and 3rd 
generation Afro-Carribeans, whilst the North East region serves a 
generally deprived area with over 30 % of the population being 
derived from the Asian continent. Both regions are reported to 
have people who inject drugs. 
GPs who did not reply within the first six weeks were sent a postal 
reminder with a repeat questionnaire. After a further six weeks if 
they still had not replied they were telephoned and were offered 
an appointment for an interviewer to come to the surgery or 
telephone them at a convenient time to aid filling in the 
questionnaire. 
After 6 months the study was closed. 
We randomly selected 10 GPs for face-to-face open-ended 
interviews derived from the cohort of GPs from the North East of 
London who had been invited to complete the questionnaire. This 
was performed in order to try and assess the reasons for GPs 
lack of knowledge and means by which this knowledge could be 
improved. The interview was carried out in a standardised 
manner in the form of a list of structured open ended questions 
with responses recorded. Selected GPs were telephoned and 
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asked if they were willing to participate. Only six agreed and a 
further four were selected. These latter four consented to be 
interviewed. All ten physicians were sent a letter thanking them 
for participating and confirming the time and date of the interview. 
2.41 Improving General Practitioners Knowledge of 
Chronic Hepatitis C Infection 
Methods 
Educational programmes were set up for general practitioners 
about hepatitis C at Queen Marys School of Medicine and 
Dentistry in North East London. The educational programmes 
consisted of 'Iunch-and-Iearn' sessions. Previous studies have 
shown that for an educational initiative to be successful it requires 
five key elements (Fischer et al. 2000; Davis et al. 1995):-
1) value to healthcare staff (quality and importance of the 
topic) 
2) incentives (ie convenience, free lunch and continuing 
medical education pOints) 
3) repeated exposures (multiple opportunities for learning) 
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4) commitment by key stakeholders at the OH and clinicians 
5) an exceptionally well-organised implementation plan 
Our group incorporated these elements into our four lunch time 
meetings. The goal of this project was to provide basic information 
about the diagnosis and treatment of HCV that was relevant to 
General Practitioners. A development team including members of 
the study team (myself and Professor GR Foster) and a practising 
GP (Dr Comfort Osonnoya) met to ensure that both administrative 
and clinical perspectives were represented during the design and 
implementation of the education programmes. 
The educational programme for GPs was titled 'Hepatitis C: All 
You Need To Know', and consisted of 1-hour lunch-and-Iearn 
sessions. They were advertised widely to all GPs in East London 
via the primary care trusts four months in advance. GPs then 
telephoned or returned a reply slip to book one of the four 
sessions. If they were unable to attend they were asked to give a 
reason so that future meetings would take this into account. Eight 
weeks prior to the sessions they were sent a self-questionnaire 
composed of eight closed and two open ended questions that had 
previously been used by our group to assess GPs knowledge of 
chronic HCV (O'Souza et al. 2003). This assessed participants' 
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knowledge of basic HeV facts, risk factors, diagnosis, and 
treatment options and baseline knowledge. To the general 
practitioners who attended educational meetings all programmes 
were offered on site, and participants received lunch and 
continuing medical education credits. The programme was 
conducted during October 2003 and November 2003. Two 
experienced presenters with research and clinical experience of 
HeV presented information on chronic HeV infection and at the 
end of the session the participants were evaluated and were 
asked to complete the original questionnaire once more. 
Participants also completed an anonymous evaluation form at the 
end of the session to assess whether the meeting was of use and 
what improvements could be made in the future. 
To address the needs of GPs who were unable to attend the 
meetings we developed a summary sheet that incorporated the 
key educational messages. This single page information sheet 
was sent to 200 GPs from East London who were selected on the 
basis of a poor response to our original questionnaire (all had 
answered three or more questions incorrectly) and the general 
practitioners were asked to complete and return the original 
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questionnaire for the second time after reading the summary 
sheet. 
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2.5 Treatment Study 
2.51 Study to assess the safety and effectiveness of 
Phynova-17 (PYN-17) in the treatment of Hepatitis C 
Virus related symptoms 
This was a double blind, randomised, placebo-controlled, parallel 
group study of PYN-17 - a combination of traditional Chinese 
herbal medicines (TCM) for the treatment of chronic hepatitis C. 
The effectiveness of herbal treatment was assessed using quality 
of life data (symptom improvement), liver function tests and HCV 
viral load. Male and female subjects aged between 18 and 70 with 
biopsy proven hepatitis C who were refractory to, unwilling or 
unable to take interferon/ ribavarin therapy were recruited. 
STUDY OBJECTIVES 
The primary objective of this study was to indicate whether 
chronic hepatitis C patients on active treatment showed significant 
improvement in the SF36 quality of life questionnaire scores when 
compared to the placebo group. 
Secondary objectives were: 
131 
• to indicate whether patients on active treatment showed 
significant reduction in AL T when compared to the placebo 
group 
• to indicate whether patients on active treatment showed 
significant reduction in AST when compared to the placebo 
group 
• to determine whether treatment reduced serum viraemia 
• to demonstrate the clinical safety of the product. 
• to show an improvement in Fatigue Symptom Score (FSS) 
INCLUSION CRITERIA 
Subjects met all of the following criteria at screening in order to 
be considered for this study. 
1. Male or female aged 18 - 70 inclusive on date of screening 
2. HCV RNA and antibody positive 
3. HbsAg negative 
4. HIV antibody negative 
5. Liver biopsy within the last 5 years which showed features of 
chronic hepatitis C without cirrhosis 
6. Normal thyroid function tests 
7. Serum ferritin within 2x upper limit of normal 
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8. Normal serum albumin 
9. Normal prothrombin index 
10. Refractory to, unwilling or unable to take interferon! ribavarin 
therapy 
11. Showed symptoms typically associated with chronic hepatitis 
C infection 
12. Sterilized, used hormonal contraception or prepared to use 
barrier forms of contraception 
13. Full understanding of the study requirements and the need to 
comply with the protocol 
14. Signed Informed Consent Form 
EXCLUSION CRITERIA 
Subjects who met any of the following criteria at screening were 
excluded from study participation: 
1. Ongoing chronic illness that required regular medication 
including unstable diabetes, hypertension and asthma 
2. History of significant cardiovascular disease/disorder 
3. Administration of antiviral therapy within the 6 months prior to 
screening 
133 
4. Concurrent administration of any other investigational drug or 
participation in a research study within the last three months 
5. Sexually active females not employing reliable contraceptive 
methods 
6. Pregnant women and nursing mothers 
7. A history of recent (within 6 months) alcohol or drug abuse 
8. Clinically significant abnormal haematological or biochemical 
parameters other than those associated with hepatitis. 
WITHDRAWAL FROM THE STUDY 
Participation in the study was strictly voluntary. Subjects could 
withdraw from the study at any moment for any reason. This 
would not in anyway affect their further medical care. The 
investigator had the right to terminate participation of any subject 
at any time if it was in the subject's best interest or if the protocol 
was violated. The reason and circumstances for premature 
discontinuation were documented. 
METHODS:- STUDY DESIGN AND PLAN 
Study medication were taken over a 24-week period, and patients 
attended a follow-up visit at four weeks after the final dose was 
taken. 
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ASSESSMENT (See Table 4) 
Table 4 Assessments to be performed during the study 




Demographics & vital signs 
Review of concomitant medication 
Laboratory blood and urine sampling 
Pregnancy tests (females only) 
SF36 Quality of life questionnaire & FSS 
Physical examination 
Significant Medical history & Concurrent disease 
Quantitative PCR for HCV RNA 
Dispense medication for first 2 weeks treatment 
VISITS 2 - 5 Review of Adverse events and concomitant 
(after 2, 6, 12 and 16 medication 
weeks treatment) Laboratory blood and urine sampling 
Measurement of vital signs, and weight 
Pregnancy test (females only) 
VISIT 6: 
(after 24 weeks 
treatment) 
Dispense medication to last until the next visit. 
NB - at week 12 (visit 4) thyroid function will also 
be assessed 
Review of Adverse events and concomitant 
medication 
Laboratory blood and urine sampling 
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Measurement of vital signs, and weight 
SF36 Quality of life questionnaire & FSS 
Physical examination 
Quantitative PCR for HCV RNA 
Patients discontinued their trial medication at this stage and four weeks later 
a final assessment was made involving: 
COMPLETION Review of Adverse events and concomitant 
VISIT 7: medication 
Laboratory blood and urine sampling 
Measurement of vital signs, and weight 
Physical examination 
Quantitative PCR for HCV RNA 




quality of life associated with chronic hepatitis C 
infection by improving the symptoms of fatigue and 
poor concentration associated with Hepatitis C 
infection. 
Secondary Endpoints: To reduce hepatic 
inflammation (measured as an improvement in liver 
function tests) in patients with chronic hepatitis C 
and to reduce circulating viral load. 
Adverse events 
General well being 
Laboratory parameters 




At the first meeting, the subjects were informed about the study 
and the randomisation process; and provided with information 
about PYN-17. They received the study information leaflet that 
described in more detail the risks and benefits implicit in taking 
part. Subjects were then encouraged to consider the implications 
of participating, to discuss the possibility with, if appropriate their 
partner, their general practitioner, and to ask for any further advice 
as necessary. The investigator and/or research nurse were 
available to answer any additional questions. Subjects who 
wished to take part attended a study screening visit. 
Screening Visit 
Subjects who agreed to take part were asked to sign a consent 
form in the presence of the investigator for the study. The 
general practitioner was informed if the subject agreed. 
At the screening visit, the following information were collected and 
assessments performed: 
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• subject's initials and demographics 
• age, weight and height 
• vital signs 
• Physical exam 
• medical history of significant or severe past illnesses) 
• method of contraception and pregnancy test for females 
• understanding of TCM principles regarding treatment of 
hepatitis 
• concomitant diseases and hypersensitivities 
• concomitant medication 
• quality of life questionnaire 
• fatigue symptom scale 
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Laboratory blood and urine tests were carried out which 
included the following: 
• Quantitative PCR for HCV RNA 
• Liver function tests 
• Renal Profile 
• Thyroid function tests 
Subjects who met the entry criteria were randomised on a 1: 1 
basis to an Active (PYN-17) or Control (placebo) group. The 
active group received 1.41 gm of PYN-17 twice daily in the form 
of sachets of dry powder reconstituted to form a suspension. The 
placebo preparation was a similar dry powder that was dissolved 
in water with a similar taste. 
Visits 2 - 5 
Subjects were seen within approximately 2, 6, 12 and 16 weeks 
after start of treatment at which times the following procedures 
were carried out: 
• Review of Adverse events and concomitant medication 
• Laboratory blood and urine sampling 
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• Measurement of vital signs and weight 
• Physical exam 
• Pregnancy test (females only) 
• Dispense medication to last until next visit 
Laboratory blood and urine tests were performed as follows: 
• Liver function tests 
• Full blood count 
• Renal profile 
At week 12, thyroid function was assessed. 
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Visit 6 
Subjects were seen at 24 weeks after start of treatment for Visit 6. 
This visit included 
• Review of Adverse events and concomitant medication 
• Laboratory blood and urine samples 
• Measurement of vital signs, and weight 
• Quality of life questionnaire 
• FSS 
• Physical examination 
• Pregnancy test (females only) 
Laboratory blood and urine tests were performed as follows: 
• Quantitative PCR for HCV RNA 
• Liver function tests 
• Full blood count 
• Renal profile 
• Thyroid function tests 
Medication were not dispensed at this visit. 
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Follow-up visit 
Subjects were asked to return four weeks after stopping study 
medication for a follow-up visit. At this visit the following 
procedures were carried out: 
• Review of Adverse events and concomitant medication 
• Laboratory blood and urine sampling 
• Measurement of vital signs and weight 
• Physical examination 
• Quantitative PCR for HCV RNA 
• Pregnancy test (females only) 
Final laboratory samples were taken for the following tests: 
• Quantitative PCR for HCV RNA 
• Liver function tests 
• Full blood count 
• Renal profile 
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The PYN-17 was designed by the herbal company and was 
claimed to reduce fatigue and tiredness in chronic hepatitis C 
patients and normalise liver function Le. AST and ALT. The 
formula comprises four herbs:- Astragalus root, Milk thistle, 
Schisandra fruits and Salvia root made up into a dry powder 
(1.41 g) that can be reconstituted in 15-25 ml of a taste masked 
suspension (See Table 5). The herbal company also provided the 
placebo as a sachet of dry powder that can be reconstituted into 
15-25 ml of a taste masked suspension. 
No significant side effects had been observed in the clinical 
studies conducted for milk thistle fruit and astragalus root; 
Schisandra fruit had been made into drinks and was available for 
sale in the UK; Sa/via miltiorrhiza root as one of the three 
ingredients in a different herbal formula had obtained an indication 
from the FDA. 
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Table 5: Properties of the ingredients of PYN 17 (based on Chinese, 
German and Russian Pharmacopoeia). 
Name Actions Indications 
Astragalus root Liver protection - Chronic hepatitis 
Prevent decrease of hepatic Cancer 
glycogen and raised levels of total 
serum protein and albumin 
Immunorestorative activity -
Increased phagocytic activity 
Milk thistle Liver protector - Toxic liver damage, 
antioxidative, anti-lipid supportive treatment in 
peroxidative, antifibrotic, anti- chronic inflammatory liver 
inflammatory, immunomodulating disease and hepatic 
and liver regenerating effects cirrhosis, ischemic injury, 
radiation toxicity and viral 
hepatitis 
Schisandra fruits Tonic Hepatitis A, B or C 
Tranquillising 
Liver protector-
Lowers elevated SGPT levels 
Reduces! inhibits liver damage 
Anti-oxidant activity 
CNS action-
Increased concentration, fine co-
ordination, sensitivity and 
endurance 
Salvia root Various Cardiovascular effects Acute liver damage 
Liver protector - Chronic hepatitis 
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Regulates liver enzyme 
production, reduces! reverses 
fibrosis 
Lowers elevated SGPT levels 
Immune regulator-
Increased macrophage activity 
SELECTION OF STUDY POPULATION 
The SF36 questionnaire measured 8 different health modalities. 
These was combined to provide a physical and mental health 
summary scale and changes of greater than 5 points in the 
summary score were regarded as clinically significant. Assuming 
a p value of 0.05 to be significant 33 patients in each group were 
required to detect a difference between the two treatments with a 
power of 80%. To allow for treatment withdrawals we aimed to 
recruit a total of 76 patients. 
BLINDING 
This was a double blind study, neither the investigators nor the 
subjects were aware who was on active treatment or placebo 
during the trial. Active preparations and placebo were 
indistinguishable by appearance. Knowledge of the randomisation 
list was limited to the pharmacist responsible for creation of the 
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randomisation list, preparation of the random code envelopes and 
preparation of the study medication. Once treatment of the last 
subject (Le. final examination of the last subject), and entry of the 
case report forms into the database were completed, then the 
randomisation list was unblinded. 
The randomization list allocated each treatment number to one of 
the two possible groups. The randomization list was initially drawn 
up for 100 treatment numbers in order to provide for drop-outs 
and will be computer generated. Randomization was not stratified 
for age or other criteria. 
Together with the study medication the investigator received a 
sealed random code envelope for each individual subject number. 
The sealed random code envelope was opened only in case of 
emergency when knowledge of the actual treatment became 
medically necessary. 
PRIOR AND CONCOMITANT THERAPY 
The use of any new medication, other than study medication, was 
avoided where possible during the double-blind phase 
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TREATMENT COMPLIANCE 
The subjects returned all used and unused medication containers 
and any remaining study drug at the next scheduled visit, where 
the returns were counted and documented. 
EFFICACY AND SAFETY VARIABLES 
Safety was measured and assessed by means of Adverse Event 
recording, pregnancy tests (females only), laboratory results, and 
patients general health. 
Every randomised subject who received at least one dose of study 
medication was included in the safety analysis. Quality of Life 
Questionnaire scores were recorded and summarised by 
treatment group. Laboratory parameters taken at each visit were 
recorded and summarised by treatment groups. All adverse 
events were recorded and summarized by treatment group. 
Serious and non-serious adverse events were reported to 




An adverse event was any undesirable experience that occurred 
in a subject during the clinical trial, regardless of whether or not it 
was considered to be related to the investigational product. 
With respect to intensity, adverse events were classified as 
follows: 
Mild Some awareness of symptoms, but easily tolerated. 
Moderate Symptoms that caused enough discomfort to 
interfere with usual activity. 
Severe Incapacitating event that caused inability to work or 
to perform usual activity. 
ASSESSMENT OF CAUSALITY 
The following criteria were used for the assessment of the causal 
relationship to the test medication. 
None (Unrelated, Not related, No relation): The time course 
between administration of the study drug and occurrence or 
worsening of the adverse event ruled out a causal relationship 
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and another cause (concomitant drugs, therapies and 
complications etc.) was confirmed 
Remote (Unlikely, doubtful, Improbable): The time course 
between administration of the study drug and occurrence or 
worsening of the adverse event made a causal relationship 
unlikely and another cause (concomitant drugs, therapies and 
complications etc.) was probable. 
Possible: The time course between administration of the study 
drug and occurrence or worsening of the adverse event was 
consistent with a causal relationship but another cause 
(concomitant drugs, therapies and complications etc.) could not 
be ruled out. Or where the time course between administration of 
the study drug and occurrence or worsening of the adverse event 
was not consistent with a causal relationship but other cause was 
denied. 
Probable: The time course between administration of the study 
drug and occurrence or worsening of the adverse event was 
highly consistent with a causal relationship and other cause 
(concomitant drugs, therapies and complications etc.) was denied. 
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Certain (Definite, very likely): The time course between 
administration of the study drug and occurrence or worsening of 
the adverse event was highly consistent with a causal relationship 
and other cause (concomitant drugs, therapies and complications 
etc.) was denied. 
INDEPENDENT ETHICS COMMITTEE (IEC) and REGULATORY 
APPROVAL 
Prior to the start of the study, the East London Local Research 
Ethics Committee (LREC) approved the study protocol (PI 
02/241) and were informed of any changes to the protocol. Prof. 
Foster obtained a Doctors and Dentists Certificate of Exemption 
(DDX) from the Medicines Control Agency (MCA) for this study. 
ETHICAL CONDUCT OF THE STUDY 
This study was performed in compliance with Good Clinical 
Practice (GCP), the Declaration of Helsinki (with amendments) and 
local legal and regulatory requirements. 
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MY ROLE IN THE STUDY 
The Herbal study was originally designed by Professor Foster and 
initiated three years ago. Owing to the bankruptcy of the original 
company the trial was suspended and recommenced in 2003 
when Phynova assumed financial responsibility. I was responsible 
for the re-initiation of the study and enrolled and supervised the 
care of all patients at The Royal London. I collected data from the 
other centre, St Marys Hospital, London and analysed the results 
and prepared the final report. The trial was formally monitored by 
Dr E. Blair, Phynova. 
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CHAPTER 3: RESULTS - Natural History Of 
Hepatitis C Infection In The North-East Of 
London 
3.1 Natural History of Chronic Hepatitis C 
Infection: Long Term Follow-up of a Population 
Infected in Early Childhood 
To this date studies on prolonged (>30 years) follow up of 
chronically infected patients has not been performed and 
therefore it is not known whether the proportion of patients with 
severe liver disease will increase with increasing length of 
infection. Studies of the natural history of chronic HCV infection in 
untreated patients infected for over 50 years are still awaited. 
At the time of this study it was recognized that the large 
population of elderly Asian patients with childhood HCV infection 
in North-East London provided an ideal opportunity to study the 
life long natural history of chronic HCV infection in a population of 
patients attending local hospitals. We included a control group of 
non-Asian patients managed in an identical fashion. 
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RESULTS 
3.11 Patients Demography 
A total of 545 patients had a diagnosis of chronic HCV infection 
(HCV antibody and HCV PCR positive) (Figure 3). 24 HCV 
infected patients were from other ethnic minorities and were 
excluded from this study. The demographic details of the 
remaining 521 Asian and Caucasian patients are shown in Table 
6. The median age was 50 years (range 25-80 y). Asian patients 
(median age, 56 y; range, 26-80 y) were significantly older than 
Caucasian patients (median age, 47 y; range, 25-79 y; p= 
0.0001). The majority of patients (369) were diagnosed during the 
later part of the study, 1997-2003). A percutaneous liver biopsy 
was performed in 382 patients (Table 6, Figure 3). A minority of 
patients (84 - 16%) underwent a transjugular liver biopsy - either 
because they had a significant clotting disorder (usually 
haemophilia A) or signs of decompensated cirrhosis and a small 
proportion of patients (55 - 110/0) did not undergo a liver biopsy. 
For the purpose of this research patients who had not undergone 
liver biopsy or a transjugular liver biopsy were excluded from this 
study. 
153 
Table 6 Demography of the population studied and proportion of patients with 
HCV related cirrhosis in the different study groups. 
Caucasian Patients Asian Patients 
All HCV Positive 20-40 yrs 41-60 yrs >61 yrs 20-40 yrs 41-60 yrs >61 yrs 
Patients HeV HeV HeV HeV HeV HeV 
RNA+ve. RNA+V8. RNA+ve. RNA+ve. RNA+V8. RNA +ve. 
Number of Men 46 109 49 21 57 43 
patients Women 35 52 24 11 41 33 
All 81 161 73 32 98 76 
Patients Men 2(4%) 18 (17%) 9(18%) 5(24%) 29 (51%) 30 (70%) 
w"h Women 0(0%) 3(6%) 9(38%) 0(0%) 12 (29%) 24 (73%) 
cirrhosis All 2 (2%) 21 (13%) 18 (25%) 5(16%) 41 (42%) 54 (71%) 
N(%) 
Percutaneous 20-40 yrs 41-60 yrs >61 yrs 20- 40 yrs 41-60 yrs >61 yrs 
Liver Biopsy Percutaneous Percutaneous Percutaneous Percutaneous Percutaneous Percutaneous 
liver biopsy liver biopsy liver biopsy liver biopsy liver biopsy liver biopsy 
Number of Men 30 81 38 9 40 27 
patients Women 28 45 17 9 30 28 
All 58 126 55 18 70 55 
Pallents Men 1 (3%) 18(22%) 6(16%) 2 (22%) 16(40%) 21 (77%) 
w"h Women 0(0%) 1 (2%) 8(47%) 0(0%) 7(23%) 22 (79%) 
cirrhosis All 1 (2%) 6(5%) 14(25%) 2(11%) 23 (33%) 43(78%) 
N(%) 
Transjugular 20-40 yrs 41-60 yrs >61 yrs 20-40 yrs 41-60 yrs >61 yrs 
Liver Biopsy Transjugular Transjugular Transjugular Transjugular Transjugular Transjugular 
biopsy biopsy biopsy biopsy biopsy biopsy 
Number 01 Men 11 17 4 9 14 9 
patients Women 4 4 1 2 5 3 
All 15 22 5 11 19 12 
Patients Men 1 (9%) 13 (76%) 3(75%) 3(33%) 13(93%) 9 (100%) 
w"h Women 0(0%) 2 (50% 1 (100%) 0(0% 5 (100%) 2(67%) 
cirrhosiS All 1 (7%) 15(68%) 4 (80%) 3(27%) 18 (95%) 12(100%) 
N(%) 
No Liver Biopsy 20-40 yrs 41-60 yrs >61 yrs 20- 40 yrs 41-60 yrs >61 yrs 
Performed 
Number of Men 6 8 9 2 5 8 
patients Women 2 5 4 1 4 3 
All 8 13 13 3 9 9 
% not 10% 8% 18% 9% 9% 12% 
blopsied 
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Figure 3: Proportion of total HCV infected Asian and Caucasian patients 
that have had a liver biopsy 
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3.12 Disease progression in patients with a single 
liver biopsy 
Table 6 shows the details of the liver biopsy and percentage of 
patients who had cirrhosis in the entire population (Figure 4). In 
the Caucasian population cirrhosis was very rare in young 
patients (20-40); uncommon in middle-aged patients and the 
prevalence increased in elderly patients. 25% of Caucasians over 
the age of 61 had cirrhosis. These data are very similar to 
previous cross sectional studies (8eeff et al. 2002) and are 
compatible with prospective natural history studies (8eeff et al. 
2002) and suggest that our methodology did not lead to 
significant over-representation of patients with advanced liver 
disease, as might occur in a tertiary referral center that specializes 
in managing patients with advanced liver disease. The prevalence 
of cirrhosis in patients of Asian origin was markedly increased in 
all age ranges. However the proportion of Asian patients who 
were HCV RNA positive and underwent liver biopsy (185 from 
206) was not significantly different from the proportion of 
Caucasian patients who underwent liver biopsy (281 from 315 -
p= non-significant, Chi Square) suggesting that selection of Asian 
patients with advanced disease for liver biopsy was not 
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responsible for the increased prevalence of cirrhosis in this group 
(Table 5). 
Our study revealed that there was a very high prevalence of 
cirrhosis in elderly Asian patients - 71 % of Asian patients over the 
age of 61 had cirrhosis, compared to 25% of Caucasian patients 
of a similar age. One reason for the high prevalence of cirrhosis 
could be due to the number of liver biopsies performed in the 
different age groups such that elderly patients were less likely to 
undergo biopsy than younger patients. However, there were no 
significant difference in the frequency of liver biopsies in young 
(20-40 yrs : 102 from 113 patients) compared to older patients 
(>61 years: 127 from 149 patients) (p= 0.34, Chi squared test). 
To determine whether lesser degrees of fibrosis were also present 
in increased numbers of Asian patients the proportion of patients 
with moderate fibrosis (fibrosis score of 3,4) and mild fibrosis ( 
fibrosis scores of 1, 2) were analysed. The proportion of patients 
with moderate fibrosis increased with age whilst patients with mild 
fibrosis decreased with age (Figure 4). 
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Figure 4: Prevalence of different stages of fibrosis in Asian and 
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3.13 Factors associated with cirrhosis 
To examine factors associated with cirrhosis and to try and 
ascertain the mechanism underlying the high prevalence of 
cirrhosis in Asian patients we studied patients who had undergone 
a percutaneous liver biopsy and compared Asian and Caucasian 
subjects using univariate and multivariate analyses. We excluded 
from these analyses patients who did not undergo liver biopsy 
(unknown prevalence of cirrhosis) and we also excluded patients 
who had undergone a transjugular liver biopsy as these patients 
either had haemophilia (which may be associated with atypical 
progression of fibrosis) or advanced liver disease (which may 
introduce an element of referral bias into the analysis). A total of 
382 unselected patients who had undergone a percutaneous liver 
biopsy for chronic HCV infection were studied further. 
The median (range) fibrosis score was 2 (0-6). In univariate 
analyses, there was a significant positive correlation between the 
score and increased age (correlation coefficient=0.59, p=0.0001) 
and scores were significantly higher in Asians than Caucasians 
(Asians: 4 (0-6), Caucasians: 1 (0-6), p=0.0001, Mann-Whitney U 
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test). There was no significant difference in fibrosis scores 
between males and females (p=0.46) and the majority of female 
patients were older than 40. Thus unselected, elderly, Asian 
patients with chronic HeV infection had a high prevalence of 
cirrhosis. In Asian patients this may be due to either a longer 
duration of infection or to an increase in fibrosis progression or a 
combination of these two factors. 
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3.2 Disease progression in Asian and 
Caucasian patients 
To determine whether fibrosis progression was increased in Asian 
patients we examined the relationship between fibrosis scores 
and age separately for the different ethnic and sex groups (Figure 
5). Whilst hepatic fibrosis was strongly correlated with age in all 
four groups, the slopes of the individual regression lines 
suggested that the relationship between fibrosis progression and 
age did not differ between those of Asian and Caucasian ethnicity 
i.e. the disease progressed at similar rates in both Asian and 
Caucasian patients. However, the points at which these lines 
crossed the x-axis (may give an indication of the mean age of 
infection in each group) were lower in patients from Asia than in 
Caucasians. 
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Figure 5 - Linear regression analysis of extent of hepatic cirrhosis vs 
age. Liver biopsies from Asian and Caucasian patients with chronic HCV 
infection were examined and the fibrosis score (assayed as recommended by 
Ishak and colleagues) plotted against patient age at biopsy - note that many 
points represent multiple patients. 
Linear regression analysis was performed (PRISM GraphPad) and the 
regression lines are shown. The gradient of the slopes were similar for all the 
different groups - Caucasian Males gradient = 0.064, Caucasian females = 
0.075, Asian males = 0.071 and Asian females = 0.079 but the intercepts 
differed - the X axes intercepts were 23.5yrs for Caucasian males, 29.4yrs 
for Caucasian females, -0.3 yrs for Asian men and 9 yrs for Asian females. 
For all the analyses the slope of the regression plot was significantly different 
from zero (p<0.0001). 
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In Figure 5 liver biopsies from Asian and Caucasian patients with 
chronic HCV infection were examined and the fibrosis score 
(assayed as recommended by Ishak and colleagues 1998) plotted 
against patient age at biopsy - note that many points represent 
multiple patients. 
Linear regression analysis was performed (PRISM GraphPad) 
and the regression lines are shown. The gradient of the slopes 
were similar for all the different groups - Caucasian Males 
gradient = 0.064, Caucasian females = 0.075, Asian males = 
0.071 and Asian females = 0.079 but the intercepts differed - the 
X axes intercepts were 23.5yrs for Caucasian males, 29.4yrs for 
Caucasian females, -0.3 yrs for Asian men and 9 yrs for Asian 
females. For all the analyses the slope of the regression plot was 
significantly different from zero (p<0.0001). 
3.21 Fibrosis Severity in Asian and Caucasian 
patients. 
When considering the patients as a single group, simple linear 
regression models confirmed that there was a significant 
relationship between fibrosis score and increased age and that 
Asians had higher fibrosis scores than Caucasians. To further 
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examine this relationship we performed a multivariable analysis. 
This showed that both age and ethnicity were significantly 
associated with the fibrosis score (p=0.0001 for each) and 
confirmed the visual impressions noted above - the mean fibrosis 
score was 1.81 (95% Cl 1.51-2.11) units higher in Asians than in 
similarly aged Caucasians and the fibrosis score increased by 
0.72 (95%) Cl 0.61-0.82) units for each 10-year increase in age. 
An interaction term between ethnic group and age was non-
significant (p=0.64) suggesting that the relationship between the 
fibrosis score and age was not modified by ethnicity. As in the 
earlier analyses, neither fibrosis scores themselves (p=0.22) nor 
the relationship with age (p=0.34) were modified by gender. 
Hence, liver fibrosis advanced at a similar rate in both Asian and 
Caucasian populations, therefore it was postulated that the 
increase in the degree of fibrosis in elderly Asian patients was due 
to their being infected for a longer period of time than the 
Caucasians rather than to an increase in the rate of fibrosis 
progression in Asian patients. 
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3.22 Disease progression in paired liver biopsies 
To further examine the rate of disease progression in Asian and 
Caucasian patients we analysed 48 paired liver biopsies from 
untreated patients whose initial liver biopsy showed mild or 
moderate disease. These patients all had mild disease which did 
not reach the UK criteria for the introduction of anti-viral therapy or 
had declined to receive treatment for their infection. This sub-
sample of 48 patients had repeat biopsy samples over a median 
(range) period of 5 (1-16) years and allowed us to compare rates 
of fibrosis progression in Asian and Caucasian patients in a 
prospective manner. The median (range) scores were 0.4 (0-4) at 
the time of the first biopsy and 0.9 (0-5) at the time of the second. 
The median (range) time between the two biopsies was 5 (1-16) 
years and the median (range) rate overall was 0.04 (0-3) per year. 
Among the 29 Caucasians the median (range) rate was 0.04 (0-2) 
which did not differ from the rate (0.04, range 0-3) in the 19 
Asians (p=0.45, Mann-Whitney U test) (Figure 6). Hence 
prospective studies on fibrosis progression in a small subset of 
patients also indicated that the rate of disease progression is 
similar in both Asian and Caucasian patients. 
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Figure 6: Fibrosis progression in Asian and Caucasian patients 
who had more than one liver biopsy performed 
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Liver biopsies from Asian and Caucasian patients with chronic 
HCV infection were examined and the fibrosis score (assayed as 
recommended by Ishak and colleagues. 1998 ) calculated. The 
difference between the fibrosis stage on the first and second 
biopsies was calculated and divided by the time (in years) 
between the biopsies to derive a 'fibrosis progression rate', The 
plot (Figure 6) shows fibrosis progression rates for both Asian and 
Caucasian patients. 
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3.3 Factors influencing fibrosis progression 
3.31 Viral and host factors 
To identify factors that might be responsible for the increased 
prevalence of cirrhosis in elderly Asians with HCV we studied a 
number of viral and host factors. Viral genotype was available for 












For the purposes of our analysis the genotypes were combined 
into three groups: genotype 1, genotype 3 and others. Among 
Caucasians, the numbers (%) with genotype 1, 3 and other were 
84 (44.9%), 21 (11.2) and 82 (43.9) respectively, compared to 13 
(23.2), 38 (67.9) and 5 (8.9), respectively among Asians (p=0.006, 
Chi-squared test). In multivariable analyses, after controlling for 
ethnicity and age, genotype 3 was associated with a significantly 
lower score than genotype 1 (mean fibrosis score was 0.48 (0.07 -
0.88) lower than those with genotype 1, p=O.02). Other 
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genotypes were not associated with any change in the score 
(p=O.77). After controlling for the different distribution of 
genotypes in the two populations, both age and ethnicity remained 
significantly associated with the fibrosis score. The age effect 
remained similar to that reported in our earlier analysis, whereas 
the ethnicity effect was, if anything, stronger (with Asians having a 
score that was 2.36 (1.91-2.81) higher than that of similarly-aged 
Caucasians infected with the same HCV genotype (p=O.0001)). 
3.32 Alcohol 
Information on alcohol consumption was available for 336 patients 
(207 Caucasians, 129 Asians) and is shown in Table 6. In 
multivariable analyses, heavy consumption (> 14 units per week 
for females and >21 units per week for males) was associated 
with an increase in the fibrosis score (increase in mean fibrosis 
score of 0.66 (95% Cl 0.23-1.09), p=O.003). However, neither the 
relationship between fibrosis score and age, nor that between 




3.33 Acquisition of HCV 
Elderly Asian patients have a high prevalence of cirrhosis that 
cannot be accounted for by an increase in the rate of fibrosis 
progression. Multivariable analyses of factors known to be 
associated with rapidly progressive fibrosis did not identify any 
variable that could account for the increased prevalence of 
cirrhosis in elderly Asians. However extrapolation of the linear 
regression analysis (Figure 5) suggested that Asian patients were 
infected at a younger age than Caucasian patients and suggests 
that the increase in elderly Asian patients with HCV induced 
cirrhosis may be due to a longer duration of infection in these 
patients. To confirm that Asian patients were infected at an earlier 
age than Caucasians, we studied the route and probable time of 
infection in these patients (Table 7). 
The majority of Caucasian patients acquired HCV infection in 
adult life from blood transfusions or drug use. In contrast, Asian 
patients were commonly infected by blood transfusion before the 
age of 20 (91 patients) or had no obvious source of infection. 
Among the Asian patients with no obvious route of infection, 14 
out of 24 had been born or lived in Asia during childhood. 
Although the precise age of infection is unknown for the majority 
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of our Asian patients most (105/134, 78.4% ) had a single risk 
factor for infection in childhood compared to only 13 Caucasian 
patients (13/236, 5.50;0) who were at risk of infection before the 
age of 20. Thus the available evidence indicates that Asian 
patients were infected in childhood and that elderly Asian patients 
had been infected with HCV for many decades. Taken together 
these data indicate that life long infection with HCV leads to 
cirrhosis in a large proportion of those who are infected. 
TABLE 7 - Mode of acquisition and alcohol consumption In Caucasian 
and Asian patients. The mode of acquisition and alcohol intake at the time 
of the liver biopsy were identified from a study of the patients records. 
Alcohol consumption was scored as nil/moderate if less than 14 units per 
week in a female (21 units for a man) and excessive if greater than these 
amounts. 
Total Caucasian Asian 
N (% of total) N N (% of 
(% of Caucasians) Asians) 
Mode of Acquisition of 
HCV 
Number studied 382 239 143 
Illicit drug use in adults 156 (40.8) 148 (61.9) 8 (5.6) 
Blood product before 104 (27.2) 13 (5.4) 91 (63.6) 
20 yrs old 
Blood product after 72 (18.8) 54 (22.6) 18 (12.6) 
20 yrs old 
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Sexual/occupational 5 (1.3) 3 (1.3) 
Unknown 45 (11.8) 21 (8.8) 
Alcohol Consumption 
Number with available 336 207 
information 
Nil/moderate 287 (85.4) 166 (80.2) 
Excessive 49(14.6) 41 (19.8) 







Patients from Asia have a high prevalence of diabetes and 
obesity. One possible explanation for the high prevalence of HCV 
related cirrhosis in Asian patients is that they may have non-
alcoholic steatohepatitis (NASH) in addition to their HCV. If this 
were the case, then the interaction between NASH and HCV may 
lead to accelerated disease. Information on steatosis was 
available for 382 patients (160 grade 0; 177 grade 1; 36 grade 2; 
9 grade 3). Multivariable analyses revealed no independent 
relationship between steatosis and fibrosis score, however Asian 
ethnicity remained significantly associated with a higher fibrosis 
score (p< 0.0001). Information on body mass index (BMI) was 
available for 357 patients (median 28.3, range 20.2-41.5 kg/m2). 
As expected, BMls were significantly lower in Caucasians 
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(n=222, 27.2 (20.2-39.6) kg/m2) compared to Asians (n=135, 29.4 
(24.0-41.5) kg/m2, p=0.0001, Mann-Whitney U test) and there was 
a significant correlation between BMI and the fibrosis score 
(Spearmans correlation coefficient = 0.20, p=0.0002). However, 
after controlling for ethnicity and age in a multivariable analysis, 
BMI did not remain significantly associated with the fibrosis score 
(p=O.27), and adjusting for BMI did not modify the relationship 
between the fibrosis score and either ethnicity or age. 
Paired Liver biopsies:- the Role of Steatosis 
The characteristics of the 48 HCV-infected patients who had 
paired biopsies is shown in Table 8. This comprised 28 
Caucasians and 20 Asians. Steatosis was present in 810/0 of the 
paired biopsies. 
There appears to be a moderate positive correlation between the 
rate of fibrosis progression and the change in steatosis between 
the two biopsies (Table 9). The rate of fibrosis progression was 
more rapid in males than females (p=0.002) a.nd in those with 
higher levels of steatosis in their first biopsy (p =0.004). Moderate 
and severe steatosis in paired liver biopsies is a major risk factor 
for fibrosis progression as compared to mild steatosis. 
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Table 8: Characteristics of patients included in study 
Number of patients 48 (100.0) 
Genotype: 1 23 (46.9) 
2 7 (14.3) 
3 19 (38.8) 
Median (range) stage at biopsy 1 0.25 (0 to 4) 
Median (range) stage at biopsy 2 0.75 (0 to 5) 
Median (range) years between 
5 (1 to 16) paired biopsies 
Median (range) rate of fibrosis 0.04 (0 to 3) 
progression/year 
Steatosis: 0 9 (18.4) 
1 23 (46.9) 
2 13 (26.5) 
3 4 (8.2) 
Ethnicity: White 28 (59.2) 
Asian 20 (40.8) 
Sex: Male 25 (51.0) 
Female 23 (49.0) 
Median (range) BMI 25 (23 to 33) 
Median (range) change In grade 0.5 (-4 to +4) 
Median (range) age (years) 51 (30 to 68) 
Unfortunately, the small number of patients in the study, and the 
rather non-Normal distribution of the rates of fibrosis progression, 
mean that it is not possible to run multivariable analyses to 
assess whether any of these factors are independently associated 
with fibrosis progression. 
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Table 9: Associations between rate of fibrosis progression and other 
categorical measurements 
Median Range ~-value 
Steatosis: 0 0 (0 to 2) 
1 0 (0 to 2) 
2 0.09 (0 to 3) 
3 0.1 (0.02 to 1) 0.02 
Steatosis 
(combined 
groups): None/Mild 0 (0 to 2) 
Moderate/Severe 0.1 (0 to 3) 0.004 
Genotype: 1 0.06 (0 to 3) 
2 0 (0 to 0.05) 
3 0.02 (0 to 2) 0.13 
Ethnicity: White 0.04 (0 to 2) 
Asian 0.03 (0 to 3) 0.56 
Sex: Male 0.1 (0 to 3) 
Female 0 (0 to 1) 0.002 
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3.36 Influence of Iron on Fibrosis Progression and 
Causation of Diabetes Mellitus in a Population with 
Chronic Hepatitis C. 
339 HCV patients in total were included in the study (Table 10). The 
median age of the patients was 50 years (range 25-79) and 560/0 
were male. Of the 339 patients, 131 (38.60/0) had mild fibrosis, 68 
(20.1 0/0) severe fibrosis and 87 (25.70/0) cirrhosis. 215 out of 339 
HCV patients had genotype data available of which 87 were 
genotype 1, 24 genotype 2, 99 genotype 3, 4 genotype 4 and 1 
genotype 5. HFE genotyping was performed on seventy-two patients 
of whom 68 were negative and four heterozygotes. 
Serum ferritin levels ranged from 3 to 782 (median 86) ug/L (Table 
11 ). Ferritin levels were significantly different among the fibrosis 
stages (p= 0.004). This can be explained largely as a 
consequence of lower values in individuals with severe fibrosis 
and cirrhosis (Table 11) I as ferritin levels in those with no fibrosis 
and mild fibrosis were similar. Caucasians had significantly 
higher ferritin levels (median 139, range [13-782]) than Asians 
(71 [3-782], p=0.0001). Males also had significantly higher ferritin 
levels (172 [18-782]) as compared to females (61 [3-365], 
p=0.0001). The proportions of males (ferritin levels > 300 ug/I) 
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and females (ferritin levels > 200 ug/l) were not significantly 
different ( 6.30/0 of males and 2.0% of females, p = 0.10, Chi-
squared test). When stratified by sex, the relationship between 
stage of fibrosis and ferritin levels was only significant in men 
(p=0.0001, Table 11). There was no significant relationship 
between ferritin levels and BMI. 
Hepatic iron deposition was assessed on the basis of a positive 
iron stain on liver biopsy using Perls' Prussian blue. This was 
graded by the histopathologist on a scale from 0 to 4 (Searle et al. 
1994). 28 patients (8.3%) had grade 1 (minimal deposition of 
iron), 5 patients (1.5%) had grade 2 and 4 patients (1.2%) had 
grade 3 positive staining (intermediate deposition). This resulted 
in 37 (10.9%) patients having some level of iron deposition. No 
patients had massive deposition of iron (grade 4). Iron deposition 
was more common in men (n=33; 17.3%) than women (4; 2.7%, 
p=0.0001), and in Caucasians (30; 15.0%) than Asians (7; 5.00/0, 
p=0.006). No relationship was found between the presence of 
iron deposition and either age (p=O. 73), BM I (p=0.11) or the stage 
of fibrosis (p=0.44). Iron deposition was more common, however, 
in those with a high ferritin. All 15 (100.0% ) patients with a high 
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ferritin level had iron deposition compared to only 22 (6.8%) of 
those with lower ferritin levels (p=0.0001, Fisher's exact test). 
Univariable analyses revealed that lower alcohol consumption 
(p=0.0001), Asian ethnicity (p=0.0001), older age (p=0.0001) and 
higher BMI (p=0.007) were all associated with an increased 
fibrosis stage. However, in multivariable linear regression 
analyses, only Asian ethnicity and age remained significantly 
associated with an advanced stages of fibrosis. For example, 
those of Asian ethnicity had a mean fibrosis score that was 1.72 
(95% confidence interval: 1.40 to 2.04) units higher, on average, 
than that seen in Caucasians. A 10-year increase in age was 
associated with an average increase in fibrosis score of 0.75 (95% 
confidence interval: 0.63 to 0.86). Once these two variables were 
controlled, there were no significant associations between the 
stage of fibrosis and either ferritin levels or iron deposition. When 
stratifying for sex, multivariable analyses gave similar results with 
the exception that a diagnosis of diabetes was independently 
associated with a worse stage of fibrosis in women (effect on 
mean score: 0.82, 95% confidence interval: 0.22 to 1.43, p=0.009) 
but not in men (-0.03, -0.54 to 0.47, p=0.89). 
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Sixty-four patients (19.2%) had a diagnosis of diabetes mellitus or 
impaired glucose tolerance. The number of patients with a 
diagnosis of diabetes mellitus or impaired glucose tolerance did 
not vary by stage of fibrosis (11.3%, 12.2%, 11.8% and 8.1 % of 
those with no fibrosis, mild fibrosis, severe fibrosis and cirrhosis 
respectively, p=O.75, Chi-squared test) and was not associated 
with the presence of iron deposition (25; 9.3% of those without 
diabetes had iron deposition compared to 11; 17.2% of those with 
diabetes, p=O.11). However, ferritin levels were found to be 
significantly higher in those with diabetes (141.5 [13-514] ug/L) 
compared to those without diabetes (83 [3-782] ug/L, p=O.02, 
Mann-Whitney U test). 
178 
Table 10: Characteristics of patients included in study 
Number of patients 339 (100.0) 
Male: n (%) 191 (56.3) 
Ethnicity: n (%) Caucasian 200 (59.0) 
Asian 139 (41.0) 
Age (years): median (range) 50 (25-79) 
Fibrosis stage: Median (range) 2 (0-6) 





68 (20.1 ) 
(stage 3-4) 
Cirrhosis (stage 5-6) 87 (25.7) 
BMI (kg/m2): median (range) (n=311) 28 (22-40) 
Alcohol 
None 104 (37.8) 
consumption·: 
Mild/moderate 138 (50.2) 
High 33 (12.0) 
Diabetes mellitus/impaired glucose 64 (19.2) 
tolerance·: 
BMI, Body Mass Index 
• Information on alcohol consumption available for 275 patients; information 
on diabetes/impaired glucose tolerance available for 334 patients. 
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3.37 The Role of Diabetes Mellitus in Fibrosis 
Progression 
In the original main study we determined whether diabetes 
mellitus was a pre-requisite for the development of cirrhosis in 
Asian patients. We examined the proportion of Asian patients who 
were known to have diabetes or who had had investigations at the 
time of the liver biopsy to exclude it (fasting glucose assessment). 
All 143 Asian patients were assessed of whom 34 (23.8 0/0) had 
diabetes mellitus. The prevalence of diabetes in patients with mild 
fibrosis (stage 1-4, 21 from 75 had cirrhosis) was not significantly 
different from the prevalence in Asian patients with 
moderate/severe fibrosis (fibrosis score 5-6 - 13 from 68 had 
cirrhosis), p= non-significant, Chi square, suggesting that co-
existing diabetes mellitus is not responsible for the high 
prevalence of cirrhosis in elderly Asian patients. 
3.38 Clinical Significance of Insulin Resistance in 
Fibrosis Progression in Hepatitis C Virus Infection. 
Recently, there is increasing evidence that insulin resistance can 
contribute to fibrosis progression in chronic hepatitis C infection 
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(Hui et al. 2003; Furantani et al. 2003). With this in mind we sought 
ethical approval for a follow up study to assess insulin resistance 
on a population of HCV-infected patients. All these patients were 
enrolled in the study if they had a liver biopsy within the last six 
months and were eligible for antiviral therapy. Some of these 
patients were from the previous study but the majority of patients 
were newly referred patients to the department. 
RESULTS 
Anthropometric, biochemical and histological findings by 
ethnicity 
The median age of the 59 patients was 47 (range 34-60) years; 51 
(83.6%) of them yvere male, and the median BMI was 26 (23-30) 
kg/m2 (Table 12). 
30 Caucasian and 31 Asian patients were entered into this study. 
None of the following factors such as sex, age, BMI, alcohol 
consumption, liver function tests, fibrosis stage, portal and lobular 
scores nor grade of steatosis differed significantly between the 
two groups (Table 12). Equal numbers of Asian patients were 
infected with HCV genotype 1/2 and 3, whilst Caucasian patients 
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were more likely to be infected with genotype 1/2 (p=O.04). Both 
fasting insulin and insulin resistance as measured using the 
HOMA model were significantly higher in Asians than in 
Caucasians (p=O.007 and p=O.004 respectively). Asians also had 
higher glycosylated haemoglobin levels than Caucasians 
(p=O.03). The characteristics of those infected with genotype 1/2 
or genotype 3 were similar (data not shown). 
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Table 12: Characteristics of 59 patients included in study, overall and 
stratified by ethnicity. Table entries are n (%) or median (range), as 
appropriate. 
All patients Caucasians Asians 
p-
value* 
No. of patients+ 59 (100.0) 30 (100.0) 29 (100.0) 
Male sex 49 (83.1) 25 (83.3) 24 (82.8) 1.00 
Age (years) 47 (34-60) 47.5 (34-59) 47 (36-60) 0.70 
BMI (kg/m2) 26 (23-30) 26 (23-30) 26 (25-30) 0.27 
HbA1c 5.3 (4.0-8.0) 5.1 (4.0-6.2) 5.7 (4.0-8.0) 0.03 
AST (lUll) 37 (18-124) 37 (19-99) 38 (18-124) 0.73 
ALT (lUll) 47 (15-213) 41.5 (15-213) 52 (16-146) 0.33 
AST:AL T ratio 
0.88 (0.45-
0.88 (0.45-2.54) 0.87 (0.49-1.69) 0.34 2.54) 
Fasting insulin (Omolll) 12.4 (4.2-19.7) 9.6 (4.2-19.7) 15.9 (7.9-19.2) 0.004 
Fasting glucose 5.6 (4.3-7.2) 5.6 (4.3-7.2) 5.9 (4.6-7.2) 0.31 
(mmol/l) 
HOMA-IR 
2.91 (0.98- 2.58 (0.98-5.19) 3.67 (1.90-5.83) 0.004 
5.83) 
HCV 1-2 37 (62.7) 23 (76.7) 14 (48.3) genotype 
3 22 (37.3) 7 (23.3) 15 (51.7) 0.02 
Fibrosis 
1 9 (15.3) 5 (16.7) 4(13.81) 
stage 
2 15 (25.4) 7 (23.3) 8 (27.6) 
3 14 (23.7) 8 (26.7) 6 (20.7) 
4 13 (22.0) 7 (23.3) 6 (20.7) 
5 5 (8.5) 2 (6.7) 3(10.3) 
6 3 (5.1) 1 (3.3) 2 (6.9) 0.73 
Portal 
score 
1 44 (77.2) 23 (79.3) 21 (75.0) 
2 13 (22.8) 6 (20.7) 7 (25.0) 0.94 
Lobular 
score 
1 21 (84.0) 13 (86.7) 8 (80.0) 
2 4 (16.0) 2 (13.3) 2 (20.0) 1.00 
Steatosis None 10 (17.5) 6 (20.7) 4 (14.3) 
Mild 36 (63.2) 17 (58.6) 19 (67.9) 
Moderate 11 (19.3) 6 (20.7) 5 (17.9) 0.75 
Alcohol None 29 (50.0) 14 (46.7) 15 (53.6) 
Mild! 
13 (22.4) 6 (20.0) 7 (25.0) Moderate 
High 16 (27.6) 10 (33.3) 6 (21.4) 0.59 
* P-values obtained from Mann-Whitney U test (numerical variables) or Chi-
squared test (categorical variables). Fibrosis score treated as a numerical 
variable for the purpose of calculating p-values. 
+ Missing values: HbA 1c (n=14), portal score (n=2), lobular score (n=34), 
steatosis (n=2), alcohol consumption (n=1) 
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Insulin Resistance (HOMA-IR) and Anthropometric, 
Biochemical and Histological Findings 
There was a strong positive correlation between the patient's BMI 
and the value of HOMA-IR (Spearman's r = 0.53; p=0.001). On 
stratifying by ethnicity, this correlation was slightly stronger in 
Caucasian (0.58; p=0.007) than in Asian (0.43; p=0.01) patients. 
In addition, the level of HOMA-IR was positively correlated with 
fasting insulin (Spearman's r=0.93; p=0.005), glucose (0.36; 
p=0.005) levels, HbA 1 c (0.30; p=0.05), AST (0.31; p=0.01) and 
ALT (0.34; p=0.007). HOMA-IR levels were also higher in those 
with high (median 3.52; range 0.98-5.83) alcohol consumption, 
compared to those with mild/moderate (2.45; 1.10-5.51) or no 
(2.87; 1.25-5.16) alcohol consumption (p=0.04, Kruskal-Wallis 
test). In addition, HOMA-IR levels were higher in those with portal 
scores of 2 (4.13; 2.30-5.23) compared to those with scores of 1 
(2.81; 0.98-5.83, p=0.03). There were no significant relationships 
seen between HOMA-IR and age, sex, HCV genotype, lobular 
score, steatosis grade or the AST:AL T ratio. 
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Fibrosis and Anthropometric, Biochemical and Histological 
Findings. 
In univariable analyses the following factors such as age, BMI, 
fasting insulin and glucose, HOMA-I R, glycosylated haemoglobin, 
AST and AL T were all positively correlated with fibrosis stage 
(Table 13). If cirrhotic patients (fibrosis stage 5 or 6) were 
excluded from the analysis this did not change the association 
between HOMA-I R and fibrosis stage (Spearman's correlation 
after excluding these patients: 0.69; p=0.001). No significant 
relationships were seen between the fibrosis stage and either sex, 
HeV genotype, steatosis, alcohol consumption, fasting glucose or 
the AST:ALT ratio. In multivariable analyses, HOMA-IR was still 
significantly associated with fibrosis stage, even after adjusting for 
all other variables associated with fibrosis stage in univariable 
analyses (age, fasting glucose, HbA 1 c, AST, AL T, BMI and high 
alcohol consumption). In this multivariable model, a 1-unit 
increase in HOMA-I R was associated with an increase in the 
estimated fibrosis score of 0.85 (95% confidence interval: 0.58 to 
1.12; p=0.001). In this multivariable model, older age was the only 
other factor found to be independently associated with a worse 
fibrosis stage. 
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Table 13: Univariable relationships between each variable and fibrosis 
score on liver biopsy 
Median (range) fibrosis score or p-value* 
Spearman's correlation coefficient 
Sex:3q'1 3 3 (1-6) 
Female 3 (1-4) 0.28 
HCV 1-2 3 (1-6) Genotype: 
3 3 (1-6) 0.99 
Steatosis: None 3 (1-5) 
Mild 3 (1-6) 
Moderate 4 (2-6) 0.09 
Alcohol: 
None 3 (1-5) 
Mild/moderate 3 (1-5) 
High 4 (1-6) 0.16 
Spearman's rank 
correlation between 
fibrosis score and: 
Age 0.42 0.0009 
Fasting insulin 0.73 0.0001 
Fasting glucose 0.20 0.13 
HOMA-IR 0.75 0.0001 
HbA1c 0.31 0.04 
AST 0.30 0.02 
ALT 0.25 0.06 
AST:AL T ratio -0.09 0.50 
BMI 0.39 0.003 
* P-value obtained from Mann-Whitney U test or from a test of the correlation 
coefficient 
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3.4 Clinical Significance of Insulin 
Resistance in Response to Antiviral Therapy. 
Insulin resistance preceeds diabetes mellitus by 10-20 years. 
In the second part of this study we assessed whether insulin 
resistance plays a part in determining which patients respond 
to anitiviral therapy. 
Results 
We assessed the same group of 59 patients previously assessed 
for insulin resistance in the small pilot study on fibrosis 
progression. Their characteristics are described in Table 12. 
Although all patients started treatment, seven (11.50/0) did not 
tolerate the treatment and withdrew from treatment during the 
first 12 weeks. 
Factors associated with Sustained Virological Response 
Overall, 52 patients completed a full course of antiviral 
treatment. Of these 29 (55.80/0) experienced a sustained 
virological response. In univariable analyses (Table 14), 
patients with a sustained virological response were less likely to 
be male (p=0.03) and had lower fasting insulin (p=0.01), 
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fasting glucose (p=O.0007), HOMA-IR (p=O.0009), AST 
(p=O.01), AL T (p=O.003) levels but higher AST:AL T ratios 
(p=O.004). Also those with a sustained virological response 
tended to have lower BMls (p=O.005) and more likely to be 
infected HeV genotype 3 (p=O.05) compared to those patients 
without a sustained virological response. In multivariate 
regression analyses (Table 14), three different models gave a 
very similar fit to the data. In each model, HeV genotype 3 was 
found to be independently associated with an increased 
likelihood of sustained viral response (with odds ratios ranging 
from 9.9 to 29.2 depending on which model was chosen). In 
contrast, higher fasting glucose levels and higher AST levels 
were both independently associated with a poorer virological 
response to treatment. After adjusting for these three variables, 
Asian ethnicity, higher fasting insulin levels and higher HOMA· 
IR levels were all independently associated with a poorer 
virological response to treatment. However, due to the strong 
correlations between these variables, it was not possible to 
tease out the independent effects of these three variables. 
There was a strong relationship between the sustained 
virological response and HeV genotype 3. The analyses was 
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therefore repeated after excluding those patients with genotype 
3. Although the power to consider factors associated with 
sustained virological response was much reduced in this 
subgroup, the association between fasting glucose, Asian 
ethnicity, fasting insulin and HOMA-IR levels and sustained 
virological response still remained significant. 
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Table 14: Results from univariable analyses of factors associated 
with sustained virological response to antiviral treatment (n=52) 
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* p-value obtained from Mann-Whitney U or Kruskal-Wallis tests 
(numerical variables) or Chi-squared test (categorical variables) as 
appropriate. 
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Table 15: Factors independently associated with treatment 
response from multivariable logistic regression analysis. 
Odds ratio 95% Cl 
Model 1 
HeV genotype 3 29.24 
Fasting glucose (per mmol/l higher) 0.10 
Asian ethnicity 0.05 
AST (per lUll higher) 0.96 
Model 2 
HCV genotype 3 9.91 
Fasting glucose (per mmol/l higher) 0.12 
Fasting insulin (per Dmol/l higher) 0.79 
AST (per lUll higher) 0.96 
Model 3 
HCV genotype 3 10.16 
Fasting glucose (per mmolll higher) 0.19 
HOMA-IR (per unit higher) 0.44 



























In this chapter I have explored the natural history of hepatitis 
C in the North-East of London. Studies on prolonged (> 30 
years) follow-up of chronically infected patients have not been 
performed and will not be performed in the future due to 
universal use of antiviral therapy. We had a unique opportunity 
to study an untreated elderly population of first and second 
generation Bengali and Pakistani patients. These patients had 
been infected with HCV at a young age whilst living in their 
country of origin. We were able to carry out a prolonged (>30 
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years) follow up of chronically infected patients. Fibrosis 
progression measured in several hundred single biopsies and 
in nearly 50 paired liver biopsies was the same in Asian and 
Caucasian patients. We found the longer the exposure to 
hepatitis C virus the greater the degree of fibrosis progression. 
We feel that as fibrosis progression was the same in Asians as 
Caucasians that the same rates of fibrosis progression would 
be expected in Caucasians after the same duration after 
infection. 
We confirm that factors such as age and alcohol excess as 
reported by Poynard et al. (1997) are associated with faster 
fibrosis progression. There was no association between 
fibrosis stage and sex, which may be due to the large majority 
of postmenopausal women in the cohort. Despite the small 
sample of paired biopsies moderate to severe steatosis was 
associated with rapid fibrosis progression. Insulin resistance 
was associated with fibrosis progression, however serum 
ferritin and hepatic iron played no role. 
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CHAPTER 4: RESULTS - Management Of 
Chronic Hepatitis C Among East London 
Primary Care Physicians. 
4.1 Knowledge of Chronic Hepatitis C among 
East London Primary Care Physicians 
following the Department of Health's 
Educational Campaign 
Chronic hepatitis C is an important public health problem with 
the development in time of advanced liver disease in a large 
proportion of those who are infected. General practitioners 
are often the first health care professionals to see infected 
patients and it is paramount that they are able to investigate, 
diagnose and refer these patients for treatment 
We report our findings on the effectiveness of the Department 
of Health Hepatitis C information campaign amongst East 
London GPs ten months following the campaign. Because of 
the pivotal role of GPs in the identification and screening of 
patients at risk we have specifically asked about risk factors 
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and indications for hepatitis C testing in our questionnaire. 
RESULTS 
FACE-TO-FACE INTERVIEWS 
Ten GPs were randomly selected for face-to-face open-ended 
interviews from the cohort of GPs from the East End of 
London. They had previously been invited to complete the 
questionnaire. The selected GPs were then telephoned and 
asked if they were willing to participate. Only six agreed and a 
further four were randomly selected. These latter four 
consented to be interviewed. GPs were interviewed in their 
surgery after confirming a time and date of the interview on 
the telephone. The four practitioners who decided not to take 
part declined because of time constraints or understaffing in 
their practices. In the interviews we discussed opinions and 
beliefs about hepatitis C, including transmission, screening, 
treatment, and ways of improving services. The general 
practitioners were encouraged to speak freely, raise issues 
important to them and give examples from their clinical 
practice. 
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Each general practitioner saw an average of 4.2 hepatitis C 
infected patients per year (range 0-15). All ten GPs were 
aware that infection was common in drug users and could be 
prevented by meticulous hygiene. Three practices had access 
to needle exchange facilities. However, four practices were 
unaware of these facilities and three did not refer patients as 
they believed it encouraged them to abuse drugs. Therefore 
only 30% actively facilitated access to needle exchange 
programmes. All ten GPs were aware of local drug services 
and nine believed that they were effective. 
Although our entire panel recognized that drug use was a 
major route of transmission, knowledge of other modes of 
transmission were limited. The majority (90%) believed that 
materno-fetal transmission was common (in fact transmission 
occurs in 5% (Zanetti et al. 1995») and pregnant women were 
advised wrongly that there was a 50:50 chance of 
transmission to their baby. All of our GPs told breast feeding 
mothers not to breast feed due to the risk of HCV 
transmission. This is wrong, as is the view of six practitioners 
who believed that blood transfusion until the end of the 19908 
carried a high risk of transmitting the virus. 
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Diagnosis and screening of hepatitis C were reviewed in the 
practitioners surgery. Two general practitioners believed that 
the presence of antibodies against hepatitis C indicated that 
patients had eradicated the virus and had immunity from 
further infection. The majority of primary care physicians 
(90%) did not screen active intravenous drug users until they 
believed that they were "clean". In their opinion if the first test 
was negative, unreformed drug addicts remained at high risk 
of re-infection and therefore screening was futile. They 
claimed that, in their experience 'these patients' (i.e those 
currently using intravenous drugs) consistently do not turn up 
for their appointments and are not compliant with treatment. 
They strongly felt that these patients should take responsibility 
for their own health and show a commitment to being 'clean' 
prior to seeking testing or treatment. Two (200/0) general 
practitioners do not screen patients at high risk for hepatitis C 
as resources in their practice are poor. Two doctors (20%) 
indicated that all homosexuals should be screened. All of our 
panel of GPs wanted routine screening of all pregnant women 
for HCV introduced. 
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All of our panel of GPs would welcome open access clinics 
manned by hospital staff as they had insufficient time to 
counsel patients prior to hepatitis C testing. In their opinion 
antibody positive patients should be followed-up by hospitals 
and should be referred directly by the virology department. 
Only two of the ten general practitioners routinely vaccinate 
hepatitis C infected patients for hepatitis A and 8 and all 
advise their infected patients to cease all alcohol intake as this 
worsens progression of liver disease. 
Knowledge about treatments for hepatitis C was limited, and 
this probably reflects the rapidity of progress in this field. GPs 
were unaware of the availability of pegylated interferon (which 
is now the treatment of choice for HCV-infected patients 
(Manns et al. 2001; Fried et al. 2002)) and only 3 were aware 
of the value of combination therapy (ribavarin and interferon). 
Five general practitioners believed that chronic hepatitis C 
should be treated with standard interferon monotherapy, and 
two suggested combination treatment with lamivudine and 
interferon (Iamivudine is recommended for therapy for HIV and 
hepatitis 8). Three (30%) primary care physicians agreed that 
treatment is effective in more than 50% of patients and four, 
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who recommended therapy with interferon and ribavirin, were 
aware of the main side effects of this combination therapy. 
Three GPs selected patients for referral based on their 
assessment of their fitness for antiviral therapy. 
Knowledge of the complications of hepatitis C were discussed 
- 600/0 of practitioners believed that 500/0 of patients develop 
cirrhosis from their HCV in 20 years (current opinion suggests 
that 20% develop cirrhosis after 20 years (Poynard et al. 
1997)) and 20 % only refer patients with cirrhosis who have 
decompensated liver disease for treatment (Le. patients with 
ascites, encephalopathy or variceal bleeding). The primary 
care physician followed up patients with compensated 
cirrhosis but none of these doctors screened these patients for 
hepatocellular carcinoma by either ultrasound or alpha-
fetoprotein evaluation. Our practitioners believed that the 
Department of Health booklet was good to refer to, but was 
too detailed and long. A short checklist with bullet pOints would 
have been much better. More investment was promised in the 
document but is still awaited. 
Primary care physicians were of the view that more should be 
done to improve education in hepatology. Their suggestions 
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comprised hepatitis C workshops and liver clinics in primary 
care which they felt should be set up by hepatologists. There 
should be training of primary care physicians with a specialist 
interest in hepatology. General practitioners complained that 
they are often not involved in liver meetings and wish to have 
more involvement. They also saw a need for more public 
education and were concerned that ethnic minorities were 
particularly poorly informed about hepatitis C. 
POSTAL QUESTIONNAIRE 
The pilot study was performed in the South-East of London 
and comprised 250 GPs who were randomly selected from 
750 GPs. The main study selected 600 GPs from a total of 
650 GPs in the North East of London. 
The questionnaire is shown below (Table 16). It was posted to 
850 GPs in total with 482 responses. This comprised one 
hundred and forty one out of 250 general practitioners in 
South East London (56%) and 341 of 600 (590/0) practitioners 
from North East London completed the questionnaire. There 
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were no clear differences between the two groups and Table 
16 summarises the responses. 
Table 16 GP Questionnaire 
1. Patients who are hepatitis C antibody positive Yes No 
no longer have active disease 
2. Hepatitis C is common (> 40 %) in those who Yes No 
have ever used intravenous drugs 
3. The prevalence of HIV is higher than hepatitis Yes No 
C in the East End 
4. More than 50 % of pregnant women infect their Yes No 
children 
5. Blood transfusion in the 1990s carries a high Yes No 
risk of transmitting hepatitis C 
6. In patients using intravenous drugs, Yes No 
transmission of hepatitis C can be prevented 
by meticulous hygiene and non-sharing of all 
paraphenalia 
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7. Therapy for hepatitis C is effective in more Yes No 
than 50% of patients treated 
8. Out of 100 patients with chronic hepatitis C 
which proportion of patients will develop 
cirrhosis in 30 years 
5 10 20 50 70 
9. Where do you refer your patients with hepatitis C 
...................................................................................... 
10. What changes do you feel would improve the services offered to 
your patients with hepatitis C in your area 
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The majority of general practitioners (> 86% ) were aware that 
hepatitis C was common in drug users and that the prevalence 
is higher than HIV. Yet 14 % believed that the presence of 
antibodies to hepatitis C indicated that the patient no longer 
had active disease. Another common misconception was that 
49 % thought that materno-fetal transmission occurred in more 
than 50% of infected women (transmission occurs in around 
5%) whilst 50 % of practitioners believed that blood 
transfusion in the 1990s carried a high risk of infection. 
Knowledge of the natural history of HCV was limited - only 23 
% of general practitioners knew that 20% of patients develop 
cirrhosis after 20 years and only 580/0 were aware that 
treatment was effective in more than 50% of cases. 
I n response to our open-ended questions every doctor who 
responded could name either a district general hospital or 
tertiary referral centre that they referred to. The majority 
screened some patients for hepatitis C ( 23% did not) and of 
those who screened 14% tested homosexuals or patients with 
learning difficulties. Every general practitioner wanted more 
information about hepatitis C and 71 % believed that there 
should be more public education, together with linguistically 
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and culturally appropriate patient information for the different 
ethnic groups in the East End. Links between primary care 
physicians and hepatologists should be strengthened, with 
representatives from the primary care trusts invited to hospital 
hepatology meetings. 
Table 17: Percentage of correct responses 
S-E N-E AVERAGE 
LONDON LONDON 
STUDY STUDY 
1. Patients who are hepatitis C antibody 84% 88% 86% 
positive no longer have active disease 
2. Hepatitis C is common (> 40 %) in those 
who have ever used intravenous drugs 
85% 90% 88% 
3. The prevalence of HIV is higher than 
hepatitis C in the East End 
86% 88% 87% 
4. More than 50 % of pregnant women 
infect their children 
43% 55% 49% 
5. Blood transfusion in the 1990s carries a 
high risk of transmitting hepatitis C 
44% 55% 50% 
6. In patients using intravenous drugs, 
transmission of hepatitis C can be 
prevented by meticulous hygiene and non- 85% 95% 90% 
sharing of all paraphernalia 
7. Therapy for hepatitis C is effective in 
eradicating the virus in more than 50% of 
patients treated 64% 52% 58% 
8. Out of 100 patients with chronic 
hepatitis C which proportion of patients will 
develop cirrhosis in 30 years 
510 20 50 70 
25% 20% 23% 
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4.2 Improving GPs knowledge by educational 
programmes or learning via a postal service 
A Hepatitis C educational programme 
A total of 43 GPs attended the four sessions of which 13 were 
GP trainees. All those who registered to attend did so. 
Circulars had been sent out to 150 GPs by the PCP Trusts. 
Attendance was poor however, a large proportion of the GPs 
(91) who did not attend replied and explained that they were 
unable to get cover and time off due to work constraints. 
The evaluation forms were very positive. Almost all the 
attendees rated speaker knowledge, speaker effectiveness, 
and the overall programme as good or excellent. Participants 
felt the most important things they learned about included a 
general overview of the topic, how to diagnose and test for 
HCV, risk factors and treatment methods. 
Due to the poor attendance the information sheet on HCV with 
the post test questionnaire was sent out to 200 GPs with the 
worst scores on the questionnaire. 123 replied back within the 
next four weeks; and a further 41 were retrieved after several 
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telephone calls and in some cases travelling to the surgery. All 
GPs were unaware that they had answered the pre-test 
questionnaire poorly. All felt the information sheet was 
beneficial. 
The pre- and post-tests questionnaires show substantial 
improvement in basic HCV knowledge and includes the 
educational meeting and postal information sheet results 
separately (Table 18). All eight questions had a percentage of 
correct responses of more than 900/0. GPs were also able to 
list more than three groups that they would screen compared 
to pre-test where only one or a wrong group such as patients 
with learning difficulties were listed. They were also now 
aware of ways in which the DH is improving HCV services 
such as increased drug counselling facilities, needle exchange 
services and provision of harm minimisation information and 
activities to prevent transmission of HCV. All GPs requested 
further information on HCV. Considerable frustration was 
expressed regarding access to reliable information about 
treatment outcomes and to linguistically and culturally 
appropriate patient information. 
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Table 18: Percentage of correct responses 
Educational Meeting I Postal Information 
Survey Sheet 
Pre-Test Post- Pre - Post-Test 
1. Patients who are hepatitis C 65% 
antibody positive no longer have 
active disease 
2. Hepatitis C is common (> 40 %) in 80% 
those who have ever used 
intravenous drugs 
3. The prevalence of HIV is higher 58% 
than hepatitis C in the East End 
4. More than 50 % of pregnant women 55 % 
infect their children 
5. Blood transfusion in the 1990s 55% 
carries a high risk of transmitting 
hepatitis C 
6. In patients using intravenous 
drugs, transmission of hepatitis C 8501c 
can be prevented by meticulous ° 
hygiene and non-sharing of all 
paraphernalia 
7. Therapy for hepatitis C is effective 
in eradicating the virus in more than 
50% of patients treated 52% 
8. Out of 100 patients with chronic 
hepatitis C which proportion of 
patients will develop cirrhosis in 30 
years 
510 205070 20% 
Test Test 
100% 45% 96% 
100% 72% 98% 
92% 47% 89% 
94% 35% 90% 
96% 41% 92% 
100% 81% 100% 
100% 43% 98% 
86 % 10% 94% 
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SUMMARY 
In the second part of the thesis we assess the knowledge of 
General Practitioners (GPs) in the East End of London 
following the Department of Health campaign. The knowledge 
from the two regions in the East End of London were similar. 
Therefore it is likely to assume that this is a good reflection of 
the knowledge in the UK. Our survey clearly revealed that 
significant deficits in knowledge regarding hepatitis C among 
GPs continue to exist despite the provision of a 45 page 
booklet discussing all aspects of HCV. This booklet was sent 
to every GP in the United Kingdom by the Department of 
Health approximately 10 months prior to our questionnaire. 
Several factors may contribute to the knowledge deficits 
regarding hepatitis C among GPs: the rapid evolution of new 
information, the lack of established guidelines catered for 
GPs, the need for GPs to keep up with advances in many 
diverse areas of medicine, and the possible ineffectiveness of 
current educational resources. 
We endeavored to improve GPs knowledge by inviting them to 
educational meetings on HCV or by improving their knowledge 
via a postal service. This strategy has met with success, 
although an immediate post-test does not address knowledge 
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retention. The feasibility and pick up rates of open access 
confidential hepatitis C testing clinics were ascertained. 
These clinics were found to be labour intensive and, in our 
experience unlikely to provide a cost effective solution to the 
identification of people with this treatable and sometimes fatal 
infection. GPs are the 'gate-keepers' to the NHS and will be 
the first health care professionals to have the opportunity to 
screen high risk patients for HCV. Thus, educational initiatives 
and guidelines specifically designed for GPs are needed to 
assist them in identifying patients at risk, conducting initial 
diagnostic evaluation, and initiating appropriate referrals, so 
patients with hepatitis C can be correctly diagnosed and 
treated while they are still in the early stages of disease. The 
best method of providing information should be provided and 
GPs may wish to become more directly involved in shared 
care arrangements with specialists that will broaden education 
and treatment opportunities for HCV-infected patients. The 
Department of Health has launched a second campaign for 
tackling hepatitis C in the UK. This includes an information 
pack for general practitioners. This will assist professionals 
recognise the main risk factors, advise on how to avoid 
infection, discuss testing with patients, if appropriate, and 
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follow-up if they discover patients are infected. This will be 
followed by education of the public about avoiding the risk of 
infection and considering testing where appropriate. 
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CHAPTER 5: RESULTS - Management Of 
Hepatitis C In The North-East Of London 
5.1 Study to assess the safety and 
effectiveness of ONP-17 for the treatment of 
hepatitis C 
Enrolment for the herbal study began on the 25 th of February 
2004 and continued until the 1 st October 2004 when enrolment 
was terminated as the herbal company were worried about the 
efficacy of the herbs. 
Enrolment was very difficult. In the first four months 
enrolment took place at a single centre, the Royal London 
Hospital with 36 patients recruited from clinic. However this 
tailed off and as we had previous ethical approval at St Marys 
Hospital we gained permission from our local ethical authority 
to use St Marys as a second site. This resulted in a further 4 
patients. However we were still struggling to achieve our 
target of 66 patients. We therefore sought ethical approval to 
advertise in the local paper about the herbal study. We gained 
ethical approval but this increased interest in the study; 
however only 2 patients fitted the inclusion criteria. 
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Finally by the 1 st October 2004 45 patients were entered into 
the study. This comprised 26 men and 17 women. The large 
majority (31) were unable to tolerate antiviral therapy or were 
non-responders to treatment. However nine patients had mild 
liver disease and were being monitored with serial liver 
biopsies every four to five years; whilst five patients only 
wished to take herbal treatments. 
Only 26 patients completed the course of treatment and the 4 
week washout period. Of these 12 patients (6 male, 6 female) 
(mean age 45.9) were taking placebo and 14 patients (9 male, 
5 female) (mean age 50.5) were on the herbal preparation 
(Figure 7). 
Figure 7: Demographics 
N Age Sex (M/F) 
Placebo 20 46.6 11/9 
(Total) 
Placebo (Completed) 12 45.9 6/6 
Herbs 25 49.7 15/8 
(Total) 
Herbs 14 50.5 9/5 
(Completed) 
All patients had symptoms which could be related to their 
hepatitis C and the majority of patients (36) had liver enzymes 
(AL T or AST) twice the upper limit of normal. 
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There have been three adverse events, for which the patients 
were withdrawn from the study and unblinded. One patient 
was on placebo and two on active treatment. The patient on 
placebo was withdrawn as he developed acute pancreatitis 
whilst abroad (thought to be due to hyperlidaemia). The two 
other patients on active treatment were withdrawn as one lady 
with a past history of osteoarthritis of her left knee developed 
a large knee effusion requiring drainage. The other patient had 
a liver biopsy showing mild disease who became anaemic with 
a haemoglobin value of 6 g/dl during treatment. There was no 
evidence of overt loss of blood on history or examination. On 
Upper GI endoscopy he was found to have varices. Re-
examination of his liver biopsy by the original histopathologist 
was performed. The histopathologist felt that the liver biopsy 
was a poor fragmented specimen and showed cirrhosis. 
It must be remembered that as the numbers for each arm 
were small due to problems with recruitment and treatment 
withdrawal we are unable to draw any significant results 
between the two arms. 
Comparing the small numbers that completed the study 
subjectively it seems that the herbal preparation did not have 
an effect on viral load compared to placebo (Figure 8). 
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For quality of life data- eight SF-36 scales (Figure 9). 
For the fatigue symptom score herbs had higher scores than 
placebo (Figure 10) 
AL T levels probably fell slightly during treatment with herbs 
rather than placebo (Figure11 -13). 
Both the herbs and placebo preparations did not alter the full 
blood count or renal function during the study (Figures 14 -
17). The herbal preparation did not affect glucose levels 
during the study; however the placebo seems to have 
increased the glucose levels possibly due to some sugar 
additive (Figure 18). 
Figure 9: QOL Scores -SF36 (+ = feels better) 
SF 36 Changes 
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Figure 10: QOL Scores - FSS 
FSS Scores 
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Figure 12: Herbs - ALT changes during the study. 
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Figure 14: Safety - Haemoglobin levels during the study. 
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CHAPTER 6: DISCUSSION 
The natural history of infection with chronic hepatitis Cover 2-
3 decades has been determined by studying patients infected 
20 to 30 years ago. The outcome is variable with around 15-
, 
20% of patients developing cirrhosis after 20 years (Alter et 
a1.1992; Tong et al. 1995; Kenny-Walsh 1999). However 
prolonged (>30 years) follow up of chronically infected 
patients has not been completed. The large population of 
untreated elderly Asian patients who had acquired HCV in 
childhood gave us the unique opportunity to study the natural 
history of chronic hepatitis C in patients exposed to the 
infection for more than 40 years. We were also able to look at 
factors involved in fibrosis progression in chronic hepatitis C 
patients. 
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6.1 Natural History of Chronic Hepatitis C 
Infection: Life-Long Follow-up of an 
Unselected Population Infected in Early 
Childhood 
This study addresses the outcome of chronic HCV infection up 
to 60 years after infection and represents the first very long-
term study of the natural history of this infection. Our study 
involved elderly Asian patients and therefore the high rates of 
cirrhosis may be due to either Asian origin or advanced age. 
Ethnic groups have different response rates to antiviral 
treatment and small scale, studies in America suggest that 
fibrosis progression in African Americans and Latinos may 
differ from Caucasians (Wiley et al. 2002; Bonacini et al. 
2001), perhaps indicating that our observations are only 
pertinent to Asian individuals. However in our study we found 
that fibrosis progression, measured both in single and paired 
biopsies was the same in Asian and Caucasian patients. This 
suggests that our findings may apply to other populations and 
that the high prevalence of cirrhosis, observed in Asian 
patients was due to prolonged infection and not to ethnicity. 
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During this study, patients were referred for a liver biopsy to 
one of three local hospitals (Barts and the Royal London, 
Newham District hospital and Homerton District Hospital), 
none of which operated as a tertiary referral center for 
hepatology. One of the possibilities was that the high 
prevalence of cirrhosis in elderly Asian patients may be due to 
referral bias rather than to a genuine increase in the 
prevalence of cirrhosis in this population. A number of different 
lines of evidence suggest that this was unlikely. The study 
was conducted at three local hospitals which at the time of the 
study did not offer advanced hepatological services (e.g. liver 
transplantation) and it therefore was unlikely that selective 
referrals of patients with end-stage liver disease would have 
biased our results. To reduce referral bias we actively 
excluded patients with decompensated liver disease who 
underwent a transjugular biopsy from the study and therefore 
referral bias of patients with severe liver disease does not 
explain our results. Some clinicians regard elderly patients as 
poor candidates for antiviral treatment and it is therefore 
possible that these patients did not have liver biopsies unless 
there was biochemical or other evidence of advanced fibrosis. 
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If this was the case it would have resulted in an increased 
proportion of elderly cirrhotic patients. This potential source of 
bias is unlikely to account for our results; as we show no fall in 
the frequency of liver biopsy in elderly patients and the 
increase in the prevalence of cirrhosis in Asian patients was 
seen in all age groups. Another potential source of bias is that 
Asian patients are less likely to present to their general 
practitioners than Caucasian patients unless they had 
symptoms of advanced disease. Since most patients with HCV 
are asymptomatic until the complications of cirrhosis have 
developed and as these patients with decompensated liver 
disease were actively excluded from the study, this possibility 
seems unlikely. Immigrant communities have lived in the East 
End of London for many decades and every effort has been 
made to ensure that all of the community has equal access to 
the free health care that is provided by the NHS in the UK. 
About 300/0 of the community in the East End are of Asian 
origin and as a similar percentage of Asian patients was seen 
in all of the age groups in our study there is no evidence that 
Asian patients only presented with advanced disease. 
Previous studies have shown that the prevalence of HCV 
induced cirrhosis is no more than 15-20% after 20 years 
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which compared favorably (15%) with the prevalence of 
cirrhosis in our Asian patients who had been infected for 20-40 
years. Altogether this data suggests that the increase in 
prevalence of cirrhosis in elderly Asian patients was not due to 
selective referral of patients with advanced disease we cannot 
exclude the possibility that referral bias may have had a small 
impact upon our data. 
Elderly Asian patients infected with HeV in early life who 
have a prolonged exposure to HCV (>60 years) have a very 
high prevalence of cirrhosis. Several lines of evidence indicate 
that this is so. Most of our Asian patients spent their childhood 
in Pakistan and Bangladesh where there is a high prevalence 
of HCV infection and, the majority probably acquired HCV 
infection in early life. Our data on disease progression also 
suggests that infection in childhood is likely. Disease 
progression rates are similar in Asians and Caucasians and if 
we speculate that infection in Asians occurred in adult life then 
we cannot explain the higher prevalence of cirrhosis in Asian 
patients. This evidence strongly suggests that infection in our 
Asian patients occurred in early life and the long duration of 
infection is responsible for the high prevalence of cirrhosis in 
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elderly Asians with HCV. 
The possibility that another factor contributes to the high 
prevalence of HCV associated cirrhosis in Asian patients 
cannot be excluded. We have not been able to identify any 
additional factor that might predispose Asians to advanced 
disease. Multivariable analysis found that genotype 3 
(commonest genotype in Asians) was associated with less 
fibrosis. Viral load measurements with a validated assay were 
not available for many of our cases and the effect of this 
variable on fibrosis progression could not be studied. 
However, a large French study have suggested that viral load 
and genotype did not influence disease progression (Poynard 
et al. 1997). 
Alcohol accelerates disease progression in patients with 
chronic hepatitis C (Poynard et al. 1997) and our analysis 
confirms this effect. It must be remembered Asian populations 
have a high prevalence of NASH and it is possible that this is 
the cause for the high prevalence of cirrhosis found in elderly 
Asians. Whilst increased BMI was significantly associated with 
a higher fibrosis score in univariate analyses, adjusting for 
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BMI in multivariate analyses did not change the apparent 
relationships between fibrosis score, age and ethnicity. There 
was no increase in the prevalence of diabetes mellitus or 
steatosis in those patients with advanced fibrosis. This 
suggests that NASH is unlikely to account for the excess 
cirrhosis in elderly Asian patients. In a follow up study to this 
work, in a smaller cohort of patients who were due to receive 
therapy with pegylated interferon and ribavirin, we find that 
insulin resistance is associated with more advanced fibrosis in 
elderly Asian patients suggesting that insulin resistance may 
play a role in the development of advanced fibrosis. Further 
studies of larger cohorts studied prospectively will be required 
to determine the role of insulin resistance and glucose 
homeostasis in the development of hepatic fibrosis. 
This study shows a very high prevalence of HeV induced 
cirrhosis in elderly Asians. This cannot be attributed to either 
by referral bias or more rapid disease progression and 
appears related to prolonged exposure to the virus. It is likely 
that long infection (>50 years) in other populations will also 
lead to advanced liver disease in the majority of patients. 
Some clinicians may be reassured to learn that infection for 
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30-40 years is benign in the majority but others will be 
alarmed to discover that infection for over 60 years is usually 
associated with advanced disease. All will agree that every 
effort must be made to identify and treat those infected in early 
life, as the lifetime risk of significant disease may be high. 
6.2 Factors involved in Fibrosis Progression 
i) Paired Biopsies: The role of steatosis in 
fibrosis progression 
Hepatic steatosis is common in hepatitis C, with 81 % of 
patients having some degree of steatosis. The small number 
of paired liver biopsies meant that it was not possible to run 
multivariable analysis to assess whether any of these factors 
were independently associated with fibrosis progression. We 
found a moderate positive correlation between the rate of 
fibrosis progression and the change in steatosis between the 
two biopsies and this is in agreement with other reports where 
hepatic steatosis is increasingly recognised as a cofactor 
influencing the progression of fibrosis in chronic hepatitis C ( 
Hourigan et a1.1999, Rubbia-Brandt et al. 2000, Adinolfi et al. 
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2001). Higher grades of steatosis are associated with more 
advanced stages of fibrosis as suggested by our data (Adinolfi 
et al. 2001; Serfarty et a\. 2002). However, recent data 
suggests that this association between fibrosis and steatosis 
is more complex. In one study the association was not found 
whilst other studies have only confirmed this association in 
certain patients' subgroups (Pattton et al. 2004; Rubbia-
Brandt et al. 2004). Patton et al. (2004) only found an 
association between steatosis and fibrosis between patients 
with genotype 1 infection; whilst Rubbia-Brandt et a\. (2004) 
found the association in genotype 3 patients. However, after 
closer inspection these results are not necessarily conflicting. 
The study populations are quite different as are the 
histological and clinical variables (such as alcohol abuse) and 
even referral patterns differ at different locations. Patient 
populations from Australia are characterised by a higher 
average BMI and a lower prevalence of genotype 3 (Kumar et 
al. 2002), whereas European patients have a lower BMI «25 
kg/m2 in all studies) and are more frequently infected with 
genotype 3 (Monto et al. 2002). Other factors such as genetic 
and dietary factors may also play a role. Several hypothesis 
have been put forward from the production of excess reactive 
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oxygen species and lipid peroxides to the insulin resistance 
syndrome (Okuda et al. 2002; Parola et al. 2001). If steatosis 
is associated with more rapid progression of. fibrosis, then 
exercise and weight loss may improve hepatic injury due to 
HCV. Further research is eagerly awaited to confirm whether 
or not steatosis contributes to fibrosis progression and if so 
which patient groups are affected together with the 
pathogenesis. 
ii) Relationship between Serum and Hepatic 
Markers of Iron, Diabetes Mellitus and 
Fibrosis Progression in Patients with 
Chronic Hepatitis C. 
It has been proposed that iron overload in HCV -infected 
patients, like hereditary haemochromatosis may cause 
progression of HCV-associated hepatic fibrosis; resulting in 
cirrhosis with its associated complications of hepatocellular 
carcinoma and portal hypertension. So far, studies assessing 
the effect of elevated iron stores on the natural history of 
hepatitis C have been contradictory (Di Bisceglie et al. 1992; 
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Haque et al. 1996; Thorburn et al. 2002; Metwally et al. 2004). 
The role of both serum ferritin and hepatic iron staining on 
HCV fibrosis was examined in this study by comparing a 
relatively iron-deficient Asian population with the indigenous 
Caucasian population. 
In our study 4.4 % of patients had raised serum ferritin levels. 
Elevated serum iron markers were more commonly found in 
males and Caucasian patients. Eleven percent of patients had 
elevated hepatic iron staining, which is similar to earlier 
studies where a prevalence of 10-36% has been recorded 
(Piperno et al. 1998; Tung et al. 1999; Kazemi-Shirazi et al. 
1999). Serum ferritin from our study when elevated appears 
to be a good screening tool for abnormal iron stores. 
Nevertheless, it has to be realised that ferritin can often be 
elevated in the absence of increased hepatic iron stores, due 
to non-specific effects of hepatic inflammation that result in 
increased release of iron from damaged liver cells (Di 
Bisceglie et al. 1992, Prieto et al. 1975). Raised ferritin may 
also result from acute or chronic inflammation as part of an 
acute-phase reaction (Prieto et al. 1975). This is an unlikely 
explanation for our results as patients who had inflammatory 
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markers such as C reactive protein performed at the same 
time that ferritin levels were taken, had normal readings. 
Racial differences in iron stores exist with some races 
responding to infection with HCV with an increase in iron 
stores. HCV-infected black patients were 5.4 times more 
likely to have increased iron stores (assessed by transferrin 
saturation and ferritin) than HCV-positive non-blacks (loannou 
et al. 2003). Other races were found to have only a small 
difference in the iron stores between HCV-infected and non-
infected patients (Ioannou et al. 2003). Our Asian population 
had lower iron stores (assesed by serum ferritin and hepatic 
iron staining) than Caucasians and this is because the 
majority of Asians were vegetarian and most did not drink 
alcohol. Consumption of up to 2 alcoholic drinks/day is 
associated with a reduced risk of iron deficiency, whilst 
consumption of more than 2 alcoholic drinks/day is associated 
with a significant increase in the risk of iron overload (Ioannou 
et al. 2004). 
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The quantity of iron found both histologically and 
biochemically were unrelated to the stage of fibrosis, which 
suggests that iron does not play a significant role in the 
progression of HCV related liver injury. Even when controlling 
for alcohol intake Asians who had less iron than Caucasians 
had more fibrosis on liver biopsy. 
Chronic hepatitis C infection compared to other liver 
conditions is associated with an increased risk for the 
development of type 11 diabetes mellitus (Alii son et al. 1994; 
Mehta et al. 2000; Knobler et al. 2000; Alexander G. 2000). In 
cirrhotic patients being assessed for liver transplantation, 
HCV-infection was independently associated with type 11 
diabetes (Allison et al. 1994). Furthermore, HCV infected 
patients aged 40 years or older had a three times higher rate 
of type 1I diabetes than similarly aged patients without HCV 
infection, even when cirrhotic patients are excluded (Knobler 
et al. 2000; Mehta et al. 2000; The Third National Health and 
Nutrition Examination Survey (N-HAMES Ill) (1988-1994)). 
However, a clear biological relationship between HCV 
infection and type 11 diabetes mellitus is not obvious 
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(Alexander G. 2000). One suggestion put forward is the 
association between hepatitis C and iron overload (Ford et al. 
1978-1983; Paris R. 2001; Furantani et al. 2003). A 
significant association between elevated serum ferritin levels 
and newly diagnosed diabetes mellitus was noted on further 
analysis of the N-HAMES III data (Ford et al. 1978-1983; 
Paris R. 2001). We also found that serum ferritin levels were 
significantly higher in patients with diabetes or impaired 
glucose tolerance compared to those patients without 
diabetes. However, there was no association between 
diabetes or impaired glucose tolerance and the presence of 
iron deposition in the liver. 
Other factors may also be involved. HCV infected patients can 
also have non-alcoholic fatty liver disease (NAFLD) which is 
strongly associated with features of the metabolic syndrome 
and this may explain the strong relationship between HCV 
infection' and diabetes mellitus (Sanyal et al. 2003). Insulin 
resistance as previously discussed plays an important role in 
the development of type 2 diabetes mellitus and is the best 
predictor of diabetes mellitus. The mechanism for insulin 
resistance in chronic HCV infection are not yet known. Studies 
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from transgenic mice, that specifically express high levels of 
HCV core protein in hepatocytes, showed that hepatic insulin 
resistance could be induced solely by HCV core protein 
(Shintani et al. 2004). Increased levels of tumour necrosis 
factor alpha (TNFa) were produced which blocked 
phosphorylation of the insulin receptor-insulin substrate 1 
pathway (Shintani et al. 2004). A defect in the Insulin 
receptor substrate- 1 tyrosine phosphorylation has been 
found in HCV patients' liver biopsies, but not in uninfected 
controls (Aytug et al. 2003) . This initial data suggests that 
TNF-a-mediated alterations in IRS-1 signalling are relevant to 
hepatitis C-induced insulin resistance, which may ultimately 
lead to the development of type 11 diabetes mellitus. Insulin 
resistance may cause development of liver steatosis in HCV-
infected patients making them more susceptible to the 
development of diabetes mellitus (M onto et al. 2002). 
Our study has several limitations. As it is a retrospective 
cross-sectional study it is unable to answer the question of 
causality. However, prospective studies of the natural history 
of HCV are difficult to perform due to the asymptomatic 
exceedingly prolonged course of the disease (Seeff L. 2002). 
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72 patients with an increased ferritin or hepatic iron staining 
had genetic studies performed for the haemochromatosis 
gene mutations. The numbers were too small to perform 
statistical analysis on and it is conceivable that we may have 
inadvertently included patients with heterozygosity for 
haemochromatosis in our study. However, a recent study 
showed that HCV patients who were heterozygote for HFE 
mutations did not develop iron accumulation or evidence of 
progression of liver fibrosis (Thorburn et al. 2002). We 
showed that serum ferritin levels were significantly higher in 
diabetic patients than in those patients without diabetes, 
although there was no difference between hepatic iron 
concentration between the two groups. However, we cannot 
eliminate conclusively the possibilities that the observed 
association reflected inflammation rather than excess body 
iron stores or that co-existing non-alcoholic fatty liver disease 
(NAFLD) was an important factor influencing alterations in 
serum iron markers 
In summary, it must be remembered that raised serum ferritin 
can be a good indicator of abnormal hepatic iron deposition 
within the liver; however ferritin may be raised for other 
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reasons. Both serum ferritin and hepatic iron did not appear to 
be associated with advanced liver disease in HCV infected 
patients. These findings are not supportive for a role for iron 
depletion by venesection in patients with chronic HCV 
infection with elevated serum iron stores. The association 
between chronic HCV infection and type 11 diabetes mellitus 
exists, however the biological mechanism of this association 
still remains to be discovered. Prospective studies on this 
subject are needed. 
iii) Clinical Significance of Insulin Resistance 
in Hepatitis C Virus Infection. 
Our study suggests that insulin resistance plays an important 
role in hepatic fibrosis in HCV patients, irrespective of viral 
genotype. This association still remained when diabetic and, 
cirrhotic patients were excluded. In multivariable analysis, both 
insulin resistance and older age were independently associated 
with a worse fibrosis stage. Asian HCV infected patients were 
found to have significantly higher insulin resistance than 
Caucasians. 
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HCV infection is more commonly associated with Type 2 
Diabetes Mellitus (DM) than other liver conditions ( Alexander G, 
Allison et al. 2000; Mehta et al. 2000; Knobler et al. 2000). 
Patients with cirrhosis have increased insulin resistance, and 
subsequently, a higher incidence of DM, however, when cirrhotic 
patients are excluded this association still exists (Mehta et al. 
2000). Further studies now suggest that DM may be associated 
with increased fibrosis progression in patients with HCV infection 
(Monto et al. 2002; Ortiz et al. 2002). 
Insulin resistance is a consistent finding in diabetic patients 
(Cahill et al. 1988; Reaven et al. 1976). It precedes the onset 
of DM by 10-20 years (Martin et al. 1992; Warram et al. 
1990). Insulin resistance is increased in HCV infected non-
diabetic patients when compared to healthy controls (Knobler 
et al. 2000). Our study confirms that insulin resistance is 
associated with fibrosis in HCV patients. This association 
remained when patients with Cirrhosis, which is known to 
cause insulin resistance and impaired insulin clearance, and 
diabetic patients (according to the American Diabetes 
Association guidelines) were excluded from the study. This 
relationship was independent of other factors associated with 
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fibrosis, including older age, BMI and alcohol consumption. 
These findings are in concordance with other studies that 
suggest that viral-induced insulin resistance may cause 
fibrogenesis in chronic HCV (Hui et al. 2003, Monto et al. 
2002; Ortiz et al. 2002). No genotype-specific effects on insulin 
resistance were found, which is in concordance with another 
study (Knobler et al. 2000). 
The mechanisms for insulin resistance in chronic HCV 
infection are still not known. Studies from transgenic mice that 
express high levels of HCV core protein in hepatocytes 
suggest that hepatic insulin resistance can be induced solely 
by HCV core protein (Shintani et al. 2004). This resulted in 
increased levels of tumour necrosis factor alpha (TNFa) which 
block phosphorylation of the insulin receptor-insulin substrate 
1 pathway (Shintani et al. 2004). This defect in the Insulin 
receptor substrate- 1 tyrosine phosphrylation has been found 
only in HCV patients' liver biopsies but not in non-infected 
controls (Aytug et al. 2003; Svegliati-Baroni et al. 1999; 
Knobler et al. 2003). These initial data suggest that TNF-a-
mediated alterations in I RS-1 signalling are relevant to 
hepatitis C-induced insulin resistance. Some studies have 
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ascribed the increased insulin resistance to be secondary to 
the increase of iron deposits such as ferritin in HCV patients 
(Hichman et al. 2003; Lecube et al. 2004). Insulin resistance 
may cause fibrogenesis by directly stimulating hepatic stellate 
cells to proliferate (Svegliati-Baroni et al. 1999) or by up-
regulation of connective growth factor, a cytokine involved in 
the pathogenesis of fibrosing liver diseases (Paradis et al. 
1999). 
Despite the small sample size, our study showed that 
increased insulin resistance is associated with the stage of 
fibrosis. However, worsening hepatic fibrosis can impair 
insulin degradation. This possibility has been excluded for two 
reasons. When cirrhotic patients are excluded from the 
analysis HOMA-IR is still an independent predictor of fibrosis 
score. Secondly, insulin resistance is higher in chronic 
hepatitis C than other chronic liver diseases (Knobler et al. 
2000). 
In this study, Asian HCV infected patients had significantly 
higher insulin resistance than Caucasians. BMI values for the 
diagnosis of obesity in the Asian population have been set 
lower (>22 kg/m2 ) than those for Caucasians (>25 kg/m2) 
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(WHO Expert Consultation Approprate body-mass index for 
Asian populations). According to this new definition, all of the 
Asians in our study were classified as obese compared to only 
62% of Caucasians. This may partly account for any 
ethnicity-related differences seen in insulin resistance. A 
recent study suggests that hyperinsulinaemia could be a 
factor that is responsible for the association between BMI and 
fibrosis in patients with HCV (Hickman et al. 2003). 
Our study is only a small study and as such, the results from our 
study should be interpreted cautiously. However, despite the 
small sample size, our study showed that increased insulin 
resistance is associated with the stage of fibrosis. 
In summary, insulin resistance in HCV patients is associated with 
the stage of fibrosis, even when cirrhotic patients are excluded. 
Asian patients have higher insulin resistance than Caucasians 
and the higher fibrosis progression in Asians may be related to 
this higher insulin resistance. However, numerous questions still 
need to be addressed, most notably those regarding the nature 
of the link between HCV infection and insulin resistance. Further 
studies on this subject are eagerly awaited. 
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6.3 Impact of Insulin Resistance on response 
to Therapy 
The effects of insulin resistance on treatment response were 
assessed in the second part of the study. Patients infected 
with HCV genotype 3 were independently associated with an 
increased chance of a sustained virological response. Insulin 
resistance was significantly higher in non-responders to 
antiviral therapy than responders. In multivariable regression 
analysis Asian ethnicity, higher fasting insulin levels and 
higher HOMA-IR levels were all independently associated with 
a poorer sustained virological response to treatment. 
Patients with obesity, steatosis and insulin resistance treated 
with antiviral therapy have reduced sustained virological 
response rates (Ortiz et al. 2002; Furanatani et al. 2003). 
Also, different ethnic groups have different sustained 
virological response rates to antiviral therapy (Hourigan et al. 
1999). The Asians in our group develop the metabolic features 
of the insulin resistance syndrome at lower values of BMI than 
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Caucasians. Therefore, it can be expected that insulin 
resistance might mediate the differences in the response rate 
to antiviral therapy seen here. 
Obesity, steatosis and insulin resistance have previously been 
found to be important in fibrosis progression (Ortiz et al. 
2002), and measures aimed at weight reduction prior to 
antiviral therapy may improve insulin sensitivity and the 
likelihood of viral eradication. Our study is a small study and 
as such, the results from our study should be interpreted 
cautiously. In particular, it was not possible to tease out the 
independent effects of Asian ethnicity, fasting insulin or 
HOMA-I R levels when considering factors associated with 
response to therapy. 
In conclusion, liver fibrosis is independently associated with 
insulin resistance in HCV patients confirming other studies 
and highlighting the fact that progression of liver disease in 
chronic hepatitis C infection may share the same mechanisms 
involved in the progression of non-alcoholic fatty liver disease 
(NAFLD) from fatty liver to cirrhosis, via non-alcoholic 
steatohepatitiis (NASH). This paper shows that insulin 
resistance is also an important predictor of sustained 
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virological response to antiviral therapy. Further studies on 
this subject are needed. 








A significant number of patients who are chronically infected 
with the hepatitis C virus will develop advanced liver disease 
(Fried et al. 2002; Tong et al. 1995). Early intervention is 
therefore of paramount importance in order to reduce the 
costs and mortality associated with advanced liver disease 
(Poynard et al. 1997). The Department of Health recognises 
these problems associated with chronic hepatitis C infection 
and has begun to address the issue by writing to all general 
practitioners about this virus. Our study is the first to assess 
general practitioners knowledge of hepatitis C in the UK and 
reveals that knowledge about this virus is limited. 
246 
We assessed knowledge by two approaches:- (i) an open 
interview in a small group of general practitioners and (ii) a 
postal questionnaire of over 800 general practitioners. Both 
approaches led to very similar conclusions and, resulted in 
response rates over 55%. The consistent patterns of response 
suggest the results are truly representative. The response 
rate was higher than that obtained in an American study 
(33% ) on primary care physician's knowledge and practice 
patterns concerning HCV and similar to the response rate of 
54.4% in Australia obtained in a study assessing management 
of HCV in general practice. 
Hepatitis C is a rapidly developing disease area, and it is not 
surprising to find that general practitioners are unaware of the 
latest therapy. However, we were concerned to find that a 
significant minority of general practitioners are unable to 
interpret hepatitis C antibody test results. As a result patients 
with hepatitis C are likely to be under-diagnosed and lost to 
follow-up. We were dismayed to receive feedback suggesting 
that some general practitioners appear to restrict access to 
health care to those who are actively using drugs. Further 
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urgent work will be required to assess whether there is 
discrimination against intravenous drug users. 
Our primary care colleagues acknowledge their shortcomings 
and all wish to be better informed about management of 
hepatitis C so that they can improve their clinical practice of 
this constantly changing condition. In order to improve the 
recognition of patients at risk for hepatitis C and to ensure 
appropriate testing and referral specific educational initiatives 
and practice guidelines for GPs are required. Our findings are 
similar to studies in other countries, which have also 
demonstrated the poor knowledge base and practice patterns 
of their primary care physicians (Ouzan et al. 2003; Ouzan et 
al. 2003; Shehab et al. 2001). In Canada the delivery of CD-
ROM based medical programmes to remote rural primary care 
physicians dramatically improved their knowledge and 
confidence in managing patients with hepatitis C (Stein et al. 
2002). The hepatitis C detection rates have increased since 
the French Health Insurance Fund set up open access clinics 
for HCV screening (Zdanuk et al. 2001). Hence other health 
care services have been able to improve knowledge about 
HCV in the community (Pradat et al. 2001; Fischer et al. 2000) 
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and we hope that in UK the Department of Health will 
recognize that its current information campaign has not had 
the desired effect as yet and will go on to produce and audit 
further educational campaigns. 
6.5 Improving General Practitioners 
Knowledge of Chronic Hepatitis C Infection 
Chronic hepatitis C is a significant health care problem in the 
UK and current figures indicate that the majority of infected 
individuals are unaware that they are infected (WHO 1999; 
Hepatitis C Strategy for England). To improve diagnosis and 
treatment rates among groups at high risk of infection it is 
essential that primary care physicians are well informed about 
this relatively new disease. Our previous survey showed that 
following the UK Department of Health information campaign 
in HCV the knowledge of East London GPs was still poor 
(D'Souza et al. 2004). To address this issue we launched an 
information campaign and we find that this has effectively 
increased GPs awareness and knowledge of chronic HCV, at 
least in the short term. 
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However we only assessed knowledge immediately after 
completion of the education session and, clearly, such a 
testing regime does not address knowledge retention (Fischer 
et al. 2000; Davis et al. 1995; Dillman et al. 1978) and it will be 
important to repeat our survey in the future to assess long 
term knowledge retention. It was clear from our survey that 
knowledge retention from both the lunch time educational 
sessions and the postal information leaflet were similar but the 
lunchtime sessions were relatively poorly attended. The 
lunchtime educational sessions were relatively labour 
intensive and therefore it may be more efficient to inform 
general practitioners using postal information leaflets. 
However in this study GPs were asked to complete a 
questionnaire after reading the leaflet and this may have 
contributed to the knowledge retention that was achieved. 
Educational programmes and postal surveys can serve as a 
model to provide educational programmes to health 
professionals. In remote areas of Australia practitioners are 
able to receive information via the internet concerning HCV 
and discuss cases with hospital based clinicians (Zdanuk et al. 
2001) and literature for non-English speaking patients is 
available (Dev et al. 2002) . Thus, educational initiatives and 
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guidelines specifically designed for GPs are needed to assist 
them in identifying patients at risk, conducting initial diagnostic 
evaluation, and initiating appropriate referrals, so patients with 
hepatitis C can be correctly diagnosed and treated while they 
are still in the early stages of disease. The best method of 
providing information should be provided and GPs may wish 
to become more directly involved in shared care arrangements 
with specialists that will broaden education and treatment 
opportunities for HCV-infected patients. 
6.6 Assessment of the safety and efficacy of 
ONP-17 in the treatment of Hepatitis C virus 
related symptoms. 
The use of Chinese herbal medicine is an exciting area of 
development in this field and the studies so far have been 
inconclusive. Before October 2002 there were seven 
randomised clinical studies of traditional Chinese medicine in 
the treatment of hepatitis C (Han et al. 1997; Pei et al. 1996; 
Batey et al. 1998; Chen et al. 1998; Jiang et al. 1999; Xiao et 
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al. 1999; Vu et al. 1995). Six of these studies were of poor 
methodological design. The best quality trial compared 
Chinese herbs with placebo and found a significant reduction 
in AL T levels during treatment, but no decreases in HCV RNA 
levels (Batey et al. 1998). However four patients on the active 
herbal preparation developed palpitations, diarrhoea and 
abdominal discomfort. Recently a well-designed trial by 
Jakkula et al. (2004) randomised 45 patients to receive a 
combination of Chinese herbal medications or placebo for 12 
weeks. Participants randomised to active treatment received a 
combination of 10 traditional Chinese medicinal herbs ( Radix 
astragal, Radix acanthopanax, Radix bupleuir, Radix et tuber 
curcumae, Rhizoma polygonum, Radix glycyrrhiza, Radix 
isatis, Radix paeoniae rubra, Radix salviae, and Herba 
tarazaci). Outcome measures were changes in health-related 
quality of life using the validated Hepatitis Quality of Life 
Questionnaire and alanine aminotransferase, HCV viral load 
and adverse effects. There was no improvement in quality of 
life using the health questionnaire, liver chemistry results or 
viral load. No significant adverse effects were observed. 
In our study we used two herbs namely Astragalus and Salvia 
root which have been investigated previously. In addition we 
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added Schisandra fruits and milk thistle. Unfortunately 
recruitment was poor despite extending the study to another 
site and advertising in a local newspaper. The study had to be 
terminated early as the herbal company were worried about 
the efficacy of the herbal preparation. There were a lot of 
fallouts during the study. As a result there was insufficient 
power in the study to see significant differences between the 
two arms. The results from this study show that recruitment 
and retention in trials of alternative therapies are problematic. 
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CHAPTER 7: CONCLUSIONS AND SUMMARY 
In this thesis, I have explored the natural history of hepatitis C 
in the North-East of London. Studies on prolonged (>30 
years) follow up of chronically infected patients have not been 
performed. Seeft L. (2002) has used extrapolations from the 
current natural history studies to estimate long-term natural 
history. If the progression is linear then approximately 500/0 of 
infected patients will develop cirrhosis after 50 years. If the 
rate of fibrosis progression decreases with increasing duration 
of infection then the proportion of patients who develop 
cirrhosis after 50 years will be reduced and, conversely, if the 
rate of disease progression increases with age then a greater 
proportion of infected individuals will go on to develop 
cirrhosis. Our groups' study on natural history addresses the 
outcome of chronic HCV infection up to 60 years after 
infection and reports on which of the outcomes described by 
Seeft L. (2002) are correct. 
Our study included elderly Asian patients infected in 
childhood. Fibrosis progression, measured in several hundred 
single biopsies and in nearly 50 paired liver biopsies, was the 
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same in Asian and Caucasian patients. We found that the 
longer the exposure to hepatitis C virus the greater the degree 
of fibrosis progression. A methodological limitation with this 
study was the use of cross-sectional, observational data to 
estimate longitudinal parameters. There was an absence of 
multiple liver biopsies in the same patient. The other limitation 
is the presumed variability in the estimate for duration of 
exposure. In the absence of prospective follow-up of patients 
from the date of contamination of HCV until the date of the 
liver biopsy, any estimate of the duration of infection relies on 
patient history. 
We confirm that factors such as age and alcohol excess as 
reported by Poynard et al. (1997) are associated with faster 
fibrosis progression. It must be remembered that alcohol 
consumption was a difficult factor to assess in this study and 
the risk of variabilty is great. However, all HCV-infected 
patients should strongly be advised to limit or cease alcohol 
consumption. 
Our study did not demonstrate significant differences between 
fibrosis stage and sex, which may be due to the large majority 
of postmenopausal women in the cohort. Menopause appears 
to be associated with accelerated liver fibrosis progression in 
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HCV- infected women, an effect that may be prevented by 
hormone replacement treatment (Di Martino et al. 2004; 
Codes et al. 2006). Studies have suggested a protective 
effect of oestrogens on fibrogenesis by inhibition of stellate 
cell proliferation (Bissekk D. 1999; Ashcroft et al. 1997). 
Despite the small sample of paired biopsies moderate to 
severe steatosis was associated with rapid fibrosis 
progression. However, no association was found between 
steatosis and fibrosis in single liver biopsies and the reasons 
for this may be the progressive nature of development from 
steatosis to fibrosis which would be missed on a single 
biopsy. Secondly, there are two types of steatosis - metabolic 
and genotype dependent and due to the small numbers these 
groups were not analysed separately. 
Insulin resistance was associated with fibrosis progression, 
however serum ferritin and hepatic iron played no role. 
As to the future, I see many potential areas of development of 
my research. Further longitudinal studies of untreated patients 
with chronic hepatitis C would be extremely useful. Studies 
are required to examine the pattern of natural history of HCV 
disease progression in persons infected for at least four 
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decades such as those infected as infants. However, as the 
course of chronic hepatitis C is markedly protracted and 
because treatment is now almost universal, these are 
extremely unlikely to be performed in the future. Further 
research activity should be directed toward a better 
understanding of the pathogenesis of disease progression. 
One example is the effect of age at the time of infection and of 
the process of ageing (its effects on the liver as well as the 
immune system) in the patient with established chronic 
hepatitis C infection. Ethnic minorities are often 
underrepresented in treatment studies and studies to 
determine the applicability of currently accepted treatment 
need to be performed. 
The mechanisms by which insulin resistance promotes hepatic 
fibrogenesis should be explored. Strategies to improve insulin 
sensitivity should be developed as they will complement anti-
viral therapy in the management of chronic HCV infection, and 
also will prevent fibrosis progression in non-responders to 
interferon-based antiviral therapies. 
Furthermore, research into the development of non-invasive 
dynamic measures of hepatic fibrosis is strongly encouraged. 
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The fibrosis probability index proposed by Sud et al. (2004) 
based on five parameters (insulin resistance, age, aspartate 
aminotransferase (AST), total cholesterol level, and past 
alcohol intake) should be further validated directly with the 
gold standard, fibrosis stage of the liver biopsy. The 
association between chronic HCV infection and type 2 
diabetes mellitus is highly probable, but the biological 
mechanism still needs to be addressed. Prospective studies 
assessing whether HCV associated type 2 diabetes mellitus 
can be treated with antiviral therapy need to be performed. 
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In the second part of the thesis we assess the knowledge of 
General Practitioners (GPs) in the East End of London 
following the Department of Health campaign. The knowledge 
from the two regions in the East End of London were similar. 
Therefore it is likely to assume that this is a good reflection of 
the knowledge in the UK. Our survey clearly revealed that 
significant deficits in knowledge regarding hepatitis C among 
GPs continue to exist despite the provision of a 45 page 
booklet discussing all aspects of HCV . This booklet was sent 
to every GP in the United Kingdom by the Department of 
Health approximately 10 months prior to our questionnaire. 
Several factors may contribute to the knowledge deficits 
regarding hepatitis C among GPs: the rapid evolution of new 
information, the lack of established guidelines catered for 
GPs, the need for GPs to keep up with advances in many 
diverse areas of medicine, and the possible ineffectiveness of 
current educational resources. 
We endeavored to improve GPs knowledge by inviting them to 
educational meetings on HCV or by improving their knowledge 
via a postal service. This strategy has met with success, 
although an immediate post-test does not address knowledge 
retention. GPs are the 'gate-keepers' to the NHS and will be 
259 
the first health care professionals to have the opportunity to 
screen high risk patients for HCV. Thus, educational initiatives 
and guidelines specifically designed for GPs are needed to 
assist them in identifying patients at risk, conducting initial 
diagnostic evaluation, and initiating appropriate referrals, so 
patients with hepatitis C can be correctly diagnosed and 
treated while they are still in the early stages of disease. GPs 
may wish to become more directly involved in shared care 
arrangements with specialists that will broaden education and 
treatment opportunities for HCV-infected patients. The 
Department of Health has launched a second campaign for 
tackling hepatitis C in the UK. This includes an information 
pack for general practitioners. This will assist professionals 
recognise the main risk factors, advise on how to avoid 
infection, discuss testing with patients, if appropriate, and 
follow-up if they discover patients are infected. This will be 
followed by education of the public about avoiding the risk of 
infection and considering testing where appropriate. 
In the final part of the thesis we assess treatment of hepatitis 
C. Patients with raised insulin resistance should be advised 
about lifestyle modifications (lose weight if obese, regular 
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exercise) to achieve the best chance of success from 
combination therapy for HCV. 
Studies assessing the effectiveness of Chinese herbal 
treatment for hepatitis C have been inconclusive and poorly 
designed. Our randomised double blind controlled study on 
Chinese herbal treatment had problems with recruitment and 
a lot of patients withdrew during the study from both arms. As 
a result there was insufficient power in the study to see 
significant differences between the two arms. Subjectively 
there was some improvement in AL T levels and quality of life 
data. However, this study highlights the fact that recruitment 
and retention in trials of alternative therapies are very difficult. 
As to the future, I see many potential areas of development 
of my research. Further longitudinal studies of untreated 
patients with chronic hepatitis C would be extremely useful. 
However, as the course of chronic hepatitis C is markedly 
protracted and because treatment is now almost universal, 
these are extremely unlikely to be performed in the future. 
Further research activity should be directed toward a better 
understanding of the pathogenesis of disease progression. 
One example is the effect of age at the time of infection and of 
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the process of aging (its effects on the liver as well as the 
immune system) in the patient with established chronic 
hepatitis C infection. 
The mechanisms by which insulin resistance promotes 
hepatic fibrogenesis should be explored. Strategies to improve 
insulin sensitivity should be developed as they will 
complement anti-viral therapy in the management of chronic 
HCV infection, and also will prevent fibrosis progression in 
non-responders to interferon-based antiviral therapies. 
Furthermore, the fibrosis probability index proposed by Sud et 
al. (2004) based on five parameters (insulin resistance, age, 
aspartate aminotransferase (AST), total cholesterol level, and 
past alcohol intake) should be further validated directly with 
the gold standard, fibrosis stage of the liver biopsy. The 
association between chronic HCV infection and type 2 
diabetes mellitus is highly probable, but the biological 
mechanism still needs to be addressed. Prospective studies 
assessing whether HCV associated type 2 diabetes mellitus 
can be treated with antiviral therapy need to be performed. 
General practitioners awareness of hepatitis C is clearly low 
and we await the outcome of the governments' second 
campaign launched on the 29th June 2004 whose objectives 
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are to improve the knowledge amongst general practitioners 
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APPENDIX 
Table 3 - The Short Form 36 Survey Questionnaire. 
Fatigue Symptom Scale (FSS) 
Please read each statement below and think about how well it has 
applied to you over the past week. Then circle the corresponding number 
to the left: a low value indicates that the statement is not very 
appropriate, whereas a high value indicates agreement with the 
statement. 
1. My motivation is lower when I am fatigued. 1 2 3 4 5 6 7 
2. Exercise brings on my fatigue. 1 2 3 4 5 6 7 
3. I am easily fatigued. 1 2 3 4 5 6 7 
4. Fatigue interferes with my physical 1 2 3 4 5 6 7 
functioning. 
5. Fatigue causes frequent problems for me. 1 2 3 4 5 6 7 
6. My fatigue prevents sustained physical 1 2 3 4 5 6 7 
functioning 
7. Fatigue inteferes with carrying out certain 1 2 3 4 5 6 7 
duties and responsibities. 
8. Fatigue is among my three most disabling 1 2 3 4 5 6 7 
symptoms. 
9. Fatigue interferes with my work, family, or 1 2 3 4 5 6 7 
social life. 
SF-36 Health Survey 
INSTRUCTIONS: This survey asks for your views about your health. 
This information will help keep track of how you feel and how well 
you are able to do your usual activities. 
Answer every question by marking the answer as indicated. If you 
are unsure about how to answer a question, please give the best 
answer you can. 
1. In general, would you say your health Is: 
Excellent ........................................... 1 
Very good .......................................... 2 
Good ................................................ 3 
Fair .................................. 1 •••••••••••••••• 4 
Poor ....................................... 1 •••••••••• 5 
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2. Compared to one year ago, how would you rate your health In 
general D..QY!? 
Excellent ............................................ 1 
Very good ........................................... 2 
(;()()ci •......••.••••••••••••.•••••.•••.••.••••.••.•••.. :1 
t=cair .•.••..••••..•••.•••••••••••••••••••••••••••.••••••• iI 
~()()r •••••••••••••••••••••••••••••••••••••••••••••••••• • !i 
3. The following questions are about activities you might do during 
a typical day. Does your health now limit you In these activities? 
If so, how much? 
ACTIVITIES Yes, Ves, No, Not 
Limited Limited Limited 
a Lot a Little At All 
a. Vigorous activities, such as running, 1 2 3 
lifting heavy objects, participating in 
strenuous sports 
b. Moderate activities, such as moving a 1 2 3 
table, pushing a vacuum cleaner, 
bowling or playing golf. 
c. Lifting or carrying groceries 1 2 3 
d. Climbing several flights of stairs 1 2 3 
e. Climbing one flight of stairs 1 2 3 
f. Bending, kneeling or stooping 1 2 3 
g. Walking more th~n a mile 1 2 3 
h. Walking half a mile 1 2 3 
i. Walking one hundred yards 1 2 3 
1. Bathing or dressing yourself 1 2 3 
4. During the past 4 weeks, have you had any_of the following 
problems with your work or other regular dally activities...!!..! 
result of your physical health? 
Yes No 
a. Cut down on the amount of time you spent 1 2 
on work or other activities 
b. Accomplished less thanyou would like 1 2 
c. Were limited in the kind of work or other activities 1 2 
d. Had difficulty performing the work or other activities (for 1 2 
example, it took extra effort) 
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5. During the past 4 weeks, have you had any of the following 
problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or 
anxious)? 
Yes No 
a. Cut down on the amount of time you spent 1 2 
on work or other activities 
b. Accomplished less than you would like 1 2 
c. Did not do work or other activities as carefully as usual 1 2 
6. During the past 4 weeks to what extent has your physical health 
or emotional problems interfered with your normal social 
activities with family, friends, neighbours, or groups? 
Not at all ............................................... 1 
Slightly ..................... I ••••••••••••••••••••••••••• 2 
Moderately ............................................ 3 
Quite a bit ............................................. 4 
Extremely ............... I ••••••••••••••••••••••••••••• 5 
7. How much bodily pain have you had during the past 4 weeks? 
Not at all .......................................... , .... 1 
Slightly ................................................ 2 
Moderately ............................................ 3 
Quite a bit ..................... 1 ••••••••••••••••••••••• 4 
Extremely ............................................. 5 
8. During the past 4 weeks, how much did pain interfere with your 
normal work (including both work outside the home and 
housework) ? 
Not at all ............................................... 1 
Slightly ................................................. 2 
Moderately .................................. I ••••••••• 3 
Quite a bit ............................................. 4 
Extremely ................................... , ......... 5 
9. These questions are about how you feel and how things have 
been with you during the past 4 weeks. For each question, 
please give the one answer that comes closest to the way you 
have been feeling. How much of the time during the past 4 
weeks-
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All Most A Some A None 
of of Good Of Little of the the the Bit of The the of the Time Time Time "Time Time Time 
a. Did you feel 1 2 3 4 5 6 
full of life? 
b. Have you 1 2 3 4 5 6 
been a very 
nervous 
person? 
c. Have you 1 2 3 4 5 6 
felt so down in 




d. Have you 1 2 3 4 5 6 
felt calm and 
peaceful? 
e. Did you 1 2 3 4 5 6 
have a lot of 
energy? 
f. Have you felt 1 2 3 4 5 6 
downhearted 
and low? 
g. Did you feel 1 2 3 4 5 6 
worn out? 
h. Have you 1 2 3 4 5 6 
been a happy 
person? 
i. Did you feel 1 2 3 4 5 6 
tired? 
10.During the past 4 weeks, how much of the time has your 
physical health or emotional problem interfered with your social 
activities (like visiting with friends, relatives, etc) ? 
All of the time ...................................................... 1 
Most of the ti me ................................................... 2 
Some of the time ................................................. 3 
A little of the time ............................ I ••••••••••••••••••• 4 
None of the time ............... I ••••••••••••••••••••••••••••••••• 5 
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11.How TRUE or FALSE is each of the following statements for 
you? 
Definitely Mostly Don't Mostly Definitely 
True True Know False 
a. I seem to get 1 2 3 4 
ill more easily 
than other 
people 




c. I expect my 1 2 3 4 
health to get 
worse 
d. My health is 1 2 3 4 
excellent 
Sickness Impact Profile 
Name of Questionnaire 







Generic measure used to evaluate the impact of disease on both 
physical and emotional functioning. Patients are asked to respond to 
the items as they are on that day. The measure has also been used 
in patients with COPO and asthma. 
Developer 
B Gilson & M Bergner, 1976 (revised 1981) 
Copyright is held by Johns Hopkins University, 1977. All rights 
reserved. The Medical Outcomes Trust can provide information and 
permission for use. 
Medical Outcomes Trust 
8 Park Plaza #503 
Boston, MA 02116-4313 
Address 






Cost & availability 
Fee. Contact the Medical Outcomes Trust for information and 





Time to complete 
Number of items 
Domains & categories 
2 overall domains (physical and psychosocial) 
12 categories (sleep and rest, eating, work, home management, 
recreation and pastimes, ambulation, mobility, body care and 
movement, social interaction, alertness behavior, emotional 
behavior, communication) 
Name of categories/domains 
Physical: ambulation, mobility, body care and movement 
Psychosocial: social interaction, communication, alertness behavior, 
emotional behavior; sleep and rest, eating, home management, 
recreation and pastimes, employment 
An overall score can also be computed. 
Scaling of items 
Respondents check the items that apply to them (yes/no). 
Scoring 
Overall score, 2 domain scores, and 12 category scores; items are 
weighted according to a standardized weighting scheme. 
Reliability 
a. Test-retest/reproducibility Reported 
b. Internal consistency Reported 
Validity 
Compared to clinical indices of asthma and disease-specific quality of 
life measures (AQLQ-Juniper,' SGRQ ,AQLQ-Marks, symptoms & 
clinical efficacy ) 
Responsiveness 
Reported 
Minimally important difference 
Not determined. 
Research use 






Translations: None currently authorized by the copyright holder. 
Guidelines for translation are available through the Medical Outcomes 
Trust or through Johns Hopkins University. 
Nottingham Health Profile 
VARIABLES MEASURED: 
Subjective health status in a number of areas: physical mobility, 
pain, sleep, emotional reactions, social isolation and energy 
PURPOSE: 
To provide direct access to perceived health status, which can 
give basic information required for determining goals in health care 
and assessing how far they have been met. 
DESCRIPTION/DEVELOPMENT: 
There are six sections: physical mobility, pain, sleep, emotional 
reactions, social isolation, and energy. Each contains a number of 
statements to which the respondent answers yes or no. 
Statements in each section are weighted -a score of 100 indicates 
the presence of all possible perceived problems in that section, 
while a score of zero on a section indicates the respondent does 




Re: Hepatitis C Questionnaire 
Chronic hepatitis C is an increasing health problem. The 
Department of Health has recently addressed this issue with 
the publication of its 'Hepatitis C strategy for England' in 
August 2002 and information about this virus has been sent to 
general practioners. The strategy document sets out 
proposals to improve the effectiveness of prevention, 
diagnosis and treatment services for hepatitis C. 
We are currently conducting a survey amongst general 
practitioners about hepatitis C. We want to assess your views 
of this condition and the services available for patients in your 
area. The survey may help to improve local services for 
hepatitis C. We would be grateful if you would take part and 
respond to the following questions. We thank you for your 
assistance in this study. 
With kind regards 
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Please circle the right answer or write down a single 
answer to the following questions. 
1. Patients who are hepatitis C antibody 
positive no longer have active disease 
2. Hepatitis C is common (> 40 %) in those 
who have ever used intravenous drugs 
3. The prevalence of HIV is higher than 







5. More than 50 % of pregnant women infect Yes No 
their children 
6. Blood transfusion in the 1990s carries a Yes No 
high risk of transmitting hepatitiS C 
6. In patients using intravenous drugs, 
transmission of hepatitis C can be 
prevented by meticulous hygiene and non-
Yes No 
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sharing of all paraphenalia 
7. Therapy for hepatitis C is effective in more Yes No 
than 500/0 of patients treated 
8. Out of 100 patients with chronic hepatitis 
C which proportion of patients will develop 
cirrhosis in 30 years 
5 10 20 50 70 
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9. Where do you refer your patients with hepatitis C 
.................................................................................. 
10. What changes do you feel would improve the services 
offered to your patients with hepatitis C in your area 
• •••••••••••••••••••••••••••••••••••••••••••••••••• III ••• III III ••• III •• III ••••••••• 
• • , • III •••••• III ••••• I • III •• III •••••• III • III • III •• III • III •••••••••••••••••••••••••••••••••• 
11' , ••••••• , ••• III III ••••••••••••••• III •••• III •••• III • III III III • III ••••••••••••••••••••••••• 
• ••• III III •••••• 11' ••••• III • 11' •••••••••••••••••••••••••• III •••••••• III ••••••••••••• 
Thank you for your assistance in this pilot study, your time is 
much appreciated. Please return to the following address in 
the enclosed prepaid envelope please or return this by fax to 
020 7882 7241. 
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Dear Colleague 
We received an excellent response following our 
questionnaire in hepatitis C and we would like to thank all our 
colleagues in general practice for their wholehearted support 
in this project. The majority of GPs called for a one page 
summary of the Department of Health booklet titled 'Hepatitis 
C strategy for England'. A one page summary has therefore 
been enclosed and we would be grateful if after reading this 
you could fill in the enclosed questionnaire and fax back to 
020 7882 7241. Hopefully if this proves to be useful we will 
send the information sheet out to the rest of our colleagues in 
the East End. The survey may help improve local services for 
hepatitis C. 
Thank you for your assistance. 
With kind regards 
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Hepatitis C Information Sheet 
In the UK the number of people chronically infected with 
hepatitis C is estimated to be around 200 000, the majority of 
whom are asymptomatic and unaware of their infection. HCV 
is a common infection and more common than HIV. Our aims 
together with our general practitioner colleagues is to prevent 
new cases of HCV infection and to reduce the risks of those 
infected progressing to severe liver disease 
Transmission:- In the UK HCV is mainly transmitted by 
injecting drug users sharing blood contaminated equipment. 
Other less efficient routes of transmission include sexual 
intercourse «5%) and from mother to baby «5%). Blood 
transfusion prior to 1991 carried a high risk of transmitting 
hepatitis C. 
Natural History:- 200/0 of patients who have been infected 
with HCV in 30 years will develop cirrhosis with its inherent 
complications. 
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High risk groups:- There should be increased testing of at 
risk groups by GPs. These include the following groups:-
injecting drug users (past or present), history of receiving 
blood or blood products prior to 1991, organ transplant prior to 
1991, needlestick injury, regular sexual partners of patients 
with HCV and patients being investigated for abnormal liver 
function tests. 
Testing :- patients suspected of having HCV should be 
screened with a hepatitis C antibody test. Those who are 
positive should be referred to the hospital for further testing 
(PCR HCV). 
Treatment:- Chronic infection with HCV can lead to severe 
liver disease and liver cancer, but moderate to severe disease 
can be treated successfully in at least 50% of people. Patients 
are treated with interferon and ribavirin. 
Prevention:- There should be increased public awareness, 
needle exchange services and teaching drug users about 
meticulous hygiene and nonsharing of paraphenelia. 
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Information on HCV should also be freely available, including 
prisons. 
After reading this information sheet please fill in the 
questionnaire and return this by fax to 020 7882 7241. 
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